"AHC","PY","nTotDoc","meanAUPerArt","meanAU_IN_PerArt","meanArtAU_IN","meanArtPer_AU_IN_FIRST","meanArtPer_AU_IN_LAST","meanArtPer_AU_IN_CORR","ArtOA","singleAuArt","Q1_nSJR","Q2_nSJR","Q4_nSJR","Q3_nSJR","Q1_percSJR","Q2_percSJR","Q4_percSJR","Q3_percSJR","meanTCperArt","mean_NTC","InternCoauthorship","AffCoauthorship","meanCitationTrend","GC_AUIN_wFractional","GC_AUIN_FIRSTname","GC_AUIN_LASTname","GC_AUIN_CORRESP","top_AU","top_AU_freq","top_AU_wFract","top_AU_freq_wFract","top_AUIN","top_AUIN_freq","top_AUIN_wFract","top_AUIN_freq_wFract","topAUbyCit","topAUbyCit_TC","topAUINbyCit","topAUINbyCit_TC","topAUINbyCit_norm_byYear","topAUINbyCit_TC_norm_byYear","topConcept_L0","topFreq_L0","topConcept_L1","topFreq_L1","topConcept_L2","topFreq_L2","topConcept_L3","topFreq_L3","topConcept_L4","topFreq_L4","topMESH","topMESH_n","topprimary_topic.display_name","topprimary_topic.display_name_n","topDE","topDE_n","topTI_TM","topTI_TM_n","topAB_TM","topAB_TM_n","total_docs","nDoc_wALTM","percDoc_wALTM","medianAltmetricScore","cited_by_accounts_count_mean_top25AltmScore","cited_by_accounts_count_min_top25AltmScore","cited_by_accounts_count_max_top25AltmScore","cited_by_fbwalls_count_mean_top25AltmScore","cited_by_fbwalls_count_min_top25AltmScore","cited_by_fbwalls_count_max_top25AltmScore","cited_by_feeds_count_mean_top25AltmScore","cited_by_feeds_count_min_top25AltmScore","cited_by_feeds_count_max_top25AltmScore","cited_by_gplus_count_mean_top25AltmScore","cited_by_gplus_count_min_top25AltmScore","cited_by_gplus_count_max_top25AltmScore","cited_by_msm_count_mean_top25AltmScore","cited_by_msm_count_min_top25AltmScore","cited_by_msm_count_max_top25AltmScore","cited_by_patents_count_mean_top25AltmScore","cited_by_patents_count_min_top25AltmScore","cited_by_patents_count_max_top25AltmScore","cited_by_peer_review_sites_count_mean_top25AltmScore","cited_by_peer_review_sites_count_min_top25AltmScore","cited_by_peer_review_sites_count_max_top25AltmScore","cited_by_policies_count_mean_top25AltmScore","cited_by_policies_count_min_top25AltmScore","cited_by_policies_count_max_top25AltmScore","cited_by_posts_count_mean_top25AltmScore","cited_by_posts_count_min_top25AltmScore","cited_by_posts_count_max_top25AltmScore","cited_by_rdts_count_mean_top25AltmScore","cited_by_rdts_count_min_top25AltmScore","cited_by_rdts_count_max_top25AltmScore","cited_by_rh_count_mean_top25AltmScore","cited_by_rh_count_min_top25AltmScore","cited_by_rh_count_max_top25AltmScore","cited_by_tweeters_count_mean_top25AltmScore","cited_by_tweeters_count_min_top25AltmScore","cited_by_tweeters_count_max_top25AltmScore","cited_by_videos_count_mean_top25AltmScore","cited_by_videos_count_min_top25AltmScore","cited_by_videos_count_max_top25AltmScore","cited_by_wikipedia_count_mean_top25AltmScore","cited_by_wikipedia_count_min_top25AltmScore","cited_by_wikipedia_count_max_top25AltmScore","cohorts.com_mean_top25AltmScore","cohorts.com_min_top25AltmScore","cohorts.com_max_top25AltmScore","cohorts.doc_mean_top25AltmScore","cohorts.doc_min_top25AltmScore","cohorts.doc_max_top25AltmScore","cohorts.pub_mean_top25AltmScore","cohorts.pub_min_top25AltmScore","cohorts.pub_max_top25AltmScore","cohorts.sci_mean_top25AltmScore","cohorts.sci_min_top25AltmScore","cohorts.sci_max_top25AltmScore","readers.citeulike_mean_top25AltmScore","readers.citeulike_min_top25AltmScore","readers.citeulike_max_top25AltmScore","readers.connotea_mean_top25AltmScore","readers.connotea_min_top25AltmScore","readers.connotea_max_top25AltmScore","readers.mendeley_mean_top25AltmScore","readers.mendeley_min_top25AltmScore","readers.mendeley_max_top25AltmScore","readers_count_mean_top25AltmScore","readers_count_min_top25AltmScore","readers_count_max_top25AltmScore"
"AOU_VERONA",2000,17,7.05882352941176,3.29411764705882,0.303571428571429,0.470588235294118,0.470588235294118,0.294117647058824,0.411764705882353,1,10,4,3,0,0.59,0.24,0.18,0,27.47,0.606000348484246,0,0.705882352941177,NA,0.508121644444056,0.15,0.214285714285714,0.25,"EMMA FIORINI;DUNIA RAMARLI;GIUSEPPE TRIDENTE;GUIDO POLESE;ERCOLE CONCIA;ANDREA ROSSI;ROMOLO M. DORIZZI;MONICA BRENTEGANI;ORNELLA POFFE;MARIA TERESA SCUPOLI;S. TURAZZI;ELDA TAGLIABUE;MICHELE MUGGEO;PIER CARLO MARCHISIO;P. CAVALLO‐PERIN;NOVELLA SCATTOLO;LORENZO VOLPIN;DOMENICO CUCINOTTA;G. MASTELLA;GIULIANO DALL’OLIO","3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1","ALBERTO TERZI;ROMOLO M. DORIZZI;GIULIANO DALL’OLIO;ROBERTA FONTANA;FRANCESCA BRUNELLO;GUIDO POLESE;ANDREA ROSSI;ERCOLE CONCIA;EMMA FIORINI;DUNIA RAMARLI;NOVELLA SCATTOLO;GIANNI MISTRELLO;GIANENRICO SENNA;D. RONCAROLO;GIOVANNI MARCHI;ANTONIO FORTUNATO;ANNARITA DAMA;GIUSEPPE TRIDENTE;MONICA BRENTEGANI;ORNELLA POFFE","1;0.75;0.5;0.5;0.5;0.37;0.37;0.34;0.32;0.32;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.22;0.22;0.22","EMMA FIORINI;DUNIA RAMARLI;GIUSEPPE TRIDENTE;GUIDO POLESE;ERCOLE CONCIA;ROMOLO M. DORIZZI;MONICA BRENTEGANI;S. TURAZZI;MICHELE MUGGEO;P. CAVALLO‐PERIN;DOMENICO CUCINOTTA;FAUSTO SANTEUSANIO;LUCA LAZZARINI;RICCARDO VIGNERI;KARL THOMASETH;R GIORGINO;G BOMPIANI;GIACOMO ZOPPINI;ROBERTO LUZZATI;ALBERTO TERZI","3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","ALBERTO TERZI;ROMOLO M. DORIZZI;ROBERTA FONTANA;FRANCESCA BRUNELLO;GUIDO POLESE;ERCOLE CONCIA;EMMA FIORINI;DUNIA RAMARLI;GIANENRICO SENNA;GIUSEPPE TRIDENTE;MONICA BRENTEGANI;LUCA LAZZARINI;MASSIMILIANO LANZAFAME;S. TURAZZI;LUISA ZANOLLA;A. POLO;MICHELE MUGGEO;ROBERTO LUZZATI;L. BOSCHIERO;MICHELE TONINI","1;0.75;0.5;0.5;0.37;0.34;0.32;0.32;0.25;0.22;0.22;0.2;0.2;0.2;0.2;0.2;0.15;0.14;0.14;0.14","S. TURAZZI;ALBA A. BRANDES;BIANCA GUGLIELMI;CARLA CAROLLO;DANIELA DANIELI;G PINNA;LORENZO VOLPIN;MARINA GARDIMAN;PIETRO AMIST�;S. MONFARDINI;DUNIA RAMARLI;EMMA FIORINI;ANDREA ROSSI;GUIDO POLESE;MICHELE MUGGEO;FRANCESCA GIANNONI;FRANCESCA POLI;G. SIRCHIA;GIUSTO ANCONA;L. BOSCHIERO","144;109;109;109;109;109;109;109;109;109;74;74;62;62;59;55;55;55;55;55","G PINNA;S. TURAZZI;DUNIA RAMARLI;GUIDO POLESE;GIUSTO ANCONA;L. BOSCHIERO;MICHELE TONINI;F. BELLAVERE;GIACOMO ZOPPINI;KARL THOMASETH;M. L. GEMMA;ME DE GREGORI;MICHELE MUGGEO;PAOLO MOGHETTI;ROBERTO CASTELLO;V. CACCIATORI;EMMA FIORINI;FRANCESCA BRUNELLO;ROBERTA FONTANA;MONICA BRENTEGANI","109;109;74;62;55;55;55;52;52;52;52;52;52;52;52;52;35;35;35;27","DUNIA RAMARLI;GUIDO POLESE;ROMOLO M. DORIZZI;A GNUDI;ALBERTO TERZI;B. A. TIENGO;DARIO GIUGLIANO;DOMENICO CUCINOTTA;DOMENICO FEDELE;ELE FERRANNINI;EMMA FIORINI;F CAPANI;F. BELLAVERE;FAUSTO SANTEUSANIO;FRANCESCA BRUNELLO;G BOMPIANI;G PAGANO;G PINNA;G. MENZINGER;G. POZZA","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PHYSICS;ENGINEERING;CHEMISTRY;MATHEMATICS","14;9;3;2;1;1","INTERNAL MEDICINE;IMMUNOLOGY;ENDOCRINOLOGY;GENETICS;SURGERY;ANESTHESIA;CANCER RESEARCH;CELL BIOLOGY;THERMODYNAMICS;BIOCHEMISTRY;CARDIOLOGY;GASTROENTEROLOGY;RADIOLOGY;BIOTECHNOLOGY;BOTANY;FOOD SCIENCE;MICROBIOLOGY;ONCOLOGY;ORGANIC CHEMISTRY;PALEONTOLOGY;PATHOLOGY;PEDIATRICS;RELIABILITY ENGINEERING;STATISTICS;STRUCTURAL ENGINEERING;VIROLOGY","11;5;4;4;4;3;3;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","GENE;CANCER;CELL;CONFIDENCE INTERVAL;CYTOKINE;DIABETES MELLITUS;LUNG;RESPIRATORY SYSTEM;TUMOR NECROSIS FACTOR ALPHA;VENTILATION (ARCHITECTURE);ADHESION;AIRWAY;ALLERGY;ANTIBIOTICS;ANTIBODY;APOPTOSIS;ARTERIAL BLOOD;ARTHROPLASTY;BACTERIA;BLOOD PRESSURE;BODY MASS INDEX;BRAZIL NUT;BRONCHOSCOPY;CELL ADHESION MOLECULE;CENTRAL NERVOUS SYSTEM;CHEMOTHERAPY;COHORT;COHORT STUDY;COPD;CREATININE;DISEASE;DOSING;ENZYME;EPITHELIUM;FERRITIN;HEMOGLOBIN;HISTOLOGY;HUMAN IMMUNODEFICIENCY VIRUS (HIV);IMMUNE SYSTEM;IN VITRO;IN VIVO;INFLAMMATION;LUNG CANCER;LYMPHATIC SYSTEM;MAGNETIC RESONANCE IMAGING;MECHANICAL VENTILATION;NECROSIS;NONPARAMETRIC STATISTICS;NUT;PERCENTILE;PHARMACOKINETICS;PINUS <GENUS>;POLLEN;POWER (PHYSICS);RADIATION THERAPY;RECEPTOR;REFERENCE VALUES;REGIMEN;RETROSPECTIVE COHORT STUDY;SCHWANN CELL;SENSITIZATION;SIGNAL TRANSDUCTION;STAGE (STRATIGRAPHY);STROMAL CELL;SURVIVAL ANALYSIS;SURVIVAL RATE;SWEAT;TRANSPLANTATION;TUBERCULOSIS;URINE","4;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CELL ADHESION;RESPIRATORY PHYSIOLOGY;TRANSCRIPTION FACTOR;AIRWAY RESISTANCE;ALLERGEN;BREAST CANCER;CENTRAL NEUROCYTOMA;CHEMOTHERAPY REGIMEN;COMPLETE REMISSION;CROSS REACTIONS;CYCLOPHOSPHAMIDE;ETOPOSIDE;GENOTYPE;GLYCEMIC;GLYCOSURIA;HEART RATE;HEMOGLOBIN A;HYPERCAPNIA;IMMUNOGLOBULIN E;INTEGRIN;ISONIAZID;KIDNEY TRANSPLANTATION;MYCOBACTERIUM TUBERCULOSIS;MYELIN;NF-ΚB;PATHOGNOMONIC;PERIPROSTHETIC;PHENOTYPE;POLYURIA;POSITIVE END-EXPIRATORY PRESSURE;PROGRESSIVE DISEASE;PROTEASE;PULMONARY COMPLIANCE;RELIABILITY (SEMICONDUCTOR);RESPIRATORY DISEASE;RESPIRATORY MINUTE VOLUME;SERUM FERRITIN;STAPHYLOCOCCUS AUREUS;STREPTOMYCIN;SUBGROUP ANALYSIS;T CELL;TIDAL VOLUME;TYPE 2 DIABETES;TYPE 2 DIABETES MELLITUS;URINE SAMPLE;VIRAL LOAD","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANTIRETROVIRAL THERAPY;ARTIFICIAL VENTILATION;AUTONOMIC NERVOUS SYSTEM;CROSS-REACTIVITY;ETHAMBUTOL;HEART RATE VARIABILITY;MASTECTOMY;MYCOBACTERIUM TUBERCULOSIS COMPLEX;NFKB1;PEAK INSPIRATORY PRESSURE;RADIOALLERGOSORBENT TEST;THYMOCYTE;VANCOMYCIN","1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;ADULT;MIDDLE AGED;NF-KAPPA B;EPITHELIAL CELLS;MALE;T-LYMPHOCYTES;BRAIN NEOPLASMS;NEOPLASM RECURRENCE, LOCAL;NEUROCYTOMA;TUMOR NECROSIS FACTOR-ALPHA;AGED;CARCINOMA IN SITU;CARCINOMA, NON-SMALL-CELL LUNG;CARCINOMA, SQUAMOUS CELL;CARDIOVASCULAR DISEASES;CLINICAL CHEMISTRY TESTS;DIABETES MELLITUS;INTEGRINS","15;11;7;7;7;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4","MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;DIAGNOSIS AND TREATMENT OF LUNG CANCER;GLIOMAS;GUILLAIN-BARRÉ SYNDROME AND RELATED NEUROPATHIES;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;INNATE IMMUNE RECOGNITION AND SIGNALING PATHWAYS;LYMPHANGIOGENESIS IN CANCER METASTASIS AND DISEASE;MANAGEMENT OF DIABETES MELLITUS AND HYPOGLYCEMIA;MEDICAL SERIAL KILLERS AND FORENSIC TOXICOLOGY;REGULATION OF IRON METABOLISM AND ANEMIA;REGULATORY T CELL DEVELOPMENT AND FUNCTION;TUBERCULOSIS;WEARABLE NANOGENERATOR TECHNOLOGY","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GLUCOSE TRANSPORTER DEFICIENCY;NONINVASIVE VENTILATION;POSITIVE END-EXPIRATORY PRESSURE;RESPIRATORY;RESPIRATORY PHYSIOLOGY;ADHERENCE TO MEDICATION;ARTERIAL BLOOD;ARTIFICIAL VENTILATION;BRAZIL NUT;BREATH ANALYSIS;CARDIOPULMONARY EXERCISE TESTING;CENTRAL NEUROCYTOMA;CHEMOTHERAPY REGIMEN;CONTINUOUS GLUCOSE MONITORING;CROSS-REACTIVITY;DIABETES;FOOD ALLERGY;GLYCEMIC CONTROL;GLYCOSURIA;HEART RATE VARIABILITY","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","DIABETES MELLITUS;HUMAN THYMIC;IL- GENE;THYMIC EPITHELIAL;ADHESION PROMOTES;ANTITUBERCULOUS DRUGS;ASSIST VENTILATION;CANCER Â;CARDIOVASCULAR DISEASES;CELL DEATH;CELL SURVIVAL;CELLS INDUCES;CELLS SIGNALLING;CELLS TEC;CENTRAL NEUROCYTOMA;CLASSIC GIBSON;CLINICAL ASPECTS;COLLECTION METHOD;COMPLEX ISOLATES;CONDUCTIVITY ANALYSIS;COOKE TECHNIQUE;EPITHELIAL CELL;EPITHELIAL CELLS;EXPRESSION ROLE;FACTOR Α;FACTOR-ALPHA GENE;FACTORS NF-ΚB;FASTING GLYCEMIA;FAVORABLE PROGNOSIS;GENE EXPRESSION","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CMHO NA;HEART RATE;ALPHABETA HETERODIMERS;ASSIST VENTILATION;POWER SPECTRAL;PROPORTIONAL ASSIST;CHRONIC OBSTRUCTIVE;HYPOTHYROID PATIENTS;HYPOTHYROID SUBJECTS;OBSTRUCTIVE PULMONARY;PULMONARY DISEASE;SPECTRAL DENSITY;TEC SURFACE;TISSUE CONCENTRATIONS;ARTERIAL BLOOD;BACTEC TB;BETA INTEGRINS;BLOOD GASES;CARBON DIOXIDE;CARDIOVASCULAR SYSTEM;CONTROL SUBJECTS;CONTROLS LYING;DAYS MEDIAN;DISEASE PATIENTS;EPITHELIAL CELLS;LFHF RATIO;MEDIAN DAYS;NASAL PROPORTIONAL;PHYSIOLOGICAL EFFECTS;PLT NA","5;5;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",17,1,0.06,3,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,33,33,33,33,33,33
"AOU_VERONA",2001,21,8.95238095238095,2.47619047619048,0.403846153846154,0.571428571428571,0.285714285714286,0.0952380952380952,0.285714285714286,1,9,5,4,3,0.43,0.24,0.19,0.14,47.05,1.02965896220755,0.0952380952380952,0.714285714285714,NA,0.40297243421315,0.288770053475936,0.311111111111111,0,"MASSIMO FRANCHINI;G GANDINI;FELICE PASINI;GIAN LUIGI CETTO;GIUSEPPE APRILI;ALBERTO TERZI;FRANCO CAPRA;MARZIA DE GIRONCOLI;GIUSEPPE TRIDENTE;ANTONELLA BASSI;JEAN‐CHRISTOPHE SABOURIN;A. MOLINO;GIULIANO SOFFIATI;GIOVANNI PIETRO SOLERO;DARIO REGIS;EMANUELA SCARPI;DEL BRAVO P;ELISABETTA GUIZZARDI;EMMA FIORINI;SERGIO MALUTA","4;4;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","A DORIZZI;SILVIO GARATTINI;MASSIMO GEROSA;MASSIMO FRANCHINI;G GANDINI;U TELLINI;D OLIVIERI;LUCIA PELLIZZARI;FRANCO CAPRA;FELICE PASINI;GIULIANO SOFFIATI;DAVIDE GIAVARINA;CORINNE ALBERTI;ROMOLO M. DORIZZI;FRANCESCA VENTURINI;GIOVANNA SCROCCARO;GABRIELLA MEZZENA;MARCO ALBERTI;GIUSEPPE APRILI;MARZIA DE GIRONCOLI","1;0.5;0.5;0.49;0.49;0.33;0.33;0.33;0.31;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.18;0.18","MASSIMO FRANCHINI;G GANDINI;GIUSEPPE APRILI;ALBERTO TERZI;MARZIA DE GIRONCOLI;ELISABETTA GUIZZARDI;SERGIO MALUTA;U TELLINI;FABIO CALABRÒ;ELENA DONATA AGOSTINI;AURORA VASSANELLI;D. BERTUZZO;LUIGINO BOSCHIERO;ROBERTO LUZZATI;MARCO LIGOZZI;ISABELLA FERRO;CORINNE ALBERTI;ROBERTA FONTANA;MICHELE TONINI;ROMOLO M. DORIZZI","4;4;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","A DORIZZI;MASSIMO GEROSA;MASSIMO FRANCHINI;G GANDINI;U TELLINI;CORINNE ALBERTI;ROMOLO M. DORIZZI;FRANCESCA VENTURINI;GIOVANNA SCROCCARO;MARCO ALBERTI;GIUSEPPE APRILI;MARZIA DE GIRONCOLI;MARCO LIGOZZI;ROBERTA FONTANA;ALBERTO BELTRAMELLO;EMANUELA CRISTELLI;FRANCESCA BRUNELLO;ALBERTO TERZI;LUIGINO BOSCHIERO;MICHELE TONINI","1;0.5;0.49;0.49;0.33;0.25;0.25;0.25;0.25;0.25;0.18;0.18;0.17;0.17;0.17;0.17;0.17;0.16;0.12;0.12","GIUSEPPE LIPPI;FELICE PASINI;ANTONELLA BASSI;ANTONIO LUPO;GIORGIO BROCCO;GIOVANNI FACCINI;GIOVANNI PIETRO SOLERO;GIUSEPPE MASCHIO;GIUSEPPE RESTIVO;LINDA GAMMARO;NICOLA TESSITORE;PATRIZIA BERNICH;VALERIA BEDOGNA;ALBERTO TERZI;ANGELICA SONZOGNI;ANTONIO IANNUCCI;CARMELO LUPO;ENRICA BRESAOLA;F. VALDUGA;FILIPPO FRAGGETTA","215;208;207;207;207;207;207;207;207;207;207;207;207;191;176;176;176;176;176;176","NICOLA TESSITORE;ALBERTO TERZI;ANTONIO IANNUCCI;EMANUELA CRISTELLI;FRANCESCA BRUNELLO;MARCO LIGOZZI;ROBERTA FONTANA;CRISTINA OLIANI;GIAN DOMENICO PINNA;STEFANIA RODELLA;MASSIMO FRANCHINI;ROMOLO M. DORIZZI;G GANDINI;GIUSEPPE APRILI;MARZIA DE GIRONCOLI;ANNACHIARA GIUFFRIDA;D. BERTUZZO;ISABELLA FERRO;ANDREA BONETTI;ROBERTO LUZZATI","207;191;176;150;150;150;150;105;91;83;46;44;38;35;35;21;21;21;17;17","MASSIMO FRANCHINI;G GANDINI;ALBERTO TERZI;GIUSEPPE APRILI;MARZIA DE GIRONCOLI;A DORIZZI;ALESSANDRO GANDINI;ANDREA BONETTI;ANNACHIARA GIUFFRIDA;ANTONIO IANNUCCI;AURORA VASSANELLI;C ZANUSO;CORINNE ALBERTI;CRISTIAN-ENE ROATĂ;CRISTINA OLIANI;D. BERTUZZO;DUNIA RAMARLI;ELENA DONATA AGOSTINI;ELISABETTA GUIZZARDI;EMANUELA CRISTELLI","4;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;POLITICAL SCIENCE;SOCIOLOGY;BUSINESS;COMPUTER SCIENCE;ECONOMICS;PSYCHOLOGY","18;9;2;2;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;GASTROENTEROLOGY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;GENETICS;BIOCHEMISTRY;CANCER RESEARCH;ENDOCRINOLOGY;PATHOLOGY;FAMILY MEDICINE;INTENSIVE CARE MEDICINE;LAW;NEUROSCIENCE;ONCOLOGY;PSYCHIATRY;AGRONOMY;ANESTHESIA;CELL BIOLOGY;DEMOGRAPHY;ECOLOGY;ECONOMIC GROWTH;MICROBIOLOGY;MOLECULAR BIOLOGY;OBSTETRICS;PEDIATRICS;PHARMACOLOGY;PHYSICAL THERAPY;PUBLIC ADMINISTRATION;RADIOLOGY;SOCIAL SCIENCE;VIROLOGY;WORLD WIDE WEB","13;7;5;5;4;4;3;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","POPULATION;CANCER;CHEMOTHERAPY;GENE;REGIMEN;ANTIBODY;ENZYME;IMMUNOHISTOCHEMISTRY;THYROID;AGAROSE;ALTERNATIVE MEDICINE;ANEMIA;ANTIBIOTICS;ARTHROPLASTY;AUTOLOGOUS BLOOD;BACTERIA;BLOOD TRANSFUSION;BONE MARROW;CARCINOMA;CENTRAL NERVOUS SYSTEM;CLINICAL PRACTICE;CLINICAL TRIAL;COAGULOPATHY;COMBINATION THERAPY;COMPETITION (BIOLOGY);CONFIDENCE INTERVAL;CYTOKINE;D-DIMER;DIAGNOSTIC TEST;DONATION;ERYTHROPOIETIN;ETHICS COMMITTEE;FERRITIN;GEL ELECTROPHORESIS;GLIOMA;HEMOGLOBIN;HORMONE;IMMUNE SYSTEM;INDEX (TYPOGRAPHY);INFLAMMATION;INTENSIVE CARE;LEGISLATION;LUNG;LUNG CANCER;META-ANALYSIS;NATURAL HISTORY;NAUSEA;NEUROLOGY;NORMALITY;ORTHOPEDIC SURGERY;PNEUMONIA;POLITICS;PREGNANCY;PULMONARY EMBOLISM;RADIATION THERAPY;RADIOLOGICAL WEAPON;RECOMBINANT FACTOR VIIA;REFERENCE RANGE;RESEARCH DESIGN;RESEARCH ETHICS;STAINING;THROMBOSIS;TRANSPLANTATION;VIRUS;VOLUNTEER;VOMITING","4;3;3;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","COLORECTAL CANCER;PHASES OF CLINICAL RESEARCH;ADENOCARCINOMA;AGAROSE GEL ELECTROPHORESIS;ASTROCYTE;ASTROCYTOMA;BLOOD MANAGEMENT;CHEMOTHERAPY REGIMEN;CYCLOPHOSPHAMIDE;DACARBAZINE;ENTEROCOCCUS;FLUOROURACIL;GEMCITABINE;GENOTYPE;HEME;HEPATITIS A VIRUS;HEPATITIS C VIRUS;HIP REPLACEMENT;IMMUNOSTAINING;INDUCTION CHEMOTHERAPY;INFORMED CONSENT;IRON DEFICIENCY;MONOCLONAL ANTIBODY;NEUROINFLAMMATION;NEUTROPENIA;NUCLEIC ACID SEQUENCE;POLYACRYLAMIDE GEL ELECTROPHORESIS;POLYMERASE CHAIN REACTION;PROGRESSION-FREE SURVIVAL;PROMOTION (CHESS);PROTOCOL (SCIENCE);RECOMBINANT DNA;RENAL TRANSPLANT;RESTRICTION ENZYME;RESTRICTION FRAGMENT;SALVAGE THERAPY;SECOND-LINE THERAPY;STAPHYLOCOCCUS AUREUS;SUBGROUP ANALYSIS;T CELL;TEMOZOLOMIDE;THYROID DISEASE;THYROID-STIMULATING HORMONE;TITER;TRIIODOTHYRONINE;VENOUS THROMBOEMBOLISM","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANAPLASTIC ASTROCYTOMA;DNA MISMATCH REPAIR;FEBRILE NEUTROPENIA;HYPOTHALAMIC–PITUITARY–THYROID AXIS;IMMUNOPEROXIDASE;IRINOTECAN;IRON STATUS;OLIGODENDROGLIOMA;OXALIPLATIN;POLYMORPHISM (COMPUTER SCIENCE);RESTRICTION DIGEST;RESTRICTION FRAGMENT LENGTH POLYMORPHISM;RESTRICTION MAP;RESTRICTION SITE;THYROID TRANSCRIPTION FACTOR 1;TRANSFERRIN SATURATION;VINCRISTINE;ZINC PROTOPORPHYRIN","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;AGED;CARCINOMA, NON-SMALL-CELL LUNG;LUNG NEOPLASMS;ADULT;MIDDLE AGED;ADENOCARCINOMA;CARCINOMA, ADENOSQUAMOUS;CARCINOMA, LARGE CELL;CARCINOMA, SQUAMOUS CELL;HEMOPHILIA A;INTERLEUKIN-6;ITALY;ADOLESCENT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;CELLS, CULTURED;CHOLANGITIS;CHOLESTASIS","18;12;10;9;9;9;8;8;5;5;5;5;5;5;5;4;4;4;4;4",";ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS;DIAGNOSIS, TREATMENT, AND EPIDEMIOLOGY OF NONTUBERCULOUS MYCOBACTERIAL DISEASES;EFFECTS OF BLOOD TRANSFUSION IN CLINICAL PRACTICE;ETHICAL CONSIDERATIONS IN MEDICAL RESEARCH PARTICIPATION;GLIOMAS;HEMATOPOIETIC STEM CELL BIOLOGY;HEPATITIS C INFECTION AND TREATMENT;HUMAN T-CELL LEUKEMIA VIRUS TYPE 1 INFECTION;HYPERGLYCEMIC CHOREA AND BASAL GANGLIA LESIONS;KIDNEY TRANSPLANTATION;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;MANAGEMENT AND TREATMENT OF HEMOPHILIA;MANAGEMENT OF VENTILATOR-ASSOCIATED PNEUMONIA IN ICU PATIENTS;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;REGULATION OF IRON METABOLISM AND ANEMIA","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","REGIMEN;METASTATIC COLORECTAL CANCER;AGAROSE;AGAROSE GEL ELECTROPHORESIS;ANAPLASTIC ASTROCYTOMA;AUTOLOGOUS BLOOD;BILIARY DRAINAGE;BLOOD DONATION;BLOOD MANAGEMENT;BLOOD TRANSFUSION;BONE MARROW BIOPSY;CHEMOTHERAPY REGIMEN;CLINICAL PRACTICE;COMBINATION THERAPY;D-DIMER;DACARBAZINE;DNA MISMATCH REPAIR;EPIDEMIOLOGY;ETHICS COMMITTEE;HEPATITIS C VIRUS","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","II STUDY;PHASE II;ACADEMIC PROMOTION;ACQUIRED HEMOPHILIA;ACTIVATED FACTOR;ACUTE BLEEDING;ADVANCED NON-SMALL;ALLOGENEIC BONE;ALTERED VALUES;ANDOR THYROTROPIN;AUTOLOGOUS BLOOD;BILATERAL PALLIDAL;BILIARY DISEASES;BLEEDING EPISODE;BLOOD DONATION;BONE MARROW;CANCER HNPCC--RESULTS;CANCER INTERIM;CARE UNITS;CASE-CONTROL STUDY;CELL CARCINOMAS;CELL LUNG;CELLCELL CONTACTS;CELLS REGULATE;CLINICAL EFFICACY;CLINICAL TRIALS;COLLABORATIVE STUDY;COLORECTAL CANCER;COLORECTAL CARCINOMA;CONSECUTIVE VOLUNTEER","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","SECOND-LINE THERAPY;HIGH-GRADE GLIOMA;RESEARCH PROTOCOLS;RESPONSE RATE;CONFIDENCE INTERVAL;FIRST-LINE CHEMOTHERAPY;FIRST-LINE THERAPY;FRAGMENT LENGTH;GEL ELECTROPHORESIS;INTERVAL CI;LENGTH POLYMORPHISM;MEDIAN SURVIVAL;PATIENTS CI;PROTOCOLS SUBMITTED;RECURRENT HIGH-GRADE;RESTRICTION FRAGMENT;SURVIVAL TIME;ACCEPTABLE TOXICITY;ACCURATE PREDICTORS;ACTIVE RESEARCH;ADMINISTERED TEMOZOLOMIDE;ADVANCED COLORECTAL;AGAROSE GEL;AGENTS CONCLUSION;ALGORITHM DESCRIBING;ALLOWED IDENTIFICATION;ANALYSIS PATTERNS;ANALYSIS RESPONSE;ANAPLASTIC ASTROCYTOMA;ANAPLASTIC OLIGODENDROGLIOMA","7;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1",21,3,0.14,9,4.5,3,6,0,0,0,0,0,0,0,0,0,0,0,0,5,5,5,0,0,0,2,1,3,5.5,5,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,37.5,31,44,37.5,31,44
"AOU_VERONA",2002,17,8.47058823529412,2.41176470588235,0.414634146341463,0.411764705882353,0.352941176470588,0.0588235294117647,0.176470588235294,0,7,6,3,1,0.41,0.35,0.18,0.06,41.88,0.759168603888654,0.294117647058824,0.88235294117647,NA,0.331802800655585,0.311111111111111,0.171428571428571,0,"MASSIMO FRANCHINI;GIUSEPPE APRILI;FRANCO MANZATO;ALBERTO TERZI;MARZIA DE GIRONCOLI;G GANDINI;GIUSEPPE LIPPI;MAURO ZAMBONI;OTTAVIO BOSELLO;GIUSEPPE TRIDENTE;QUIRINO PIUBELLO;S GAMBINA;ELISABETTA BROGGIO;GIULIO FRACASSO;NADIA BRUTTI;CHIARA PRONZATO;MARIA CRISTINA ARTESANI;BEATRICE CARUSO;A. ANTICO;SILVIA SARTORIS","4;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","MASSIMO FRANCHINI;GIUSEPPE APRILI;MARZIA DE GIRONCOLI;QUIRINO PIUBELLO;STEFANIA MONTEMEZZI;C. D'ATRI;FRANCO MANZATO;GIUSEPPE LIPPI;ALBERTO TERZI;GIORGIO GANDINI;G GANDINI;MAURO ZAMBONI;OTTAVIO BOSELLO;ITALO VANTINI;GABRIO BASSOTTI;MATTEO BRUNELLI;GUIDO MARTIGNONI;GIORGIO BROCCO;WILLIAM E. WHITEHEAD;JOHN N. EBLE","0.69;0.49;0.38;0.33;0.33;0.33;0.32;0.32;0.29;0.25;0.24;0.21;0.21;0.2;0.2;0.2;0.2;0.2;0.2;0.2","MASSIMO FRANCHINI;GIUSEPPE APRILI;FRANCO MANZATO;ALBERTO TERZI;MARZIA DE GIRONCOLI;G GANDINI;GIUSEPPE LIPPI;QUIRINO PIUBELLO;S GAMBINA;ELISABETTA BROGGIO;NADIA BRUTTI;BEATRICE CARUSO;G. BELLISOLA;ANTONIO SANTO;SARA MAZZUCCO;GIANENRICO SENNA;ITALO VANTINI;MATTEO BRUNELLI;CEDRIC S. RAINE;GIORGIO BROCCO","4;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","MASSIMO FRANCHINI;GIUSEPPE APRILI;MARZIA DE GIRONCOLI;QUIRINO PIUBELLO;FRANCO MANZATO;GIUSEPPE LIPPI;ALBERTO TERZI;G GANDINI;ITALO VANTINI;MATTEO BRUNELLI;GIORGIO BROCCO;JOHN N. EBLE;MAURIZIO PEA;GIAN CESARE GUIDI;GIUSEPPE CHIARIONI;FRANCO BONETTI;ERNESTO AMELIO;ANTONIO SANTO;G. BELLISOLA;SARA MAZZUCCO","0.69;0.49;0.38;0.33;0.32;0.32;0.29;0.24;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.17;0.14;0.12;0.12","ERNESTO AMELIO;ERNST MARLINGHAUS;GIOVANNI GOTTE;GIOVANNI MUSCI;HIROSHI SUZUKI;S. RUSSO;GABRIO BASSOTTI;GIUSEPPE CHIARIONI;ITALO VANTINI;SAMUELA STEGAGNINI;WILLIAM E. WHITEHEAD;DEBORAH CASTELLETTI;FRANCESCO PAGANO;G. BELLISOLA;GIULIO FRACASSO;GIUSEPPE TRIDENTE;MARCO COLOMBATTI;SARA CINGARLINI;TOMMASO PRAYER‐GALETTI;MAURO ZAMBONI","131;131;131;131;131;131;124;124;124;124;124;91;91;91;91;91;91;91;91;89","ERNESTO AMELIO;GIUSEPPE CHIARIONI;ITALO VANTINI;G. BELLISOLA;BEATRICE CARUSO;S. TURAZZI;FRANCO BONETTI;JOHN N. EBLE;MATTEO BRUNELLI;MAURIZIO PEA;MASSIMO FRANCHINI;BRUNO BONETTI;CEDRIC S. RAINE;CHIARA STEGAGNO;ELISA ZULIANI;GIANLUIGI ZANUSSO;GIUSEPPE MORETTO;PAOLA VALDO;SARA MAZZUCCO;G GANDINI","131;124;124;91;65;62;55;55;55;55;46;40;40;40;40;40;40;40;40;38","MASSIMO FRANCHINI;G GANDINI;GIUSEPPE APRILI;ALBERTO TERZI;ANNA PIA RIVIERA;ANNARITA DAMA;ANTONIO SANTO;BEATRICE CARUSO;BRUNO BONETTI;CEDRIC S. RAINE;CHIARA STEGAGNO;ELISA ZULIANI;ELISABETTA BROGGIO;ERNESTO AMELIO;FRANCO BONETTI;FRANCO MANZATO;G. BELLISOLA;GIAN CESARE GUIDI;GIANENRICO SENNA;GIANLUIGI ZANUSSO","4;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;ECONOMICS;GEOGRAPHY;PHYSICS;PSYCHOLOGY","16;7;2;1;1;1;1;1","INTERNAL MEDICINE;IMMUNOLOGY;SURGERY;BIOCHEMISTRY;INTENSIVE CARE MEDICINE;ONCOLOGY;PATHOLOGY;ECOLOGY;ENDOCRINOLOGY;GASTROENTEROLOGY;PALEONTOLOGY;PHYSICAL THERAPY;UROLOGY;BIOPHYSICS;CANCER RESEARCH;COGNITIVE SCIENCE;COMPUTER VISION;ECONOMIC GROWTH;GERONTOLOGY;ORGANIC CHEMISTRY;PEDIATRICS;PHYSICAL MEDICINE AND REHABILITATION;QUANTUM MECHANICS;RADIOLOGY;THERMODYNAMICS;VIROLOGY","14;5;5;4;4;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;ADVERSE EFFECT;ANTIBODY;ANTIGEN;DISEASE;IMMUNOHISTOCHEMISTRY;IN VITRO;LUNG CANCER;STAGE (STRATIGRAPHY);ADJUVANT;AMINO ACID;ANOREXIA;ANTHROPOMETRY;AUTOLOGOUS BLOOD;BALANCE (ABILITY);BIOFEEDBACK;BIOPSY;BLOOD DONOR;CARCINOMA;CHEMOTHERAPY;CLEARANCE;COAGULATION;DEFECATION;DESMOPRESSIN;DONATION;ENERGY BALANCE;ENERGY EXPENDITURE;ENZYME;EOSINOPHILIC;EPIDEMIOLOGY;FECAL INCONTINENCE;FILTER (SIGNAL PROCESSING);GASTROINTESTINAL TRACT;HAEMOPHILIA;HEMOSTASIS;HEPATITIS C;HOMOCYSTEINE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);HYDROGEN PEROXIDE;IMMUNE SYSTEM;INTERFERON;KIDNEY;KINETICS;LECTIN;LUNG;MALIGNANCY;MULTIPLE SCLEROSIS;NITRIC OXIDE;OBESITY;OXIDE;PERCUTANEOUS;PLATELET;POLLEN;RADIATION THERAPY;RECEPTOR;RECTUM;REGIMEN;SENSORY THRESHOLD;SHOCK (CIRCULATORY);SHOCK WAVE;SPHINCTER;STIMULATION;SURVIVAL RATE;THYROID;TOXICITY;VIRUS;VITAMIN;VITAMIN B12","3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ALZHEIMER'S DISEASE;ANAL CANAL;ANGIOMYOLIPOMA;ANORECTAL MANOMETRY;ARGININE;ATYPICAL HYPERPLASIA;BREAST CANCER;CHRONIC HEPATITIS;COAGULATION DISORDER;CUPRESSACEAE;CYCLOPHOSPHAMIDE;CYTOTOXIC T CELL;DEMENTIA;EPITHELIOID CELL;HMB-45;HYPERHOMOCYSTEINEMIA;IMMUNOTHERAPY;METASTASIS;MONOCLONAL ANTIBODY;NERVE GROWTH FACTOR;NITROSOUREA;ONCOCYTOMA;PHASES OF CLINICAL RESEARCH;PNEUMONECTOMY;POLYCLONAL ANTIBODIES;PROGRESSION-FREE SURVIVAL;PROSTATE;PROSTATE CANCER;SAMPLING (SIGNAL PROCESSING);TEMOZOLOMIDE;THYROID DISEASE;VON WILLEBRAND FACTOR;WEIGHT LOSS;WHEAT GERM AGGLUTININ","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","DUCTAL CARCINOMA;EXTERNAL ANAL SPHINCTER;GLUTAMATE CARBOXYPEPTIDASE II;IMMUNOTOXIN;LNCAP;MAMMOGRAPHY;PRIMARY TUMOR;RENAL ONCOCYTOMA;RIBAVIRIN;TROPOMYOSIN RECEPTOR KINASE A;VINCRISTINE;VON WILLEBRAND DISEASE","1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;ADULT;MIDDLE AGED;AGED;CARCINOMA, NON-SMALL-CELL LUNG;LUNG NEOPLASMS;NEOPLASMS, SECOND PRIMARY;ADENOMA, OXYPHILIC;ANGIOMYOLIPOMA;BREAST DISEASES;BREAST NEOPLASMS;CALCINOSIS;CARCINOMA IN SITU;CARCINOMA, DUCTAL, BREAST;CARCINOMA, INTRADUCTAL, NONINFILTRATING;CARCINOMA, LOBULAR;DACARBAZINE;HEPATITIS C, CHRONIC","14;10;10;9;8;6;6;6;6;4;4;4;4;4;4;4;4;4;4;4","DIAGNOSIS AND TREATMENT OF LUNG CANCER;BREAST PATHOLOGY AND IMAGING TECHNIQUES;CONTRACEPTION AND UNINTENDED PREGNANCY PREVENTION;DIVERSITY AND EVOLUTION OF FUNGAL PATHOGENS;GLIOMAS;HEPATITIS C INFECTION AND TREATMENT;HEREDITARY ANGIOEDEMA: MOLECULAR MECHANISMS AND CLINICAL MANAGEMENT;IMMUNOTOXIN THERAPY FOR CANCER TREATMENT;MANAGEMENT AND OPTIMIZATION OF BLOOD SUPPLY CHAIN;NANOTECHNOLOGY IN CANCER TREATMENT AND DIAGNOSIS;PELVIC FLOOR DISORDERS;PRODUCTION OF RECOMBINANT PHARMACEUTICALS IN PLANTS;ROLE OF HOMOCYSTEINE IN HEALTH AND DISEASE;ROLE OF NITRIC OXIDE IN HEALTH AND DISEASE;ROLES OF NEUROTROPHINS IN NERVOUS SYSTEM FUNCTION;TUBEROUS SCLEROSIS COMPLEX AND RELATED DISORDERS","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","LUNG CANCER;NON-SMALL CELL LUNG CANCER;SMALL-CELL LUNG CANCER;TREATMENT;ANGIOMYOLIPOMA;ANORECTAL MANOMETRY;ANOREXIA;ATYPICAL HYPERPLASIA;AUTOLOGOUS BLOOD;BIOFEEDBACK;BIOPSY;BLOOD DONATION;BLOOD TRANSFUSION;BREAST BIOPSY;CLEARANCE;COAGULATION DISORDER;CONTRACEPTION;CUPRESSACEAE;DESMOPRESSIN;DISEASE EPIDEMIOLOGY","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CELL LUNG;LUNG CANCER;ACQUIRED VON;ADVERSE EVENT;ALZHEIMERS DISEASE;ANTITUMOR EFFECTS;ATYPICAL HYERPLASIA;AUTOLOGOUS BLOOD;BIOFEEDBACK THERAPY;BLOOD DONATION;BREAST CALCIFICATIONS;CANCER EXPERIENCE;CHRONIC HEPATITIS;CLINICAL IMPLICATIONS;CLINICAL PROGNOSTIC;COMPLETION PNEUMONECTOMY;CUPRESSACEAE POLLENOSIS;DIETARY WHEAT;DISEASE UNDERGOING;ELDERLY PATIENT;ENERGY BALANCE;ENHANCED EXPRESSION;EPIDEMIOLOGICAL SURVEY;FECAL INCONTINENCE;FORMED STOOL;GERM DEPRIVATION;HIVNEGATIVE HAEMOPHILIACS;HOMOCYSTEINE LEVELS;HYDROGEN PEROXIDE;HYERPLASIA CORRELATIONS","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","LUNG CANCER;MS LESIONS;ACTIVE MS;CANCER CLASSIFIED;CELL LUNG;COMPLETION PNEUMONECTOMY;LONG-TERM SURVIVAL;NGF RECEPTORS;NON-SMALL CELL;NORMAL CNS;POLYCLONAL ANTISERUM;PRIMARY LUNG;ADVERSELY AFFECTED;ANTI-NGFRP MABS;ANTIBODIES MABS;APOPTOTIC FIGURES;AUTOIMMUNE RESPONSE;BIOCHEMICAL RESPONSIBLE;CANCER DISTINCTION;CELL LEVELS;CELL REACTIVITY;CELLS IMMUNOREACTIVITY;CELLULAR DISTRIBUTION;CENTRAL NERVOUS;CHRONIC ACTIVE;CHRONIC MULTIPLE;COMPLETELY RESECTED;COMPLICATIONS OCCURRED;CONFLICTING OPINIONS;EXPERIENCED HANDS","5;4;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",17,2,0.12,7.5,19,19,19,0,0,0,0,0,0,0,0,0,0,0,0,19,19,19,0,0,0,0,0,0,19,19,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,31,31,31,31,31,31
"AOU_VERONA",2003,24,9.25,1.91666666666667,0.521739130434783,0.416666666666667,0.0833333333333333,0.0833333333333333,0.416666666666667,2,16,2,4,2,0.67,0.08,0.17,0.08,82.17,1.55242630080755,0.125,0.708333333333333,NA,0.500249832604081,0.278846153846154,0,0.166666666666667,"MASSIMO FRANCHINI;GIUSEPPE TRIDENTE;RICCARDO C. BONADONNA;ANTONIO BONALDI;SILVIA SARTORIS;TIZIANA CESTARI;GIANCARLO ANDRIGHETTO;C. GUERRIERO;ALBERTO TERZI;FELICE PASINI;GIUSEPPE PELOSI;GIOVANNI DE MANZONI;ROBERTO CHIGNOLA;GIORGIO GANDINI;ELISABETTA STEFANI;ANNA PIA RIVIERA;KITT FALK PETERSEN;FRANCO MANZATO;TIMON W. VAN HAEFTEN;WILLIAM V. TAMBORLANE","4;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","MASSIMO FRANCHINI;ANTONIO BONALDI;GIORGIO GANDINI;GABRIELE ROMANO;MARCO ZAFFANELLO;STEFANO TARDIVO;CONCETTA PETRINI;SIMONE RUGOLOTTO;GIAMPAOLO MERLINI;MARIASTELLA GRAZIANI;GIUSEPPE APRILI;DINO VENERI;ALBERTO TERZI;FELICE PASINI;GIUSEPPE PELOSI;GIOVANNI DE MANZONI;RICCARDO C. BONADONNA;ALBERTO DALL’ANTONIA;MAURIZIO GOVERNA;GIORGIO MARCHINI","1.75;1.33;0.36;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.25;0.25;0.21;0.21;0.21;0.21;0.21;0.2;0.2;0.2","MASSIMO FRANCHINI;RICCARDO C. BONADONNA;ANTONIO BONALDI;ALBERTO TERZI;ANNA PIA RIVIERA;GIOVANNI OSSI;A TOMEZZOLLI;ALBERTO DALL’ANTONIA;SILVIA MARCONI;LUIGINO BOSCHIERO;BÁRBARA MASOTTO;CRISTINA OLIANI;E. NARDELLI;ANTONIO BENITO PORCARO;MAURIZIO GOVERNA;GIOVANNA ZANONI;ENZO BONORA;FABIO LUGOBONI;G. CHIEREGO;PAOLA VALDO","4;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MASSIMO FRANCHINI;ANTONIO BONALDI;MARIASTELLA GRAZIANI;ALBERTO TERZI;RICCARDO C. BONADONNA;ALBERTO DALL’ANTONIA;MAURIZIO GOVERNA;D. BARISONI;ANNA PIA RIVIERA;FABIO LUGOBONI;ENZO BONORA;MICHELE MUGGEO;GIOVANNI OSSI;SILVIA MARCONI;BÁRBARA MASOTTO;E. NARDELLI;PAOLA VALDO;BRUNO BONETTI;LUCA DE TONI;MASSIMO FRANCHINI","1.75;1.33;0.33;0.21;0.21;0.2;0.2;0.2;0.19;0.17;0.14;0.14;0.11;0.11;0.11;0.11;0.11;0.11;0.11;0.11","RICCARDO C. BONADONNA;ANTONIO CURNIS;ANTONIO RAVIELE;CRISTINA BASSO;D. IGIDBASHIAN;DOMENICO CORRADO;F NACCARELLA;FIORENZO GAÏTA;FRANCESCO MADDALENA;GABRIELE ZANOTTO;GAETANO THIENE;GIANFRANCO BUJA;GIUSEPPE VERGARA;JORGE URIARTE SALERNO;LOIRA LEONI;M DISERTORI;MARK S. LINK;N.A. MARK ESTES;PAOLO DELLA BELLA;PIETRO DELISE","583;568;568;568;568;568;568;568;568;568;568;568;568;568;568;568;568;568;568;568","RICCARDO C. BONADONNA;GABRIELE ZANOTTO;LINDA BOSELLI;MASSIMO FRANCHINI;B. DALLA BERNARDINA;ALBERTO TERZI;MARIA FIRPO;ANTONIO IANNUCCI;LUIGINO BOSCHIERO;ENZO BONORA;MICHELE MUGGEO;STEFANIA RODELLA;MARIASTELLA GRAZIANI;BRUNO BONETTI;BÁRBARA MASOTTO;E. NARDELLI;GIOVANNI OSSI;LUCA DE TONI;NICOLO’ RIZZUTO;PAOLA VALDO","583;568;507;166;165;115;107;97;95;76;76;67;52;28;28;28;28;28;28;28","MASSIMO FRANCHINI;ALBERTO TERZI;ANNA PIA RIVIERA;RICCARDO C. BONADONNA;A TOMEZZOLLI;A. TONON;ALBERTO DALL’ANTONIA;ANTONIO BENITO PORCARO;ANTONIO IANNUCCI;B. DALLA BERNARDINA;BRUNO BONETTI;BÁRBARA MASOTTO;C. MANFRINI;CLAUDIO CORDIANO;CRISTINA OLIANI;D. BARISONI;E. NARDELLI;ENZO BONORA;FABIO LUGOBONI;G G DELAINI","5;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;BUSINESS;COMPUTER SCIENCE;ENGINEERING;PHILOSOPHY;PHYSICS;CHEMISTRY;ECONOMICS;POLITICAL SCIENCE;PSYCHOLOGY","22;11;2;2;2;2;2;1;1;1;1","INTERNAL MEDICINE;IMMUNOLOGY;GASTROENTEROLOGY;SURGERY;PATHOLOGY;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;ENDOCRINOLOGY;ONCOLOGY;PALEONTOLOGY;GENETICS;MOLECULAR BIOLOGY;NUCLEAR MEDICINE;NURSING;OPTICS;PEDIATRICS;PROCESS MANAGEMENT;RADIOLOGY;AGRONOMY;ANESTHESIA;CANCER RESEARCH;CARDIOLOGY;CELL BIOLOGY;CHROMATOGRAPHY;COMPUTATIONAL BIOLOGY;ECONOMIC GROWTH;EPISTEMOLOGY;HUMANITIES;INTENSIVE CARE MEDICINE;LAW;MANAGEMENT SCIENCE;MECHANICAL ENGINEERING;MEDICAL EDUCATION;OPERATING SYSTEM;OPERATIONS MANAGEMENT;PROGRAMMING LANGUAGE;PSYCHIATRY;SOCIAL PSYCHOLOGY;TOXICOLOGY","16;7;6;6;5;4;3;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;POPULATION;DISEASE;VIRUS;ANTIBODY;DIABETES MELLITUS;HEALTH CARE;IMMUNE SYSTEM;IN VITRO;INCIDENCE (GEOMETRY);INSULIN;INTERFERON;LUNG CANCER;PLATELET;SECRETION;STAGE (STRATIGRAPHY);ADDICTION;ANEMIA;ANTIGEN;APOPTOSIS;ARTERIOVENOUS FISTULA;ATRIAL FIBRILLATION;BETA (PROGRAMMING LANGUAGE);BLOOD FLOW;BOLUS (DIGESTION);CARBOHYDRATE METABOLISM;CARCINOMA;CASE-CONTROL STUDY;CENTRAL NERVOUS SYSTEM;CHEMOTHERAPY;CIRRHOSIS;CLAMPING;COAGULOPATHY;COMBINATION THERAPY;COMPETENCE (HUMAN RESOURCES);COMPLICATION;CONFIDENCE INTERVAL;CONTEXT (ARCHAEOLOGY);CYTOKINE;DEFEROXAMINE;DEHISCENCE;ENUCLEATION;EPIDEMIOLOGY;ETIOLOGY;FASCIA;FASCIA LATA;FERRITIN;FOREARM;GENE;HEART FAILURE;HEMODIALYSIS;HEMOSTASIS;HEPATITIS C;HEPATOLOGY;HOMEOSTASIS;HYPERTHERMIA;IMMUNOHISTOCHEMISTRY;IMPLANT;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;LEUKEMIA;LUNG;LYMPH;LYMPHOMA;MANAGEMENT SYSTEM;NEONATAL INTENSIVE CARE UNIT;NICOTINE;OCCUPATIONAL EXPOSURE;PERIOPERATIVE;PESTICIDE;PHLEBOTOMY;PLASTIC SURGERY;PREGNANCY;PROCESS (COMPUTING);PSYCHOLOGICAL INTERVENTION;QUALITY (PHILOSOPHY);RADIATION THERAPY;RECEIVER OPERATING CHARACTERISTIC;REGIMEN;RISK FACTOR;SARCOMA;SMOKING CESSATION;STEM CELL;STENOSIS;SUBCUTANEOUS INJECTION;SUDDEN CARDIAC DEATH;THROMBOSIS;TRANSPLANTATION;TUMOR NECROSIS FACTOR ALPHA;TURBIDIMETRY;ULTRASOUND;VENTRICULAR FIBRILLATION;VENTRICULAR TACHYCARDIA;VIRAL HEPATITIS;WOUND DEHISCENCE","4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ALPHA INTERFERON;CHRONIC HEPATITIS;COLORECTAL CANCER;CYTOTOXIC T CELL;INSULIN RESISTANCE;MONOCLONAL ANTIBODY;TYPE 2 DIABETES;ADENOCARCINOMA;AUTOANTIBODY;CANCER REGISTRY;CARDIOMYOPATHY;CD8;CHROMOGRANIN A;CLAMP;CRAVING;ENCEPHALITIS;EPITOPE;FIBRILLATION;GENOTYPE;GLUCOSE UPTAKE;HAEMATOPOIESIS;HAZARD RATIO;HEALTH SERVICES;HEPATITIS C VIRUS;IMMUNIZATION;IMMUNOGENICITY;IMMUNOGLOBULIN LIGHT CHAIN;IMMUNOPRECIPITATION;INTERFERON GAMMA;ISLET;KIDNEY CANCER;KIDNEY TRANSPLANTATION;METABOLIC SYNDROME;MYELIN;NEPHELOMETRY;NICOTINE REPLACEMENT THERAPY;OFFSPRING;PATHOGNOMONIC;PROGRAMMED CELL DEATH;PROSTATE CANCER;QUALITY MANAGEMENT;RESPIRATORY DISEASE;SERUM FERRITIN;STANDARDIZED MORTALITY RATIO;SYNAPTOPHYSIN;TEMPORAL FASCIA;TRANSPLANT SURGERY;VIRAL DISEASE;VON WILLEBRAND FACTOR","2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","RIBAVIRIN;ABDOMINAL OBESITY;ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA;BENCE JONES PROTEIN;BETA CELL;FAS LIGAND;GLUCOSE HOMEOSTASIS;GLUCOSE TOLERANCE TEST;HEPACIVIRUS;IMPAIRED GLUCOSE TOLERANCE;INSULIN SENSITIVITY;INTERFERON ALFA;LARGE CELL;MONOCLONAL;MYELIN BASIC PROTEIN;NEUROENDOCRINE DIFFERENTIATION;PANCREATIC HORMONE;PERFORIN;PREDIABETES;THROMBOPOIETIN;TRANSFERRIN SATURATION;VON WILLEBRAND DISEASE","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;CARCINOMA, NON-SMALL-CELL LUNG;LUNG NEOPLASMS;AGED;ITALY;MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE;NEOPLASMS;HEPATITIS C, CHRONIC;LIVER CIRRHOSIS;;ANTIVIRAL AGENTS;HEPACIVIRUS;INSULIN;INTERFERON-ALPHA;RIBAVIRIN;RNA, VIRAL","18;13;13;10;8;8;8;7;7;7;7;6;6;5;5;5;5;5;5;5","GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;HEPATITIS C INFECTION AND TREATMENT;IMMUNOBIOLOGY OF DENDRITIC CELLS;ADVANCEMENTS IN LUNG CANCER RESEARCH;BROWN ADIPOSE TISSUE FUNCTION AND PHYSIOLOGY;CLASSIFICATION AND TREATMENT OF VASCULAR ANOMALIES;DEVELOPMENT AND EVALUATION OF CLINICAL GUIDELINES;DIAGNOSIS AND MANAGEMENT OF ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;FOCUSED ULTRASOUND TECHNOLOGY AND APPLICATIONS;GENETIC AND CLINICAL STUDIES OF OCULAR DEVELOPMENT;GENETICS AND PATHOGENESIS OF TYPE 1 DIABETES;GLOBAL IMPACT OF MEDICAL TOURISM INDUSTRY;GUILLAIN-BARRÉ SYNDROME AND RELATED NEUROPATHIES;IMPACT OF PESTICIDES USE IN AGRICULTURE;MANAGEMENT OF VASCULAR ACCESS IN HEALTHCARE;MOLECULAR MECHANISMS OF AMYLOIDOSIS;PLATELET DISORDERS AND THROMBOSIS MECHANISMS;PROMOTION OF HEALTHY LIFESTYLES IN YOUNG ADULTS;SPHINGOLIPID SIGNALLING AND METABOLISM IN HEALTH AND DISEASE","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GLUCOSE CLAMP TECHNIQUE;INSULIN RESISTANCE;IRON OVERLOAD;TREATMENT;ABDOMINAL OBESITY;ANTIGEN PRESENTATION;ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY;ARTERIOVENOUS FISTULAS;BENCE JONES PROTEIN;BETA (PROGRAMMING LANGUAGE);BOLUS (DIGESTION);C-PEPTIDE LEVELS;CANCER IMAGING;CANCER INCIDENCE;CANCER TREATMENT;CARBOHYDRATE METABOLISM;CARDIAC RESYNCHRONIZATION THERAPY;CHROMOGRANIN A;CLAMP;COMBINATION THERAPY","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CHRONIC HEPATITIS;LUNG CANCER;ABDOMINAL FAT;ACCESS BLOOD;ADAPTIVE IMMUNE;ADULT PATIENTS;ADVANCED RECTAL;AGRICULTURE RESULTS;ALTERED HOMEOSTATIC;ALTERED MYOCELLULAR;ANATOMICAL SITE;ANTITUMOUR ADAPTIVE;APPLIED REGULATES;ARTERIOVENOUS FISTULAE;BASIC PROTEIN;BENCE JONES;BLOOD FLOW;BOLUS INJECTION;CANCER DISEASE-FREE;CANCER EXPERIENCE;CARDIOVERTER-DEFIBRILLATOR THERAPY;CASECONTROL STUDY;CELL LUNG;CELLS ENCOUNTER;CELLS EXPRESSING;CELLS TNFΑ;CLINICAL COMPETENCE;CONCENTRATE HAEMATE-P;COUNT INCREASE;CURING SMOKING","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BOLUS INJECTION;GLUCOSE TOLERANCE;INSULIN SENSITIVITY;IRON OVERLOAD;LUNG CANCER;NE DIFFERENTIATION;PLATELET COUNT;CONTROL SUBJECTS;DE NOVO;GLUCOSE DISPOSAL;IMPAIRED GLUCOSE;LIVER CIRRHOSIS;NEOPLASTIC CELLS;NORMAL GLUCOSE;NSCLC-ND SPECIMENS;PLASMA GLUCOSE;VENTRICULAR FIBRILLATIONFLUTTER;VENTRICULAR TACHYCARDIA;WILDTYPE SP;ABDOMINAL FAT;CANCER DEVELOPMENT;CARDIAC ARREST;CELL CARCINOMA;CONFIDENCE INTERVAL;CONTINUOUS INFUSION;CYTOTOXIC TLYMPHOCYTE;DEVELOPED CANCER;DISTINCT LINE;FAT IVSI;FERRITIN CONCENTRATION","6;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2",24,2,0.08,6,3,3,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,3,3,9,9,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,29,29,29,29,29,29
"AOU_VERONA",2004,25,7.88,3.36,0.297619047619048,0.72,0.32,0.16,0.28,3,10,6,5,2,0.4,0.24,0.2,0.08,19.32,0.410595462201525,0.08,0.64,NA,0.479495271954104,0.391534391534392,0.32,0.37037037037037,"ALBERTO TERZI;MASSIMO FRANCHINI;FABIO CALABRÒ;GIAN LUIGI CETTO;ANTONIO SANTO;GIUSEPPE LIPPI;GIORGIO GANDINI;DINO VENERI;ANTONELLA BASSI;CORRADO PEDRAZZANI;SERGIO MALUTA;ANTONIO GRANDINETTI;MILENA GABBANI;E DURANTE;GIUSEPPE APRILI;C. GRISO;SEEMA TOSO;CRISTINA OLIANI;MARCO GIOVANNINI;MARZIA DE GIRONCOLI","6;5;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","ALBERTO TERZI;MASSIMO FRANCHINI;PAOLO BIBAN;DINO VENERI;FABIO CALABRÒ;GIUSEPPE LIPPI;GIORGIO GANDINI;NICOLA TESSITORE;SONIA PERGHER;ALBINO POLI;ROBERTA FONTANA;LAURA MACCACARO;VALERIA BEDOGNA;M. PEGORARO;GIUSEPPE APRILI;MARZIA DE GIRONCOLI;GIAN LUIGI CETTO;ANTONIO SANTO;G. FALEZZA;CORRADO PEDRAZZANI","2.58;1.15;1;0.84;0.58;0.51;0.45;0.42;0.38;0.33;0.33;0.33;0.33;0.33;0.31;0.31;0.3;0.28;0.25;0.2","ALBERTO TERZI;MASSIMO FRANCHINI;FABIO CALABRÒ;GIAN LUIGI CETTO;ANTONIO SANTO;ANTONELLA BASSI;CORRADO PEDRAZZANI;SERGIO MALUTA;ANTONIO GRANDINETTI;MILENA GABBANI;E DURANTE;C. GRISO;SEEMA TOSO;CRISTINA OLIANI;MARCO GIOVANNINI;GIOVANNI DE MANZONI;STEFANIA ZOVATO;NICOLA TESSITORE;SONIA PERGHER;G. CARTEI","6;5;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ALBERTO TERZI;MASSIMO FRANCHINI;PAOLO BIBAN;FABIO CALABRÒ;NICOLA TESSITORE;SONIA PERGHER;ROBERTA FONTANA;LAURA MACCACARO;VALERIA BEDOGNA;M. PEGORARO;GIAN LUIGI CETTO;ANTONIO SANTO;G. FALEZZA;CORRADO PEDRAZZANI;SERGIO MALUTA;ANTONIO GRANDINETTI;MILENA GABBANI;E DURANTE;C. GRISO;SEEMA TOSO","2.58;1.15;1;0.58;0.42;0.38;0.33;0.33;0.33;0.33;0.3;0.28;0.25;0.2;0.2;0.2;0.2;0.2;0.2;0.2","ANDREA SBARBATI;ANNA BENINI;ELISA BERTAZZONI MINELLI;FRANCO DELLAGLIO;HENNO HENDRIKS;MARTA MARZOTTO;ORAZIO RUZZENENTE;ROSSANO FERRARIO;ALBERTO TERZI;MASSIMO FRANCHINI;GIUSEPPE LIPPI;FEDERICO SCHENA;GIAN CESARE GUIDI;GIORGIO BROCCO;ANTONELLA BASSI;FABIO CALABRÒ;SONIA PERGHER;DINO VENERI;A. LONARDONI;BIRGIT FEIL","150;150;150;150;150;150;150;150;118;109;100;71;71;71;45;43;40;34;31;31","ORAZIO RUZZENENTE;ALBERTO TERZI;MASSIMO FRANCHINI;FABIO CALABRÒ;SONIA PERGHER;A. LONARDONI;BIRGIT FEIL;CINZIA BONADIMAN;I SPILIMBERGO;PAOLO SCANAGATTA;NICOLA TESSITORE;ANTONIO SANTO;ANTONELLA BASSI;BRUNO BONETTI;DANIELA ALBERTI;E. NARDELLI;GIULIO FRACASSO;LAURA BERTOLASI;LUCA DE TONI;SILVIA MARCONI","150;118;109;43;40;31;31;31;31;31;30;24;21;21;21;21;21;21;21;21","MASSIMO FRANCHINI;ALBERTO TERZI;FABIO CALABRÒ;ANTONIO SANTO;GIAN LUIGI CETTO;ANTONIO GRANDINETTI;C. GRISO;CORRADO PEDRAZZANI;CRISTINA OLIANI;E DURANTE;F. SALMASO;G. CARTEI;GIOVANNI DE MANZONI;MARCO GIOVANNINI;MILENA GABBANI;NICOLA TESSITORE;SEEMA TOSO;SERGIO MALUTA;SONIA PERGHER;STEFANIA ZOVATO","6;6;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;BUSINESS;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;PHYSICS","23;7;1;1;1;1;1","INTERNAL MEDICINE;GASTROENTEROLOGY;SURGERY;IMMUNOLOGY;GENETICS;ONCOLOGY;PATHOLOGY;MICROBIOLOGY;RADIOLOGY;ANESTHESIA;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;PHYSICAL THERAPY;PSYCHIATRY;UROLOGY;BIOCHEMISTRY;CARDIOLOGY;EMERGENCY MEDICINE;FOOD SCIENCE;GENERAL SURGERY;MECHANICAL ENGINEERING;MEDICAL EMERGENCY;MOLECULAR BIOLOGY;NUCLEAR MEDICINE;OPTICS;PEDIATRICS;PHARMACOLOGY;PHYSIOLOGY","18;8;7;6;5;4;4;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CHEMOTHERAPY;ANTIGEN;GENE;LUNG CANCER;ALTERNATIVE MEDICINE;ANEMIA;ANTIBODY;BACTERIA;CONCOMITANT;EXPANDED ACCESS;HEMOCHROMATOSIS;IMMUNE SYSTEM;LUNG;POPULATION;RADIATION THERAPY;RASH;ALBUMIN;ANESTHESIOLOGY;ANEURYSM;ANGIOGRAPHY;ANTIBIOTICS;ARTERIOVENOUS FISTULA;ATHLETES;CARCINOID TUMORS;CARCINOMA;CARDIAC SURGERY;CARDIOTHORACIC SURGERY;CHEST PAIN;CHRONIC RENAL FAILURE;COAGULATION;CONFIDENCE INTERVAL;CREATININE;CUMULATIVE DOSE;DIABETES MELLITUS;DIALYSIS;DISCONTINUATION;DISEASE;DRUG;ELECTROENCEPHALOGRAPHY;EMBOLIZATION;ERYTHROPOIETIN;FERMENTATION;FERRITIN;HAPTOGLOBIN;HEMATOCRIT;HEMATOLOGICAL DISORDERS;HEMATOMA;HEMODIALYSIS;HEMOGLOBIN;HEMOLYSIS;HEMOLYTIC ANEMIA;HEMOSTASIS;HEPATITIS C;HUMAN IMMUNODEFICIENCY VIRUS (HIV);IMMUNOHISTOCHEMISTRY;INCIDENCE (GEOMETRY);INTENSIVE CARE;INTENSIVE CARE UNIT;INTERFERON;INTERVENTIONAL NEURORADIOLOGY;LEUKEMIA;MYELOID LEUKEMIA;NEUROINTENSIVE CARE;NEUROLOGY;NITRIC OXIDE;OSTEOPOROSIS;PATHOLOGICAL;PEDIATRIC INTENSIVE CARE UNIT;PHLEBOTOMY;PLATELET;PNEUMONIA;POLYCYTHEMIA VERA;PROSPECTIVE COHORT STUDY;PROTHROMBIN TIME;PULMONARY HYPERTENSION;RANDOMIZED CONTROLLED TRIAL;REGIMEN;RESECTION;RESPIRATORY SYSTEM;SEDATION;SEPSIS;SEQUENCE (BIOLOGY);SPIRAL (RAILWAY);STEM CELL;SUBCLINICAL INFECTION;THYROID;TOXICITY;TRANSPLANTATION;TYPING;UREMIA;URIC ACID;URINE;VIRUS;VITAMIN;VITAMIN D AND NEUROLOGY","5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","DOCETAXEL;EPIDERMAL GROWTH FACTOR RECEPTOR;ESOPHAGEAL CANCER;GEMCITABINE;HEREDITARY HEMOCHROMATOSIS;MUTATION;PERFORMANCE STATUS;A549 CELL;ALLELE;ANTIBIOTIC RESISTANCE;ARDS;AUTOIMMUNE HEMOLYTIC ANEMIA;BLOODLETTING;BRONCHOGENIC CARCINOMA;CEPHALOSPORIN;CHEMO-RADIOTHERAPY;CHRONIC HEPATITIS;CISPLATIN;COAGULATION DISORDER;COAGULATION TESTING;COMPLETE RESPONSE;EXON;FLUOROURACIL;GENOTYPE;GLYCATION;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HIP FRACTURE;HUMAN LEUKOCYTE ANTIGEN;IMATINIB;LACTOBACILLUS;LACTOBACILLUS CASEI;LEGIONELLA;LEGIONELLA PNEUMOPHILA;LIFE EXPECTANCY;MEAN CORPUSCULAR VOLUME;MISMATCH NEGATIVITY;NECK PAIN;NEURORADIOLOGY;PARTIAL THROMBOPLASTIN TIME;PERSISTENT PULMONARY HYPERTENSION;PNEUMONECTOMY;PROBIOTIC;SEROLOGY;SERUM FERRITIN;THYROID DISEASE;TRANSITION (GENETICS);VITAMIN D DEFICIENCY;VON WILLEBRAND FACTOR","2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GEFITINIB;AMINO ACID SUBSTITUTION;DONOR LYMPHOCYTE INFUSION;GENE MUTATION;HLA-A;HLA-B;IMATINIB MESYLATE;IMIPENEM;LEGIONNAIRES' DISEASE;MEAN CORPUSCULAR HEMOGLOBIN;MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION;MULTIFOCAL MOTOR NEUROPATHY;NON-SMALL CELL LUNG CANCER (NSCLC);PENTOSIDINE;POINT MUTATION;RIBAVIRIN;TRANSFERRIN SATURATION;VON WILLEBRAND DISEASE","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MIDDLE AGED;LUNG NEOPLASMS;MALE;;AGED;HEMOCHROMATOSIS;ADULT;LUNG;KIDNEY FAILURE, CHRONIC;ANEMIA;ERYTHROPOIETIN;HEPACIVIRUS;ITALY;PNEUMONECTOMY;THYROID DISEASES;THYROID GLAND;TIME FACTORS;ADENOCARCINOMA","17;10;10;9;9;8;8;8;7;6;5;4;4;4;4;4;4;4;4;3","ADVANCEMENTS IN LUNG CANCER RESEARCH;PREOPERATIVE CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER;REGULATION OF IRON METABOLISM AND ANEMIA;ANESTHESIA AND SEDATION MANAGEMENT;COMPLICATIONS AND TECHNIQUES IN THYROID SURGERY;DIAGNOSIS AND MANAGEMENT OF HEREDITARY HEMORRHAGIC TELANGIECTASIA;DIAGNOSIS AND MANAGEMENT OF PLEURAL DISEASES;DIAGNOSIS AND TREATMENT OF LUNG CANCER;DISEASES RELATED TO BLOOD GROUP VARIANTS;EFFICACY AND RESISTANCE IN CML TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;GUILLAIN-BARRÉ SYNDROME AND RELATED NEUROPATHIES;HEPATITIS C INFECTION AND TREATMENT;INTERACTIONS OF LEGIONELLA AND AMOEBAE IN DISEASE;MANAGEMENT OF VASCULAR ACCESS IN HEALTHCARE;NANOTECHNOLOGY IN CANCER TREATMENT AND DIAGNOSIS;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;PROBIOTICS AND PREBIOTICS;PROTEIN METABOLISM IN EXERCISE AND NUTRITION;REGULATORY T CELL DEVELOPMENT AND FUNCTION","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CONCOMITANT;EXPANDED ACCESS;HEMOCHROMATOSIS;HEREDITARY HEMOCHROMATOSIS;NEOADJUVANT CHEMOTHERAPY;NEOADJUVANT THERAPY;PERFORMANCE STATUS;TARGETED THERAPY;TREATMENT GUIDELINES;AMINO ACID SUBSTITUTION;ANTIGEN PRESENTATION;ARTERIOVENOUS FISTULAS;ATHLETE MONITORING;BLOODLETTING;BRONCHOGENIC CARCINOMA;CARCINOID TUMORS;CARDIOTHORACIC SURGERY;CEFOTETAN;CHEMO-RADIOTHERAPY;CHRONIC RENAL FAILURE","2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","ADVANCED NON-SMALL-CELL-LUNG-CANCER;CONCOMITANT WEEKLY;DOSE ESCALATING;ESOPHAGEAL CANCER;FAILING PRIOR;GEFITINIB ZD;NEOADJUVANT RADIOTHERAPY;NON-SMALL-CELL-LUNG-CANCER NSCLC;PATHOLOGICAL RESPONSE;PATIENTS PTS;PRIOR CHEMOTHERAPY;RADIOTHERAPY RT;RESPONSE RATE;WEEKLY CHEMOTHERAPY;ACID ALBUMIN;ACQUIRED VON;ALLELES HLAB;ALLOGENEIC STEM;ARTERIOVENOUS FISTULA;ATHLETES COMPARED;BK-F PMMA-BASED;BRONCHOGENIC CARCINOMA;BRONCHOPLASTIC PROCEDURES;CARCINOID TUMORS;CASEI STRAINS;CEFOTETAN-INDUCED SEVERE;CELL TRANSPLANTATION;CENTRAL CARCINOID;CHRONIC MYELOID;CLINICAL EXPERIENCE","2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","LUNG CANCER;SPIRAL DRAINS;ANTIGEN DETECTION;METACHRONOUS CANCER;RESPIRATORY SAMPLES;AUC RANGING;BRONCHOPLASTIC RESECTIONS;CHEST DRAINS;CONSECUTIVE PATIENTS;GENE MUTATIONS;HH GENE;LONG-TERM RESULTS;LT MLMIN;MEDIAN AGE;MEDIAN MONTHS;QA LT;QA MEASUREMENT;QA SURVEILLANCE;REMAINING LUNG;ROUND CROSS-SECTION;STANDARD CHEST;STANDARD DRAINS;URINE ANTIGEN;VISUAL ANALOG;ACCEPTABLE MORBIDITY;ACCESS BLOOD;ACCESS LIFE;ACCESS SURVIVAL;ACCURATE IDENTIFICATION;ACUTE SUDDEN","4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1",25,2,0.08,4.5,2,2,2,0,0,0,0,0,0,0,0,0,0,0,0,2,2,2,0,0,0,0,0,0,2,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,107,107,107,107,107,107
"AOU_VERONA",2005,36,7.30555555555556,2.13888888888889,0.467532467532468,0.555555555555556,0.277777777777778,0.25,0.222222222222222,5,14,8,9,3,0.39,0.22,0.25,0.08,68.5,1.29382651667535,0.166666666666667,0.611111111111111,NA,0.593036163822671,0.53030303030303,0.567901234567901,0.532608695652174,"MASSIMO FRANCHINI;DINO VENERI;GIUSEPPE LIPPI;GIAN LUCA SALVAGNO;GIAN CESARE GUIDI;MICHÈLE TINAZZI;CRISTINA OLIANI;MASSIMO FRANCHINI;FRANCO MANZATO;DANIELA BARANA;GIOVANNA DE MATTEIS;MAURO KRAMPERA;FELICE PASINI;FEDERICO SCHENA;ANDREA ATZEI;PIETRO SOLERO;GIORGIO GANDINI;G. MORETTO;EGBERTO REIS BARBOSA;GIAMPIETRO ZANETTE","17;6;5;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;1;1","MASSIMO FRANCHINI;DINO VENERI;GIUSEPPE LIPPI;GIAN CESARE GUIDI;GIAN LUCA SALVAGNO;MASSIMO FRANCHINI;MAURO KRAMPERA;GIORGIO GANDINI;FEDERICO SCHENA;FRANCO MANZATO;LARA SALANDINI;WILLIAM E. WHITEHEAD;ANNACHIARA GIUFFRIDA;GIUSEPPE CHIARIONI;MICHÈLE TINAZZI;G. MORETTO;ANDREA ATZEI;GIOVANNA DE MATTEIS;PIETRO SOLERO;B.M. ASSAEL","8.37;2.09;1.09;0.9;0.82;0.58;0.5;0.5;0.37;0.36;0.33;0.33;0.33;0.33;0.32;0.29;0.26;0.26;0.26;0.25","MASSIMO FRANCHINI;MICHÈLE TINAZZI;CRISTINA OLIANI;MASSIMO FRANCHINI;DANIELA BARANA;GIOVANNA DE MATTEIS;FELICE PASINI;ANDREA ATZEI;PIETRO SOLERO;GIORGIO GANDINI;G. MORETTO;MASSIMO MARANZANO;ANNA SALANI;FRANCESCO MONTINARO;RICCARDO C. BONADONNA;FRANCESCA FEDERICI;C CRISCI;MATTEO ANDREANI;ELISABETTA GUIZZARDI;CARLA BALDRIGHI","17;3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","MASSIMO FRANCHINI;MASSIMO FRANCHINI;GIORGIO GANDINI;LARA SALANDINI;ANNACHIARA GIUFFRIDA;GIUSEPPE CHIARIONI;MICHÈLE TINAZZI;G. MORETTO;ANDREA ATZEI;GIOVANNA DE MATTEIS;PIETRO SOLERO;A. BONIZZATO;ELENA NICOLIS;CRISTINA OLIANI;FELICE PASINI;MASSIMO MARANZANO;CARLA BALDRIGHI;GIOVANNA SCROCCARO;PAOLA MARINI;MARCO PIGNATTI","8.37;0.58;0.5;0.33;0.33;0.33;0.32;0.29;0.26;0.26;0.26;0.25;0.25;0.23;0.21;0.2;0.2;0.2;0.2;0.2","MASSIMO FRANCHINI;CRISTINA OLIANI;MICHÈLE TINAZZI;GIUSEPPE CHIARIONI;LARA SALANDINI;WILLIAM E. WHITEHEAD;A. DALLA LIBERA;A. TAVELLA;ANGELO ANTONINI;ANNELIES DE KLEIN;ANTONIO DE GAETANO;BEN A. OOSTRA;C. TASSORELLI;CHRISTAN F. ROHÉ;CRISTINA SAMPAIO;DAVID NICHOLL;E. FINCATI;E. MARTIGNONI;EGBERTO REIS BARBOSA;FABRIZIO ECCA","596;397;393;351;351;351;331;331;331;331;331;331;331;331;331;331;331;331;331;331","MASSIMO FRANCHINI;CRISTINA OLIANI;MICHÈLE TINAZZI;GIUSEPPE CHIARIONI;LARA SALANDINI;FABIO BENEDETTI;ERNESTO AMELIO;MADDALENA TROMBETTA;RICCARDO C. BONADONNA;DANIELA BARANA;C. DELL'ARINGA;G GANDINI;GIOVANNA DE MATTEIS;PIETRO SOLERO;C ZANUSO;ELISABETTA GUIZZARDI;FRANCESCA FEDERICI;MONICA GAIO;P PONTIERO;SILVIA ARENA","595;397;393;351;351;259;179;163;163;123;80;80;68;68;56;56;56;56;56;56","MASSIMO FRANCHINI;CRISTINA OLIANI;MICHÈLE TINAZZI;ANDREA ATZEI;DANIELA BARANA;GIORGIO GANDINI;GIOVANNA DE MATTEIS;PIETRO SOLERO;A. BONIZZATO;A. PASQUALIN;ANGELO CAZZADORI;ANNA SALANI;ANNACHIARA GIUFFRIDA;ANTONIO IANNUCCI;ANTONIO SANTO;C CRISCI;C ZANUSO;C. DELL'ARINGA;CARLA BALDRIGHI;ELENA NICOLIS","19;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;POLITICAL SCIENCE;ART;BUSINESS;COMPUTER SCIENCE;PSYCHOLOGY","33;11;3;2;2;1;1;1;1","INTERNAL MEDICINE;IMMUNOLOGY;GASTROENTEROLOGY;GENETICS;PHYSICAL THERAPY;SURGERY;PATHOLOGY;INTENSIVE CARE MEDICINE;BIOCHEMISTRY;PHARMACOLOGY;ECOLOGY;ENDOCRINOLOGY;LAW;ONCOLOGY;ORGANIC CHEMISTRY;PHYSICAL MEDICINE AND REHABILITATION;PHYSIOLOGY;PSYCHIATRY;QUANTUM MECHANICS;UROLOGY","25;10;7;7;6;6;5;4;3;3;2;2;2;2;2;2;2;2;2;2","PLATELET;GENE;CANCER;DISEASE;HELICOBACTER PYLORI;ATHLETES;ALTERNATIVE MEDICINE;ANTIBODY;CHEMOTHERAPY;COAGULATION;COAGULOPATHY;FERRITIN;HEPARIN;MYELOID LEUKEMIA;PATHOGENESIS;PATHOPHYSIOLOGY;PURPURA (GASTROPOD);RISK FACTOR;TERM (TIME);THROMBOSIS","10;7;4;4;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","VON WILLEBRAND FACTOR;THROMBOCYTOPENIC PURPURA;ALLELE;AUTOANTIBODY;GENOME;HELICOBACTER;LOCUS (GENETICS);MUTATION;VENOUS THROMBOSIS;AGE OF ONSET;ANORECTAL MANOMETRY;ANTITHROMBIN;BREAST CANCER;BRONCHOGENIC CARCINOMA;CADHERIN;CHROMOSOME;CISPLATIN;COAGULATION DISORDER;COBALT CHLORIDE;CYCLOPHOSPHAMIDE;DEFECOGRAPHY;DNA REPAIR;DYSSYNERGIA;ERYTHROPOIESIS;EXON;FACTOR V;FLUOROURACIL;FUSION GENE;GAMMA GLOBULIN;GASTRITIS;GEMCITABINE;GENE DUPLICATION;GENOTYPE;HAEMOPHILIA A;HEALTH TECHNOLOGY;HELICOBACTER PYLORI INFECTION;HEPARIN-INDUCED THROMBOCYTOPENIA;HEREDITARY HEMOCHROMATOSIS;HUMAN LEUKOCYTE ANTIGEN;HYPERHOMOCYSTEINEMIA;HYPOXIA (ENVIRONMENTAL);IMMUNE THROMBOCYTOPENIA;INSULIN RESISTANCE;INTERFERON GAMMA;MEAN CORPUSCULAR VOLUME;MECHANISM OF ACTION;MENDELIAN INHERITANCE;MESSENGER RNA;METASTASIS;NEURORADIOLOGY;NF-ΚB;NITRIC OXIDE SYNTHASE;PANCREATIC CANCER;PARKINSON'S DISEASE;PARKINSONISM;PELVIC FLOOR DYSFUNCTION;PHENOTYPE;PLACEBO;PLOIDY;PROINSULIN;PROSTATE;PROTEIN S;PROTOCOL (SCIENCE);RECOMBINANT DNA;REIMBURSEMENT;SERUM FERRITIN;THROMBIN;THROMBOPHILIA;THROMBOTIC MICROANGIOPATHY;THROMBOTIC THROMBOCYTOPENIC PURPURA;TYPE 2 DIABETES;URINATION","4;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","VON WILLEBRAND DISEASE;COMPOUND HETEROZYGOSITY;ADAMTS13;COAGULATION CASCADE;DNA MISMATCH REPAIR;EPIRUBICIN;FACTOR V LEIDEN;FLUORESCENCE IN SITU HYBRIDIZATION;FUSION PROTEIN;GENE CONVERSION;GENE MUTATION;GENETIC HETEROGENEITY;HAEMOPHILIA B;HUMAN GENOME;IMPAIRED GLUCOSE TOLERANCE;MISSENSE MUTATION;PANCREATIC HORMONE;PARKIN;PROSTATE-SPECIFIC ANTIGEN;PROTEIN S DEFICIENCY;PSEUDOGENE;RETICULOCYTE;SPIRILLACEAE","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;LUNG NEOPLASMS;ADULT;VON WILLEBRAND DISEASES;HELICOBACTER INFECTIONS;MIDDLE AGED;AGED;PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;BLOOD COAGULATION FACTORS;ADENOCARCINOMA;BLOOD COAGULATION DISORDERS, INHERITED;CARCINOMA, BRONCHOGENIC;HELICOBACTER PYLORI;HEMOPHILIA A;HEMORRHAGE;ADOLESCENT;DISSEMINATED INTRAVASCULAR COAGULATION;FACTOR VIII","30;20;16;15;14;13;12;12;10;10;8;7;7;7;7;7;7;6;6;6","PLATELET DISORDERS AND THROMBOSIS MECHANISMS;GENETIC BASIS OF NEUTROPENIA DISORDERS;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;MANAGEMENT AND TREATMENT OF HEMOPHILIA;REGULATION OF IRON METABOLISM AND ANEMIA;THROMBOSIS AND COAGULATION DISORDERS;CLINICAL MANAGEMENT OF TRACHEAL AND AIRWAY DISORDERS;DEEP BRAIN STIMULATION FOR NEUROLOGICAL DISORDERS;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;FUNCTIONAL BOWEL DISORDERS AND GASTROINTESTINAL HEALTH;GENETIC AND PHYSIOLOGICAL ADAPTATIONS TO HIGH-ALTITUDE ENVIRONMENTS;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;HEALTH ECONOMICS AND QUALITY OF LIFE ASSESSMENT;HEPARIN-INDUCED THROMBOCYTOPENIA AND THROMBOSIS;HYPEREOSINOPHILIC SYNDROME AND RELATED DISORDERS;LABORATORY MEDICINE AND TESTING PROCEDURES;MANAGEMENT OF VASCULAR MALFORMATIONS IN THE BRAIN;MICROSURGICAL RECONSTRUCTION TECHNIQUES;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;PANCREATIC CANCER RESEARCH AND TREATMENT","5;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","THROMBOCYTOPENIC PURPURA;VON WILLEBRAND DISEASE;CANCER GENOMICS;COMPOUND HETEROZYGOSITY;HELICOBACTER;PATHOGENESIS;PATHOPHYSIOLOGY;PURPURA (GASTROPOD);TREATMENT;ADAMTS13;ALU ELEMENT;ANGIOLOGY;ANORECTAL MANOMETRY;BIOFEEDBACK;BLOOD GROUPS;BRONCHOGENIC CARCINOMA;CHRISTIAN MINISTRY;CLINICAL FEATURES;CLINICAL PRACTICE;CLOTTING FACTOR","3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","THROMBOCYTOPENIC PURPURA;IDIOPATHIC THROMBOCYTOPENIC;ACUTE LEUKEMIA;HELICOBACTER PYLORI;PYLORI INFECTION;VON WILLEBRANDS;WILLEBRANDS DISEASE;ACQUIRED HEMOPHILIA;ADHESION SYSTEM;ADULT PATIENTS;ADVANCED PANCREATIC;AFTERIHELICOBACTER PYLORIIERADICATION;AL DR;ALFA PLASMAALBUMIN-FREE;ANALYZER PFA-;ANGIOGRAPHIC CORRELATIONS;ANTIINFLAMMATORY ACTION;ARTERIOVENOUS FISTULAS;ATYPICAL CARCINOIDS;AVULSION AMPUTATION;BICYCLE RIDING;BIOCHEMICAL IRON;BIOFEEDBACK BENEFITS;BLEEDING DISORDERS;BLOOD CELL;BLOOD DOPING;BRONCHOSCOPIC STUDY;CANCER HNPCC;CARCINOMA CLINICAL;CASO DEGLI","4;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PELVIC FLOOR;PUBMED SCOPUS;CROSSREF PUBMED;SLOW TRANSIT;FLOOR DYSSYNERGIA;BIOFEEDBACK TRAINING;TRANSIT CONSTIPATION;GUT TRANSIT;BALLOON DEFECATION;ANORECTAL MANOMETRY;MONTH FOLLOW-UP;SYMPTOM DIARY;ANAL CANAL;BOWEL MOVEMENTS;FLOOR MUSCLES;COLON RECTUM;INSULIN SECRETION;LENNARD-JONES JE;PARADOXICAL CONTRACTION;RECTAL PRESSURE;RECTUM -CROSSREF;TRANSIT STUDY;TYPE DIABETES;BIOFEEDBACK TREATMENT;GASTROENTEROL -CROSSREF;GENE CONVERSION;INCLUDED PATIENTS;KAMM MA;LYMPH NODE;ML WATER-FILLED","34;24;20;20;17;15;14;10;8;7;7;7;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4",36,9,0.25,6,5.33,3,7,1,1,1,0,0,0,0,0,0,1,1,1,5,3,7,0,0,0,0,0,0,5.33,3,7,0,0,0,0,0,0,1,1,1,0,0,0,3,3,3,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0.33,0,1,51.67,21,81,52,21,81
"AOU_VERONA",2006,41,7.07317073170732,2.21951219512195,0.450549450549451,0.463414634146341,0.292682926829268,0.170731707317073,0.268292682926829,4,17,5,8,8,0.41,0.12,0.2,0.2,34.34,0.672331025506213,0.195121951219512,0.707317073170732,NA,0.51828918270329,0.431159420289855,0.2875,0.485294117647059,"MASSIMO FRANCHINI;GIUSEPPE LIPPI;GIAN LUCA SALVAGNO;GIAN CESARE GUIDI;MARTINA MONTAGNANA;ROBERTA FONTANA;MARIA BONORA;ALDO LUZZANI;GIOVANNI POLI;M SOLBIATI;DINO VENERI;ARABELLA FONTANA;EMANUELE STAGNARO;C. LOSCHIAVO;ANTONELLA ZORZI;SILVIA MARCONI;VALERIO RAMAZZOTTI;LUCIA MILIGI;GIUSEPPE GORINI;ADELE SENIORI COSTANTINI","11;10;5;5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2","MASSIMO FRANCHINI;GIUSEPPE LIPPI;GIAN CESARE GUIDI;ALBA A. BRANDES;GIAN LUCA SALVAGNO;DINO VENERI;WILLIAM E. WHITEHEAD;GIUSEPPE CHIARIONI;ROBERTA FONTANA;MARTINA MONTAGNANA;FRANCESCO PRATTICÒ;PAOLA PERFETTI;ALDO LUZZANI;MARIA BONORA;M SOLBIATI;GIOVANNI POLI;MARCO LIGOZZI;GIULIANA LO CASCIO;E. STEPAN;ANTONELLA ZORZI","4.73;2.02;1.15;1;0.81;0.75;0.7;0.7;0.62;0.61;0.5;0.5;0.48;0.42;0.42;0.41;0.37;0.31;0.31;0.25","MASSIMO FRANCHINI;ROBERTA FONTANA;ALDO LUZZANI;M SOLBIATI;C. LOSCHIAVO;ANTONELLA ZORZI;ALBERTO TERZI;MARZIA DE GIRONCOLI;G GANDINI;E. STEPAN;GIUSEPPE CHIARIONI;T. SAVA;E. MORTANI;QUIRINO PIUBELLO;S. MALUTA;AGNESE LUPO;PIERSANDRO SETTE;R. MARIOTTO;A. BONETTI;FRANCESCO SALA","11;4;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","MASSIMO FRANCHINI;ALBA A. BRANDES;GIUSEPPE CHIARIONI;ROBERTA FONTANA;FRANCESCO PRATTICÒ;ALDO LUZZANI;M SOLBIATI;E. STEPAN;ANTONELLA ZORZI;CAMILLA MATTIUZZI;RACHEL STENNER;FABIO LUGOBONI;MARZIA DE GIRONCOLI;G GANDINI;ALBERTO TERZI;C. LOSCHIAVO;LUIGINO BOSCHIERO;FRANCESCA FIOR;FRANCESCO NACCHIA;PIERSANDRO SETTE","4.73;1;0.7;0.62;0.5;0.48;0.42;0.31;0.25;0.25;0.25;0.25;0.24;0.24;0.22;0.22;0.2;0.2;0.2;0.17","ANTONIO MORELLI;GABRIO BASSOTTI;GIUSEPPE CHIARIONI;VINCENZO PEZZA;WILLIAM E. WHITEHEAD;MASSIMO FRANCHINI;BRUNO BONETTI;ELENA ANGHILERI;LAURA LOVATO;SILVIA MARCONI;A ANDREINI;ANDREA SBARBATI;ANNALISA PASINI;FEDERICO MOSNA;GINO RIGOTTI;GIOVANNI PIZZOLO;MARTINA TINELLI;MAURO KRAMPERA;MIRCO GALIÈ;GIUSEPPE LIPPI","427;427;427;427;427;276;266;266;266;266;239;239;239;239;239;239;239;239;239;238","GIUSEPPE CHIARIONI;MASSIMO FRANCHINI;GINO RIGOTTI;ROBERTA FONTANA;M SOLBIATI;ALDO LUZZANI;E. STEPAN;ANTONELLA ZORZI;ALBA A. BRANDES;RACHEL STENNER;FERNANDO HENRIQUE FURLAN;G GORTENUTI;GIAN FRANCO VERALDI;GIOVANNI PUPPINI;N. CIROTA;QUIRINO PIUBELLO;STEFANIA MONTEMEZZI;ENRICO POLATI;PIERSANDRO SETTE;STEFANIA RODELLA","427;276;239;123;122;106;103;93;76;63;52;52;52;52;52;52;52;32;32;31","MASSIMO FRANCHINI;M SOLBIATI;ROBERTA FONTANA;ALBERTO TERZI;ALDO LUZZANI;ANTONELLA ZORZI;E. STEPAN;G GANDINI;GIUSEPPE CHIARIONI;MARZIA DE GIRONCOLI;A. BONETTI;A. GRANDINETTI;A. LONARDONI;A. MINICOZZI;AGNESE LUPO;ALBA A. BRANDES;ANDREA BONETTI;ANNA CHIARA GIUFFRIDA;ANNA PAOLA FRACCON;C. BOARETTI","12;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;PHILOSOPHY;ECONOMICS;PSYCHOLOGY;ENGINEERING;MATHEMATICS;POLITICAL SCIENCE;SOCIOLOGY","37;13;4;4;4;3;2;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;GASTROENTEROLOGY;IMMUNOLOGY;GENETICS;PATHOLOGY;PHYSICAL THERAPY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;MICROBIOLOGY;NEUROSCIENCE;RADIOLOGY;VIROLOGY;ASTROBIOLOGY;BIOINFORMATICS;CARDIOLOGY;CHROMATOGRAPHY;EPISTEMOLOGY;ONCOLOGY;PALEONTOLOGY;PEDIATRICS;PSYCHIATRY;QUANTUM MECHANICS","28;10;8;8;7;7;5;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","PLATELET;DISEASE;ANTIBODY;CANCER;CHEMOTHERAPY;GENE;ANTIBIOTICS;BACTERIA;CONFIDENCE INTERVAL;HEMOSTASIS;POPULATION;ADVERSE EFFECT;ALCOHOL;ANEMIA;ATHLETES;BIOFEEDBACK;CASE-CONTROL STUDY;CENTRAL NERVOUS SYSTEM;COAGULATION;CONSTIPATION;EPIDEMIOLOGY;LUNG CANCER;PELVIC FLOOR;QUALITY (PHILOSOPHY);REFRACTORY (PLANETARY SCIENCE);STAGE (STRATIGRAPHY);TOXICITY","7;6;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PHASES OF CLINICAL RESEARCH;VON WILLEBRAND FACTOR;ALCOHOL CONSUMPTION;AUTOANTIBODY;CYCLOPHOSPHAMIDE;DYSSYNERGIA;ENTEROCOCCUS FAECIUM;LAXATIVE;MYELIN;STAPHYLOCOCCUS AUREUS;TOLERABILITY;ACTIVATED CLOTTING TIME;ALCOHOL INTAKE;ALLERGEN;ANORECTAL MANOMETRY;ANTICARDIOLIPIN ANTIBODIES;ANTIPHOSPHOLIPID SYNDROME;ASTROCYTOMA;AUTOIMMUNE DISEASE;BACTEREMIA;BASAL (MEDICINE);BLOOD CULTURE;BLOOD MANAGEMENT;BONE DENSITY;BONE MINERAL;BREAST CANCER;BURKHOLDERIA;CAROTID ENDARTERECTOMY;CD20;CELLULAR DIFFERENTIATION;CELLULAR IMMUNITY;CHRONIC CONSTIPATION;CHRONIC LYMPHOCYTIC LEUKEMIA;COAGULATION DISORDER;COLORECTAL CANCER;COMPETITIVE ATHLETES;DACARBAZINE;DOCETAXEL;ENTEROCOCCUS;ERYTHROPOIESIS;EX VIVO;EXON;FACTOR VII;FLUOROURACIL;GEMCITABINE;GENOTYPE;GESTATION;HAEMOPHILIA A;HEPATITIS B VIRUS;IMMUNITY;IMMUNOSTAINING;INSULIN RESISTANCE;INTERFERON GAMMA;KIDNEY TRANSPLANTATION;LABORATORY AUTOMATION;LINEAGE (GENETIC);LUPUS ANTICOAGULANT;LYMPHOBLASTIC LEUKEMIA;LYMPHOPROLIFERATIVE DISORDERS;MEAN PLATELET VOLUME;METASTASIS;MONOCLONAL ANTIBODY;MOTOR CORTEX;MUTATION;NEURORADIOLOGY;NEUTROPENIA;PELVIC FLOOR DYSFUNCTION;PERFORMANCE STATUS;PHENOTYPE;PNEUMONECTOMY;POLYMERASE CHAIN REACTION;PROCALCITONIN;QUARTILE;REAL-TIME POLYMERASE CHAIN REACTION;REFLUX;RELIABILITY (SEMICONDUCTOR);RITUXIMAB;RNA;SAMPLING (SIGNAL PROCESSING);SEPTIC SHOCK;SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;SYSTEMIC LUPUS ERYTHEMATOSUS;T CELL;TEMOZOLOMIDE;THROMBIN;THROMBOCYTOPENIC PURPURA;THROMBOTIC THROMBOCYTOPENIC PURPURA;TISSUE FACTOR;TITER;TRADITIONAL CHINESE MEDICINE;VENOUS THROMBOSIS;WARFARIN","3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","VON WILLEBRAND DISEASE;VANCOMYCIN;VINCRISTINE;ACUTE LYMPHOCYTIC LEUKEMIA;ANAPLASTIC ASTROCYTOMA;BLOOD STASIS;BURKHOLDERIA CENOCEPACIA;BURKHOLDERIA CEPACIA COMPLEX;DUAL ENERGY;DUAL-ENERGY X-RAY ABSORPTIOMETRY;ELISPOT;ESOPHAGITIS;GENE MUTATION;GESTATIONAL DIABETES;GLUCOSE TOLERANCE TEST;MAMMOGRAPHY;MEDIASTINAL LYMPH NODE;MELTING CURVE ANALYSIS;MONOCLONAL;MULTILOCUS SEQUENCE TYPING;MYELIN BASIC PROTEIN;MYELIN-ASSOCIATED GLYCOPROTEIN;ORAL ANTICOAGULANT;OXALIPLATIN;QUANTITATIVE COMPUTED TOMOGRAPHY;RIBOSOME;SUBLINGUAL IMMUNOTHERAPY;SYBR GREEN I;THROMBIN GENERATION","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;ADULT;AGED;ENTEROCOCCUS FAECIUM;VON WILLEBRAND DISEASES;;HEMORRHAGE;ITALY;CARCINOMA, NON-SMALL-CELL LUNG;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;CROSS INFECTION;FACTOR VIII;GRAM-POSITIVE BACTERIAL INFECTIONS;LUNG NEOPLASMS;ANTIPHOSPHOLIPID SYNDROME;DEPRESSIVE DISORDER;HEMOPHILIA A","31;16;15;15;13;11;10;10;9;9;9;7;6;6;6;6;6;5;5;5","PLATELET DISORDERS AND THROMBOSIS MECHANISMS;FUNCTIONAL BOWEL DISORDERS AND GASTROINTESTINAL HEALTH;LABORATORY MEDICINE AND TESTING PROCEDURES;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS;PATHOGENESIS AND TREATMENT OF ALCOHOLIC LIVER DISEASE;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;ATRIAL FIBRILLATION;BRAIN-COMPUTER INTERFACES IN NEUROSCIENCE AND MEDICINE;CARDIAC REHABILITATION AND CARDIOVASCULAR HEALTH INTERVENTIONS;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;DIAGNOSIS AND TREATMENT OF CAROTID ARTERY DISEASE;DIAGNOSIS AND TREATMENT OF LUNG CANCER;EFFECTS OF BLOOD TRANSFUSION IN CLINICAL PRACTICE;EPIDEMIOLOGY AND MANAGEMENT OF SEPSIS AND SEPTIC SHOCK;EPIDEMIOLOGY AND TREATMENT OF BONE FRACTURES;EVOLUTION AND USAGE OF ANATOMICAL NOMENCLATURE;EXERCISE PHYSIOLOGY AND CARDIOVASCULAR HEALTH;GENETIC AND MOLECULAR STUDIES OF CONNECTIVE TISSUE DISORDERS","4;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","VON WILLEBRAND DISEASE;BIOFEEDBACK;CANCER RISK;CONSTIPATION;DYSSYNERGIA;ENTEROCOCCUS FAECIUM;LAXATIVE;LINEZOLID;REFRACTORY (PLANETARY SCIENCE);TOLERABILITY;TREATMENT;VANCOMYCIN RESISTANCE;23S RIBOSOMAL RNA;ACTIVATED CLOTTING TIME;ACUTE LYMPHOCYTIC LEUKEMIA;ADJUVANT THERAPY;ALCOHOL INTAKE;ALLERGEN-SPECIFIC IMMUNOTHERAPY;ANAPLASTIC ASTROCYTOMA;ANATOMICAL NOMENCLATURE","3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","VON WILLEBRAND;ALCOHOL CONSUMPTION;CASECONTROL STUDY;CELL LUNG;CONSECUTIVE PATIENTS;CONTINUOUS INFUSION;II STUDY;LINEZOLID RESISTANCE;LUNG CANCER;NON-SMALL CELL;PHASE II;ACQUIRED VON;ACTIVATED FACTOR;ADAPTATION QUALITY;ADJUVANT PCV;ADVANCED -FU-REFRACTORY;ADVANCED NON-SMALL;ALLERGIC RHINITIS;ALLOGRAFT RECIPIENTS;ANAPLASTIC ASTROCYTOMA;ANTI-GD-LIKE IGM;ANTIPHOSPHOLIPID SYNDROME;ATHEROSCLEROTIC PLAQUE;ATTI DEL;AUTOLOGOUS BLOOD;BLOOD DONATION;BLOOD DOPING;BONE DENSITY;BONE MARROW;BURKHOLDERIA CENOCEPACIA","3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PELVIC FLOOR;FLOOR DYSSYNERGIA;GDAY NA;GDAY CI;POLYETHYLENE GLYCOL;TRANSIT CONSTIPATION;VAN OUTRYVE;WEEK CI;ALCOHOL INTAKE;CONSTIPATION DUE;CONTRAST ENHANCEMENT;DRS VAN;NORMAL TRANSIT;PRIMARY HEMOSTASIS;PUBMED SCOPUS;SEDENTARY CONTROLS;AA TREATED;AGE EXTENT;ALLERGIC RHINITIS;ANORECTAL MANOMETRY;ATOPIC ASTHMA;BIOFEEDBACK SESSIONS;BIOFEEDBACK TRAINING;COBALT ADMINISTRATION;COBALT METABOLISM;COMPOUNDED PREPARATION;COUNSELING SESSIONS;DECREASED RISK;DELAYED TRANSIT;DYSSYNERGIA PFD","15;7;7;5;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2",41,9,0.22,4,8,3,15,1,1,1,1,1,1,0,0,0,7,7,7,1.5,1,2,0,0,0,1,1,1,8.75,3,18,0,0,0,1,1,1,4.5,1,8,0,0,0,0,0,0,1,1,1,1,1,1,2.5,1,3,2.5,1,4,0,0,0,0,0,0,91,42,136,91,42,136
"AOU_VERONA",2007,43,6.46511627906977,1.34883720930233,0.741379310344828,0.488372093023256,0.116279069767442,0.162790697674419,0.232558139534884,5,14,9,15,4,0.33,0.21,0.35,0.09,50.4,0.954891569814852,0.0465116279069767,0.651162790697674,NA,0.606677050630273,0.600340136054422,0.171428571428571,0.548148148148148,"MASSIMO FRANCHINI;GIUSEPPE LIPPI;GIAN CESARE GUIDI;GIAN LUCA SALVAGNO;MARTINA MONTAGNANA;DINO VENERI;GIOVANNI POLI;GIOVANNI GAMBARO;GIOVANNI TARGHER;GIORGIO GUAZZONI;GIUSEPPE APRILI;FILIBERTO ZATTONI;FRANCO CAPRA;DOMENICO PREZIOSO;ANDREA ATZEI;VINCENZO DE BIASE;RICCARDO BARTOLETTI;GIANPIETRO SEMENZATO;MASSIMO FRANCHINI;L CUGOLA","18;17;12;10;9;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2","MASSIMO FRANCHINI;GIUSEPPE LIPPI;GIAN CESARE GUIDI;GIOVANNI GAMBARO;GIAN LUCA SALVAGNO;MARTINA MONTAGNANA;ANDREA BARALDO;DINO VENERI;GIOVANNI TARGHER;GIOVANNI POLI;PAOLO BIBAN;ELENA BRAVI;MONICA BENEDETTI;T TRABUCCO;GIUSEPPE APRILI;ANDREA ATZEI;L CUGOLA;VINCENZO DE BIASE;FRANCO CAPRA;GIAN CARLO FALEZZA","5.83;3.77;2.53;2.25;1.81;1.62;1;0.66;0.65;0.53;0.5;0.5;0.5;0.5;0.41;0.37;0.37;0.36;0.34;0.33","MASSIMO FRANCHINI;GIUSEPPE LIPPI;DINO VENERI;GIOVANNI GAMBARO;GIUSEPPE APRILI;FILIBERTO ZATTONI;DOMENICO PREZIOSO;ANDREA ATZEI;VINCENZO DE BIASE;MASSIMO FRANCHINI;L CUGOLA;PAOLA MELOTTI;MICHÈLE TINAZZI;PAOLO BIBAN;LUCA FILIPPOZZI;ALBERTO TERZI;CRISTINA CIGANA;GIORGIO UDALI;CORRADO VASSANELLI;CRISTINA DELUCA","18;17;4;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","MASSIMO FRANCHINI;GIUSEPPE LIPPI;GIOVANNI GAMBARO;ANDREA BARALDO;DINO VENERI;PAOLO BIBAN;T TRABUCCO;GIUSEPPE APRILI;ANDREA ATZEI;L CUGOLA;VINCENZO DE BIASE;MASSIMO FRANCHINI;CORRADO VASSANELLI;ANNA LISA BONDIANI;LUISA ZANOLLA;ELENA DAL CORSO;PAOLA MELOTTI;MICHÈLE TINAZZI;LUCA FILIPPOZZI;CRISTINA CIGANA","5.83;3.77;2.25;1;0.66;0.5;0.5;0.41;0.37;0.37;0.36;0.29;0.25;0.25;0.25;0.25;0.2;0.2;0.2;0.2","ALESSANDRA MARCHI;ANDREA SBARBATI;ANNALISA PASINI;DONATELLA BENATI;G. BARONI;GINO RIGOTTI;MAURO KRAMPERA;MIRCO GALI;MASSIMO FRANCHINI;GIUSEPPE LIPPI;MARTINA MONTAGNANA;FRANCO CAPRA;BATTISTA FABIO VIOLA;GIACOMO GARIBOTTO;GIOVANNA COMO;GIOVANNI CANCARINI;GIOVANNI PARRINELLO;GIULIANO BRUNORI;ROBERTO ZUBANI;VINCENZO DE BIASE","1101;1101;1101;1101;1101;1101;1101;1101;551;496;334;266;245;245;245;245;245;245;245;245","GINO RIGOTTI;MASSIMO FRANCHINI;VINCENZO DE BIASE;MARIO MILANI;GIUSEPPE APRILI;LUCA FILIPPOZZI;ANDREA ATZEI;L CUGOLA;M. FRANCHINI;ANNA LISA BONDIANI;CORRADO VASSANELLI;ELENA DAL CORSO;GIORGIO UDALI;LUISA ZANOLLA;MARCO PIGNATTI;CRISTINA DELUCA;G. MORETTO;MICHÈLE TINAZZI;N. RIZZUTO;PAOLO BOVI","1101;551;245;74;47;37;32;32;24;17;17;17;17;17;17;13;13;13;13;13","MASSIMO FRANCHINI;ANDREA ATZEI;GIOVANNI GAMBARO;L CUGOLA;VINCENZO DE BIASE;ANNA LISA BONDIANI;B. ASSAEL;CORRADO VASSANELLI;CRISTINA CIGANA;CRISTINA DELUCA;DINO VENERI;DOMENICO PREZIOSO;ELENA DAL CORSO;ELENA NICOLIS;FILIBERTO ZATTONI;G. MORETTO;GINO RIGOTTI;GIORGIO UDALI;GIUSEPPE APRILI;GIUSEPPE LIPPI","20;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PHYSICS;PSYCHOLOGY;ENGINEERING;BUSINESS;CHEMISTRY;COMPUTER SCIENCE;POLITICAL SCIENCE;MATERIALS SCIENCE;MATHEMATICS;PHILOSOPHY;SOCIOLOGY","41;8;5;5;4;3;3;3;2;1;1;1;1","INTERNAL MEDICINE;IMMUNOLOGY;SURGERY;PATHOLOGY;ENDOCRINOLOGY;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;GENETICS;INTENSIVE CARE MEDICINE;ONCOLOGY;PSYCHIATRY;ANATOMY;ANESTHESIA;ASTROBIOLOGY;BIOCHEMISTRY;CARDIOLOGY;ECOLOGY;LAW;MARKETING;MECHANICAL ENGINEERING;NURSING;OPTICS;PEDIATRICS;PHARMACOLOGY;PHYSICAL THERAPY","34;9;8;7;6;6;5;5;5;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PLATELET;COAGULATION;CANCER;COAGULOPATHY;POPULATION;ANTIBODY;DISEASE;INFLAMMATION;PROTHROMBIN TIME;RANDOMIZED CONTROLLED TRIAL;REFERENCE RANGE;ALTERNATIVE MEDICINE;ATHLETES;CHEMOTHERAPY;CLINICAL TRIAL;COHORT;COMPETITION (BIOLOGY);D-DIMER;DESMOPRESSIN;FIBRINOGEN;FLOW CYTOMETRY;GENE;HEMATOLOGY;HEMOGLOBIN;HEMOSTASIS;LYMPHOMA;MYOCARDIAL INFARCTION;NEPHROLOGY;PERIPHERAL;PREGNANCY;QUALITY OF LIFE (HEALTHCARE);RECEPTOR;REFRACTORY (PLANETARY SCIENCE);RENAL FUNCTION","7;6;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","VON WILLEBRAND FACTOR;PARTIAL THROMBOPLASTIN TIME;C-REACTIVE PROTEIN;PROSTATE CANCER;TISSUE FACTOR;ACTIVATOR (GENETICS);ACUTE-PHASE PROTEIN;ADENOCARCINOMA;ANAPLASTIC LARGE-CELL LYMPHOMA;ANDROGEN;AUTOANTIBODY;AZITHROMYCIN;B CELL;BLOCKADE;BREAST CANCER;BRIEF PSYCHIATRIC RATING SCALE;CD19;CD5;CEREBELLAR ATAXIA;CEREBELLAR HEMISPHERE;COAGULATION TESTING;COMPETITIVE ATHLETES;CONTRAINDICATION;CORE CURRICULUM;COST–UTILITY ANALYSIS;CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;ELITE ATHLETES;FETUS;GENE EXPRESSION;GENOTYPE;GESTATION;IMMUNOASSAY;INTERIM ANALYSIS;LARGE-CELL LYMPHOMA;LIPOPROTEIN;MAJOR BLEEDING;MEAN CORPUSCULAR VOLUME;MESSENGER RNA;MULTIPLE DRUG RESISTANCE;OXYGEN SATURATION;OXYGEN TENSION;OXYGEN TRANSPORT;OXYGEN–HAEMOGLOBIN DISSOCIATION CURVE;PLATELET AGGREGATION;POST PARTUM;POSTERIOR INFERIOR CEREBELLAR ARTERY;PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA;PURE RED CELL APLASIA;QUALITY-ADJUSTED LIFE YEAR;RANDOMIZATION;RITUXIMAB;SERUM FERRITIN;SERUM IRON;STEM-CELL THERAPY;STROMAL VASCULAR FRACTION;SYSTEMIC INFLAMMATION;THROMBOCYTOPENIC PURPURA;THROMBOPLASTIN;TOLERABILITY;TRANSPORTER;TROPONIN;TROPONIN T","6;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","VON WILLEBRAND DISEASE;ANDROGEN RECEPTOR;FACTOR VIIA;THROMBIN TIME;ADJUVANT CHEMOTHERAPY;ANTIANDROGEN;ATP-BINDING CASSETTE TRANSPORTER;BLEEDING TIME;CYPROTERONE ACETATE;HAPLOTYPE;HORMONAL THERAPY;LARGE CELL;LIPOPROTEIN(A);REPORTER GENE;RISTOCETIN;TRANSFERRIN SATURATION;TROPONIN COMPLEX;VENTRICULOMEGALY","4;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;ADULT;MALE;AGED;FEMALE;MIDDLE AGED;;VON WILLEBRAND FACTOR;ITALY;VON WILLEBRAND DISEASES;BIOMARKERS;KIDNEY FAILURE, CHRONIC;AGED, 80 AND OVER;BICYCLING;FACTOR VIII;ANDROGEN ANTAGONISTS;ANTI-BACTERIAL AGENTS;BLOOD COAGULATION;CHILD;INFLAMMATION","33;17;17;14;14;11;10;9;8;8;7;7;6;6;6;5;5;5;5;5","PLATELET DISORDERS AND THROMBOSIS MECHANISMS;LABORATORY MEDICINE AND TESTING PROCEDURES;MANAGEMENT AND TREATMENT OF HEMOPHILIA;THROMBOSIS AND COAGULATION DISORDERS;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ANALYSIS OF TRAFFIC SAFETY AND DRIVER BEHAVIOR;AUTISM SPECTRUM DISORDERS;BIOETHICS AND PATIENT RIGHTS;CHOLESTEROL-LOWERING TREATMENT;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;DEVELOPMENT AND DISORDERS OF FETAL BRAIN;DIAGNOSIS AND MANAGEMENT OF ADRENAL INSUFFICIENCY;DIAGNOSIS AND TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA;DIFFUSION MAGNETIC RESONANCE IMAGING;DISEASES RELATED TO BLOOD GROUP VARIANTS;ETHICAL AND SOCIETAL IMPLICATIONS OF DOPING IN SPORT;EVOLUTION OF CHILD HEALTH SERVICES IN EUROPE;EXERCISE PHYSIOLOGY AND CARDIOVASCULAR HEALTH;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GLOBAL IMPACT OF MEDICAL TOURISM INDUSTRY","6;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","VON WILLEBRAND FACTOR;VON WILLEBRAND DISEASE;PROTHROMBIN TIME;REFERENCE RANGE;BICALUTAMIDE;CARDIOPULMONARY EXERCISE TESTING;COAGULATION;D-DIMER;DESMOPRESSIN;EXERCISE CAPACITY;FACTOR VIIA;HEMATOLOGY;HORMONE THERAPY;NEPHROLOGY;POSTPARTUM HEMORRHAGE;RECOMBINANT FACTOR VIIA;REFRACTORY (PLANETARY SCIENCE);THROMBIN TIME;ADJUVANT CHEMOTHERAPY;ALTERNATIVE MEDICINE","6;5;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1","VON WILLEBRAND;WILLEBRAND FACTOR;HEALTH CARE;PROSPECTIVE RANDOMIZED;ABO BLOOD;ACTIVATED FACTOR;ACTIVATED PARTIAL;ADIPOSE-DERIVED ADULT;ADULT POPULATION;ADULT STEM;ADVANCE DIRECTIVES;ANALYTICAL PERFORMANCES;ANTI-FACTOR VIII;ANTIANDROGEN BLOCKADE;ANTIGEN VON;ANTIHEMOPHILIC FACTORVON;ARM FLAP;ASSOCIATION STUDY;ATP BINDING;AUTOMATED IMMUNOASSAY;B-A PERIPHERAL;BCELL LYMPHOMAS;BIDIRECTIONAL INTERACTION;BINDING CASSETTE;BIOCHEMICAL CORRELATES;BLOCKADE ITALIAN;BLOOD LYMPHOCYTES;BLOOD-GAS STATUS;BRAIN INFARCTS;CANCER FINAL","6;6;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","LIMB ATAXIA;ACUTE P-PC;ADULT AGE;ULTRASOUND SCAN;UNILATERAL VENTRICULOMEGALY;VWD PATIENTS;ABO BLOOD;CEREBELLAR INFARCTS;CORTICAL DEVELOPMENT;DEVELOPMENTAL OUTCOME;DORSOLATERAL MEDULLA;INFERIOR CEREBELLAR;ISOLATED FINDING;P-PC TERRITORY;PARIETO-OCCIPITAL FISSURE;PATIENT SATISFACTION;PERIPHERAL NERVES;PICA TERRITORY;POSTERIOR INFERIOR;TINELS SIGN;VON WILLEBRAND;VWFFVIII CONCENTRATES;WILLEBRAND FACTOR;ABSTRACT WELLESTABLISHED;ABSTRACTIN CONSECUTIVE;ACCURATE PARENTAL;ACUTE CEREBELLAR;ACUTE STROKES;ADJACENT FINGERS;ADVANCED SETTING","6;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1",43,9,0.21,6.48,27,5,78,1,1,1,0,0,0,1,1,1,3,3,3,75,75,75,0,0,0,1,1,1,27.75,5,78,0,0,0,1,1,1,4.75,1,10,1,1,1,1,1,1,1,1,1,1.5,1,2,3.5,1,8,1,1,1,0.75,0,1,0,0,0,179.75,56,399,180.5,57,400
"AOU_VERONA",2008,19,8,3.10526315789474,0.322033898305085,0.526315789473684,0.473684210526316,0.157894736842105,0.31578947368421,1,11,2,3,3,0.58,0.11,0.16,0.16,29.53,0.538095665762575,0.210526315789474,0.68421052631579,NA,0.280987116717994,0.133333333333333,0.0972222222222223,0,"FEDERICO ZAGLIA;PAOLO BIBAN;MASSIMO FRANCHINI;ALBERTO TERZI;ROMOLO M. DORIZZI;R. KONCAN;MASSIMO SOFFIATI;GIAN LUCA SALVAGNO;GIAN CESARE GUIDI;GIUSEPPE LIPPI;MONICA BENEDETTI;GIULIANA LO CASCIO;F. FAVARI;EMANUELA VATTEMI;PAOLO LIONETTI;B. PAPADATOU;RAM WEISS;ALDO LUZZANI;RICCARDO C. BONADONNA;G. MASTELLA","2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","ANDREA BARALDO;R. KONCAN;GIULIANA LO CASCIO;MASSIMO FRANCHINI;ALBERTO TERZI;GIAN LUCA SALVAGNO;GIAN CESARE GUIDI;GIUSEPPE LIPPI;GIUSEPPE CORNAGLIA;ROMOLO M. DORIZZI;FEDERICO ZAGLIA;PAOLO BIBAN;MASSIMO SOFFIATI;MONICA BENEDETTI;RAM WEISS;ALDO LUZZANI;RICCARDO C. BONADONNA;ENRICO POLATI;SONIA CAPRIO;LUCA LUZZI","1;0.5;0.5;0.37;0.37;0.37;0.37;0.37;0.33;0.31;0.27;0.27;0.27;0.27;0.2;0.2;0.2;0.2;0.2;0.2","FEDERICO ZAGLIA;PAOLO BIBAN;MASSIMO FRANCHINI;ALBERTO TERZI;ROMOLO M. DORIZZI;MASSIMO SOFFIATI;MONICA BENEDETTI;GIULIANA LO CASCIO;F. FAVARI;RAM WEISS;ALDO LUZZANI;RICCARDO C. BONADONNA;G. MASTELLA;ANTONIO BONALDI;MARCO BOLOGNANI;P. IUZZOLINO;PAOLA MELOTTI;PAOLA BONETTI;ENRICO POLATI;SONIA CAPRIO","2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","ANDREA BARALDO;GIULIANA LO CASCIO;MASSIMO FRANCHINI;ALBERTO TERZI;ROMOLO M. DORIZZI;FEDERICO ZAGLIA;PAOLO BIBAN;MASSIMO SOFFIATI;MONICA BENEDETTI;RAM WEISS;ALDO LUZZANI;RICCARDO C. BONADONNA;ENRICO POLATI;SONIA CAPRIO;MASSIMILIANO BRUTI;FRANCESCO CALABRÒ;MADDALENA TROMBETTA;MAURIZIO GOVERNA;STEFANO ISCHIA;MONICA PASQUALINI","1;0.5;0.37;0.37;0.31;0.27;0.27;0.27;0.27;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2","ANNA M. G. CALI;MADDALENA TROMBETTA;RAM WEISS;RICCARDO C. BONADONNA;SONIA CAPRIO;A. BARABINO;A. LAMBERTINI;ALESSANDRO VENTURA;ANGELO CAMPANOZZI;ANGELO RAVELLI;ANNAMARIA STAIANO;B. PAPADATOU;BERNI R. CANANI;C. BARBERA;CARLO CATASSI;CLAUDIO ROMANO;CONCETTA SFERLAZZAS;D. KNAFELZ;F. BALLI;F. BASCIETTO","123;123;123;123;123;121;121;121;121;121;121;121;121;121;121;121;121;121;121;121","ANNA M. G. CALI;MADDALENA TROMBETTA;RAM WEISS;RICCARDO C. BONADONNA;SONIA CAPRIO;G. MASTELLA;GINO RIGOTTI;MARCO PIGNATTI;MASSIMILIANO BRUTI;MAURIZIO GOVERNA;MONICA PASQUALINI;MASSIMO FRANCHINI;FEDERICO ZAGLIA;MASSIMO SOFFIATI;MONICA BENEDETTI;PAOLO BIBAN;PIERANTONIO SANTUZ;ROMOLO M. DORIZZI;ALDO LUZZANI;ENRICO POLATI","123;123;123;123;123;121;89;89;89;89;89;67;34;34;34;34;34;34;32;32","FEDERICO ZAGLIA;FRANCESCO CALABRÒ;GIULIANA LO CASCIO;MASSIMO FRANCHINI;MASSIMO SOFFIATI;MONICA BENEDETTI;PAOLO BIBAN;ALBERTO TERZI;ALDO LUZZANI;ANDREA BARALDO;ANNA FERRARI;ANNA M. G. CALI;ANNA MARIA MUSSO;ANNALISA ROSSINI;B.M. ASSAEL;CLAUDIO GHIMENTON;CRISTIANO BENATO;ENRICO POLATI;FRANCESCO PRATTICÒ;G. MASTELLA","2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;POLITICAL SCIENCE;COMPUTER SCIENCE;ENGINEERING;GEOGRAPHY;PHILOSOPHY;PSYCHOLOGY;SOCIOLOGY","18;6;2;2;1;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;GENETICS;MICROBIOLOGY;BIOCHEMISTRY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;LAW;PATHOLOGY;RADIOLOGY;ANATOMY;BIOMEDICAL ENGINEERING;BIOTECHNOLOGY;CHROMATOGRAPHY;DEMOGRAPHY;DEVELOPMENTAL PSYCHOLOGY;EMERGENCY MEDICINE;FAMILY MEDICINE;GASTROENTEROLOGY;IMMUNOLOGY;LINGUISTICS;MARINE ENGINEERING;MEDICAL EDUCATION;MEDICAL EMERGENCY;METEOROLOGY;ONCOLOGY;OPERATING SYSTEM;ORGANIC CHEMISTRY;PEDIATRICS;PHARMACOLOGY;PHYSICAL THERAPY;PSYCHIATRY;SOCIAL SCIENCE","13;6;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANTIBIOTICS;CANCER;CYSTIC FIBROSIS;MAGNETIC RESONANCE IMAGING;PREGNANCY;ABDOMINAL PAIN;ANTIMICROBIAL;ATHLETES;BACTERIA;CELIAC PLEXUS;CENTRIFUGATION;CERTIFICATION;CERVICAL SPINE;CHEMOTHERAPY;COAGULATION;CONFIDENCE INTERVAL;CYTOKINE;DISEASE;EMERGENCY DEPARTMENT;ENZYME;EXACERBATION;FIBRINOGEN;FIBROSIS;GADOLINIUM;HERNIA;IN VITRO;IN VIVO;INSULIN;LATISSIMUS DORSI MUSCLE;LUNG;MATURITY (PSYCHOLOGICAL);NEPHROLOGY;ODDS RATIO;OXIDATIVE STRESS;PANCREAS;PATHOGENESIS;PERFORATOR FLAPS;PINEALOMA;POPULATION;PREPAREDNESS;PROPELLER;PROTHROMBIN TIME;QUESTIONNAIRE;READING (PROCESS);REGISTER (SOCIOLINGUISTICS);RENAL FUNCTION;RESUSCITATION;SARCOMA;SEPSIS;SOFT TISSUE;STRAIN (INJURY);TENDON;TRAINING (METEOROLOGY);WORKLOAD","3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANTIBIOTIC RESISTANCE;AZITHROMYCIN;BASAL (MEDICINE);CANCER PAIN;CARDIOPULMONARY RESUSCITATION;CIPROFLOXACIN;COAGULATION TESTING;CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;DIAGNOSTIC ODDS RATIO;ETEST;FETUS;GENTAMICIN;GERMINOMA;GESTATIONAL AGE;GLUTATHIONE;INFLAMMATORY BOWEL DISEASE;INSULIN RESISTANCE;LIKELIHOOD RATIOS IN DIAGNOSTIC TESTING;NEONATAL SEPSIS;NEPHROGENIC SYSTEMIC FIBROSIS;PANCREATIC CANCER;PARTIAL THROMBOPLASTIN TIME;PROCALCITONIN;PSEUDOMONAS AERUGINOSA;RESPIRATORY DISEASE;SYRINGOMYELIA;TESTICULAR CANCER;ULCERATIVE COLITIS","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ADVANCED LIFE SUPPORT;ANTIBIOTIC STEWARDSHIP;BRONCHUS;CEFTAZIDIME;CHIARI I MALFORMATION;CHIARI MALFORMATION;CHORIOAMNIONITIS;CONGENITAL DIAPHRAGMATIC HERNIA;GLUTATHIONE S-TRANSFERASE;IMIPENEM;IMPAIRED GLUCOSE TOLERANCE;INFLAMMATORY BOWEL DISEASES;MEROPENEM;PIPERACILLIN;RUPTURE OF MEMBRANES;SYRINX (MEDICINE);THROMBIN TIME","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;ITALY;KIDNEY DISEASES;FEMALE;ARNOLD-CHIARI MALFORMATION;MALE;SYRINGOMYELIA;ANTI-BACTERIAL AGENTS;DYSPNEA;EPITHELIAL CELLS;HERNIA, DIAPHRAGMATIC;INFANT, NEWBORN, DISEASES;RECONSTRUCTIVE SURGICAL PROCEDURES;RESPIRATORY MUCOSA;SEPSIS;;ADOLESCENT;ADULT;ANESTHETICS, LOCAL;BACTERIAL INFECTIONS","16;10;7;6;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3","CHALLENGES IN PAIN MANAGEMENT AND TREATMENT;CHRONIC KIDNEY DISEASE AND ITS IMPLICATIONS;CLINICAL MANAGEMENT OF TRACHEAL AND AIRWAY DISORDERS;DIAGNOSIS AND MANAGEMENT OF CONGENITAL DIAPHRAGMATIC HERNIA;EPIDEMIOLOGY AND MANAGEMENT OF NEONATAL SEPSIS;EPIDEMIOLOGY AND PATHOGENESIS OF RESPIRATORY VIRAL INFECTIONS;ETHICAL AND MEDICAL ASPECTS OF ORGAN DONATION;EXPANDING ACCESS TO RADIOTHERAPY GLOBALLY;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;GLOBAL BURDEN OF ANTIMICROBIAL RESISTANCE;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;IMPACT OF PARENTING STRESS ON CAREGIVERS AND FAMILIES;LABORATORY MEDICINE AND TESTING PROCEDURES;LANTHANIDE LUMINESCENCE IN BIOMEDICAL APPLICATIONS;METABOLIC SYNDROME AND CARDIOVASCULAR DISEASE;MICROSURGICAL RECONSTRUCTION TECHNIQUES;SPINA BIFIDA;TESTICULAR GERM CELL TUMORS AND TREATMENT;THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ADVANCED LIFE SUPPORT;ANTIBIOTIC PHARMACOKINETICS;ANTIBIOTIC STEWARDSHIP;ANTIMICROBIAL RESISTANCE;ANTIMICROBIAL RESISTANCE GENES;ANTIMICROBIAL STEWARDSHIP;AZTREONAM;BASAL (MEDICINE);BOCHDALEK HERNIA;CANCER PAIN;CELIAC PLEXUS;CHEMOTHERAPY;CHIARI I MALFORMATION;CHIARI MALFORMATION;CHORIOAMNIONITIS;COAGULATION TESTING;DIABETES;DIAGNOSTIC ODDS RATIO;EARLY-ONSET SEPSIS;ENDOBRONCHIAL STENTS","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ABNORMALITIES UNDERLYING;ABS INTERNATIONAL;ABS MATURITY;AERUGINOSAI ISOLATES;AIRWAY CELLS;ANTIBIOTIC MANAGEMENT;ANTIMICROBIAL SUSCEPTIBILITY;BOCHDALEKS HERNIA-CONTAINING;BOWEL DISEASE;BRONCHIAL INSUFFICIENCY;BRONCHIAL STUMP;CANCER PAIN;CELIAC PLEXUS;CF PATIENTS;CHILDREN FAMILY;COAGULATION TESTING;CYSTIC FIBROSIS;DORSI MUSCLE;EARLY-ONSET NEONATAL;EMERGENCY DEPARTMENT;EMERGENCY PREPAREDNESS;ENDURANCE ATHLETES;FAMILY EDUCATION;FIBROSIS AIRWAY;FILTRATION RATE;GLOMERULAR FILTRATION;GLUTATHIONE S-TRANSFERASES;GRAM-NEGATIVE MULTIRESISTANT;GRANULOCYTIC SARCOMA;HERNIA-CONTAINING COLON","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","INSULIN SECRETION;GLUCOSE SENSITIVITY;IFG IGT;INSULIN RESISTANCE;INSULIN SENSITIVITY;PERIPHERAL INSULIN;ABDOMINAL PAIN;BASAL HEPATIC;COUGH SCORING;FIRST-PHASE INSULIN;FIRST-PHASE SECRETION;GLUCOSE TOLERANCE;IBD INCIDENCE;ISOLATED IMPAIRED;LATISSIMUS DORSI;MAJOR ANTIBIOTICS;NGT GLUCOSE;OBESE ADOLESCENTS;SEVERE CF;SYNERGIC EFFECT;ABNORMALITIES UNDERLYING;ABSORPTIOMETRY AGE;ABSTRACT OBJECTIVE;ADDITIONAL DEFECT;ADDITIONAL EFFECT;ADOLESCENTS PERCENT;AGAR PLATE;AGE GENDER;AGE PATIENTS;ALLOWED RECOVERING","5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1",19,2,0.11,3,2.5,1,4,0,0,0,0,0,0,0,0,0,0,0,0,2.5,1,4,0,0,0,0,0,0,2.5,1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,43,26,60,43,26,60
"AOU_VERONA",2009,28,11.8214285714286,2.64285714285714,0.378378378378378,0.357142857142857,0.321428571428571,0.428571428571429,0.214285714285714,2,11,9,5,2,0.39,0.32,0.18,0.07,68.71,1.48548231850539,0.25,0.714285714285714,NA,0.368214129358471,0.161538461538461,0.214285714285714,0.119047619047619,"BEATRICE CARUSO;GIUSEPPE MORETTO;ANTONIETTA MELCHIORRE;LUISA BOMMARITO;A. ARENA;PIER PAOLO BENETOLLO;A. MOSCHELLA;RICCARDO ASERO;GIAMPIERO GIROLOMONI;MARIANGIOLA CRIVELLARO;PAOLO BIBAN;LUIGINO BOSCHIERO;MARCO CARLI;G. ROSSI;GIUSEPPINA MANZOTTI;CLAUDIO GHIMENTON;MASSIMO FRANCHINI;MARIA GRAZIA PASSARIN;SARAH OTTAVIANI;GIANENRICO SENNA","3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PAOLO BIBAN;L. BOSCHIERO;LUIGINO BOSCHIERO;FRANCESCO NACCHIA;FRANCESCA FIOR;GIAN CESARE GUIDI;GIUSEPPE LIPPI;MASSIMO FRANCHINI;GIUSEPPE MORETTO;PIER PAOLO BENETOLLO;PAOLO BOVI;JULIAN ZIELENSKI;ANTONELLA BASSI;QUIRINO PIUBELLO;ZENO FRANCHINI;MARTINA MONTAGNANA;LUCA FILIPPOZZI;GIOVANNI POLI;CLAUDIO GHIMENTON;MARIA GRAZIA PASSARIN","1.11;1;0.4;0.4;0.33;0.33;0.33;0.31;0.31;0.27;0.23;0.2;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17","BEATRICE CARUSO;GIUSEPPE MORETTO;PIER PAOLO BENETOLLO;GIAMPIERO GIROLOMONI;MARIANGIOLA CRIVELLARO;PAOLO BIBAN;LUIGINO BOSCHIERO;CLAUDIO GHIMENTON;MARIA GRAZIA PASSARIN;SARAH OTTAVIANI;GIANENRICO SENNA;FRANCESCO NACCHIA;PAOLO BOVI;ALDO SCARPA;QUIRINO PIUBELLO;NADIA BRUTTI;EMANUELE ZIVELONGHI;VINCENZO RAGAZZO;FABRIZIO COMPER;TEODORO SAVA","3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","PAOLO BIBAN;L. BOSCHIERO;LUIGINO BOSCHIERO;FRANCESCO NACCHIA;FRANCESCA FIOR;GIUSEPPE MORETTO;PIER PAOLO BENETOLLO;PAOLO BOVI;QUIRINO PIUBELLO;LUCA FILIPPOZZI;CLAUDIO GHIMENTON;MARIA GRAZIA PASSARIN;SARAH OTTAVIANI;LUCA GIOBELLI;CARLO CASTELLANI;BEATRICE CARUSO;EMANUELE ZIVELONGHI;VINCENZO RAGAZZO;A. RIZZOTTI;ISABELLA CROCCO","1.11;1;0.4;0.4;0.33;0.31;0.27;0.23;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.16;0.14;0.14;0.14;0.14","GIAMPIERO GIROLOMONI;LUIGI NALDI;AD ORMEROD;ALAN MENTER;ALESSANDRO GIUNTA;ALEXANDER NAST;BERNADETTE EBERLEIN;BERTHOLD RZANY;C. LEONARDI;C.E.M. GRIFFITHS;CATHERINE SMITH;DELANO PATHIRANA;GR BURMESTER;HANS‐DIETER ORZECHOWSKI;HB THIO;HELEN L. RICHARDS;HERBERT HÖNIGSMANN;I. KOPP;JD BOS;JOHN L. FERGUSON","683;683;670;670;670;670;670;670;670;670;670;670;670;670;670;670;670;670;670;670","GIAMPIERO GIROLOMONI;CARLO CASTELLANI;MARCO CIPOLLI;GIANENRICO SENNA;MARIANGIOLA CRIVELLARO;BEATRICE CARUSO;TEODORO SAVA;QUIRINO PIUBELLO;LUCIANO CRISTOFORI;MARIA DI CICCO;MASSIMO PIFFERI;P MACCHIA;VINCENZO RAGAZZO;ROBERTO BELLUCCI;A. RIZZOTTI;EMANUELE ZIVELONGHI;STEFANIA GUARIGLIA;ISABELLA CROCCO;ALDO SCARPA;DAVIDE ANTONELLO","670;287;286;282;282;143;91;81;74;63;63;63;63;62;56;56;56;55;51;51","GIUSEPPE MORETTO;CARLO CASTELLANI;FRANCESCO NACCHIA;GIANENRICO SENNA;LUIGINO BOSCHIERO;MARIANGIOLA CRIVELLARO;PAOLO BOVI;PIER PAOLO BENETOLLO;SARAH OTTAVIANI;A. RIZZOTTI;A.P. RIVIERA;ALDO SCARPA;ALESSANDRA MAGALINI;ALESSANDRO DI MATTEO;ANNA MARIA MUSSO;ANNAMARIA MUSSO;ANTONIO BENITO PORCARO;BEATRICE CARUSO;BÁRBARA MASOTTO;CIRO D’ORAZIO","3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;CHEMISTRY;ENGINEERING;MATHEMATICS;PSYCHOLOGY;SOCIOLOGY","27;7;4;2;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;PSYCHIATRY;CARDIOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;INTENSIVE CARE MEDICINE;OPTICS;RADIOLOGY;EMERGENCY MEDICINE;GENETICS;ONCOLOGY;PATHOLOGY;PEDIATRICS;UROLOGY;ANESTHESIA;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;MEDICAL EMERGENCY;OPTOMETRY;PALEONTOLOGY","21;10;5;4;4;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2","CANCER;DISEASE;CONFIDENCE INTERVAL;CYSTIC FIBROSIS;INCIDENCE (GEOMETRY);TRANSPLANTATION;ADVERSE EFFECT;ALLERGY;ANTIBODY;CENTRAL NERVOUS SYSTEM;CHEMOTHERAPY;GENE;MYOCARDIAL INFARCTION;NEUROLOGY;ODDS RATIO;RANDOMIZED CONTROLLED TRIAL;AIR POLLUTION;ALTERNATIVE MEDICINE;AMNESIA;ATAXIA;ATORVASTATIN;ATYPIA;BIOPSY;BLINDNESS;BLOOD DONOR;BLOOD TRANSFUSION;CARCINOMA;CARDIAC SURGERY;CAROTENOID;CELL;CHOLESTEROL;CIRRHOSIS;COHORT;COHORT STUDY;COMPLICATION;COMPUTED TOMOGRAPHY;CONE (FORMAL LANGUAGES);CONFUSION;CONTEXT (ARCHAEOLOGY);CRANIOTOMY;DELIVERY SYSTEM;DIALYSIS;DIPLOPIA;DYSTONIA;EMERGENCY DEPARTMENT;EYE DISEASE;GLASGOW COMA SCALE;HEAD INJURY;HEARING IMPAIRED;HEMODIALYSIS;IMMUNE SYSTEM;IMMUNOHISTOCHEMISTRY;INSULIN;INTRAOCULAR LENS;ISCHEMIA;KIDNEY DISEASE;LENS (GEOLOGY);LESION;LIVER DISEASE;LUNG;MALABSORPTION;MODALITIES;MULTIVARIATE ANALYSIS;MULTIVARIATE STATISTICS;NEPHROLOGY;NEUROSURGERY;OBESITY;OCCIPITAL LOBE;OCCLUSION;OSTEOPOROSIS;OUTPATIENT CLINIC;OXIDATIVE STRESS;PANCREAS;PLATELET;POISON CONTROL;POSITRON EMISSION TOMOGRAPHY;PREGNANCY;PRINCIPAL COMPONENT ANALYSIS;PSORIASIS;QUALITY OF LIFE (HEALTHCARE);RADIATION DOSE;RAPID RESPONSE TEAM;REGIMEN;ROSUVASTATIN;SHRIMP;SIGNAL TRANSDUCTION;SUBARACHNOID HEMORRHAGE;TEST (BIOLOGY);TESTOSTERONE (PATCH);TIGHT JUNCTION;TRAUMATIC BRAIN INJURY;TREATMENT MODALITY","4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;FOOD ALLERGY;IMMUNOGLOBULIN E;KIDNEY TRANSPLANTATION;NEURORADIOLOGY;PROSTATE;PROSTATE CANCER;ACUTE CORONARY SYNDROME;ALLERGEN;ANAPHYLAXIS;ANOSOGNOSIA;APHERESIS;BASAL (MEDICINE);BASAL GANGLIA;BRONCHIECTASIS;CADHERIN;CHEMOTHERAPY REGIMEN;CHOREA;CHOREOATHETOSIS;CISPLATIN;CLAUDIN;COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS;CONE BEAM COMPUTED TOMOGRAPHY;CONE BEAM CT;CORTICAL BLINDNESS;CUMULATIVE INCIDENCE;CYTARABINE;END STAGE RENAL DISEASE;EXOCRINE PANCREATIC INSUFFICIENCY;EZETIMIBE;GAIT ATAXIA;GEMCITABINE;GENOTYPE;GESTATIONAL AGE;GLASGOW OUTCOME SCALE;HAZARD RATIO;HIP FRACTURE;IMMUNOTHERAPY;INJURY PREVENTION;LDL CHOLESTEROL;LEPTOMENINGES;LUTEIN;MAJOR HISTOCOMPATIBILITY COMPLEX;MIDDLE CEREBRAL ARTERY;MULTICENTER STUDY;MUTATION;NEUTROPENIA;ORGAN TRANSPLANTATION;PARKINSON'S DISEASE;PERFORMANCE STATUS;PLACEBO;PORTAL HYPERTENSION;PRAVASTATIN;RATE RATIO;REFRACTIVE ERROR;TEMOZOLOMIDE;THROMBOLYSIS;TOLERABILITY;TRANSFUSION REACTION;VINBLASTINE;WAITING LIST;WEIGHT LOSS;WNT SIGNALING PATHWAY","2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ADHERENS JUNCTION;BETA-CATENIN;CARBOPLATIN;CORE BIOPSY;DUCTAL CARCINOMA;DYSKINESIA;FEBRILE NEUTROPENIA;INJURY SEVERITY SCORE;LDL APHERESIS;MHC CLASS I;MHC CLASS II;ORAL ALLERGY SYNDROME;PEANUT ALLERGY;PHAKIC INTRAOCULAR LENS;PLATELETPHERESIS;POSTERIOR CEREBRAL ARTERY;PRIMARY CILIARY DYSKINESIA;PROSTATE-SPECIFIC ANTIGEN;RETINOPATHY OF PREMATURITY;SYSTEMIC THERAPY;TRAMP;ZEAXANTHIN","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;ADULT;MIDDLE AGED;FOOD HYPERSENSITIVITY;AGED;ADOLESCENT;ITALY;CHILD;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BLOOD COMPONENT REMOVAL;CRANIOCEREBRAL TRAUMA;CYSTIC FIBROSIS;YOUNG ADULT;;ALLERGENS;BRAIN;BRAIN DISEASES;CHOREA","24;16;15;13;13;10;8;7;7;6;5;5;5;5;5;4;4;4;4;4","THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;DIAGNOSIS AND MANAGEMENT OF FOOD ALLERGY;KIDNEY TRANSPLANTATION;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;BIOMECHANICAL PROPERTIES OF THE CORNEA AND RELATED DISEASES;BLOOD-BRAIN BARRIER AND NEUROVASCULAR INTERACTIONS;CHOLESTEROL-LOWERING TREATMENT;CONE-BEAM COMPUTED TOMOGRAPHY IN DENTISTRY;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;DIAGNOSIS AND TREATMENT OF RETINOPATHY OF PREMATURITY;DISASTER RESPONSE AND PUBLIC HEALTH PREPAREDNESS;GLIOMAS;HEALTH EFFECTS OF AIR POLLUTION;HYPERGLYCEMIC CHOREA AND BASAL GANGLIA LESIONS;IMMUNOBIOLOGY OF DENDRITIC CELLS;INCIDENCE AND MANAGEMENT OF HIP FRACTURES;LABORATORY MEDICINE AND TESTING PROCEDURES;MANAGEMENT AND OPTIMIZATION OF BLOOD SUPPLY CHAIN;MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CYSTIC FIBROSIS;FOOD ALLERGY;KIDNEY TRANSPLANTATION;METASTATIC PROSTATE CANCER;NEURORADIOLOGY;ADHERENS JUNCTION;AIR QUALITY MONITORING;ALLERGEN IMMUNOTHERAPY;ANAPHYLAXIS;ANOSOGNOSIA;ATYPIA;BASAL (MEDICINE);BETA-CATENIN;BLOOD DONATION;BLOOD TRANSFUSION;BYSTANDER INTERVENTION;CARBOPLATIN;CFTR;CHEMOTHERAPY REGIMEN;CHOREOATHETOSIS","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PROSTATE CANCER;CYSTIC FIBROSIS;ITALIAN ADULTS;MULTICENTRE STUDY;ACINAR CELL;ACRYSOF PHAKIC;ACTIVATES TUMOR-SPECIFIC;ACUTE CORONARY;ADULTS ATTENDING;ADVERSE REACTIONS;AIR POLLUTION;ALLERGY CLINICS;ALLOGRAFT RECIPIENTS;ANGLE-SUPPORTED INTRAOCULAR;APHERESIS DONORS;ATTENDING ALLERGY;AUTOMATIC SYSTEM;BILATERAL OCCLUSION;BIMODAL DISTRIBUTION;CANCER PATIENTS;CARDIOVASCULAR EVENTS;CEREBRAL ARTERY;CFTR DEFINING;CFTR MUTATIONS;CHOREOATHETOTIC SYNDROME;CILIARY DYSKINESIA;CLINICAL PREDICTORS;CLINICAL STUDY;COHORT STUDY;CONE-BEAM CT","3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PSORIASIS VULGARIS;LIVER DISEASE;PASI RESPONSE;DISEASE SEVERITY;PURE FEA;TREATMENT GOALS;CONSENSUS PROCESS;DELPHI PROCEDURE;NATIONAL GUIDELINES;PLAQUE-TYPE PSORIASIS;PSYCHOLOGICAL DISTRESS;PUSTULAR PSORIASIS;SEVERE LIVER;ADVERSE EVENTS;CLINICAL TRIALS;CNB DIAGNOSIS;CONSENSUS CONFERENCE;CONSISTENT RESULTS;GUTTATE PSORIASIS;LITERATURE SEARCH;OUTCOME MEASURE;PATIENT SURVEYS;PLAQUE PSORIASIS;PREDOMINANTLY CONSISTENT;PSORIASIS PATIENTS;REQUIRING CONSENSUS;STUDIES ASSIGNED;SYSTEMIC INTERVENTIONS;SYSTEMIC THERAPIES;TEST RESULTS","8;6;6;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3",28,7,0.25,8,2.33,1,4,0,0,0,1,1,1,0,0,0,0,0,0,3,3,3,0,0,0,1,1,1,2.33,1,4,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.33,0,1,0,0,0,65,22,149,65.33,22,150
"AOU_VERONA",2010,47,10.4893617021277,2.91489361702128,0.343065693430657,0.425531914893617,0.425531914893617,0.382978723404255,0.319148936170213,2,24,8,2,8,0.51,0.17,0.04,0.17,38.32,0.847945243992866,0.25531914893617,0.723404255319149,NA,0.424778634287312,0.241086587436333,0.170940170940171,0.157004830917874,"ANTONIO BENITO PORCARO;FRANCESCA B. PIZZINI;BEATRICE CARUSO;CLAUDIO GHIMENTON;ALBERTO BELTRAMELLO;MARIO ROMANO;GIUSEPPE TRIDENTE;MICHELE RENI;ALDO PETROZZIELLO;FILIPPO MIGLIORINI;ANTONIO VELLA;SERGIO MALUTA;LARA MARIA PASETTO;VINCENZO LACOLA;STEFANO CEREDA;EMANUELE RUBILOTTA;L. COMUNALE;STEFANO CORDIO;ROSSANA BERARDI;SIMONE CESARO","4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PAOLO BIBAN;GIACOMO MUGNAI;FRANCESCA B. PIZZINI;ALBERTO BELTRAMELLO;E. SALONINI;SNEŽANA RADIĆ;GIOVANNA FATTOVICH;ERICA VILLA;COSTANTINO CAROSELLI;FRANCESCO FIORINO;FRANCO BARBIERI;FRANCO ALESSANDRINI;ANTONIO BENITO PORCARO;ANTONIO VELLA;SALVATORE CHIRUMBOLO;RICCARDO ORTOLANI;ANTONIO BONALDI;GUGLIELMO BRUNO;FRANCESCO MANARA;MASSIMO SOFFIATI","1.33;1;0.65;0.65;0.64;0.5;0.5;0.5;0.46;0.45;0.45;0.4;0.37;0.35;0.35;0.35;0.33;0.33;0.33;0.33","ANTONIO BENITO PORCARO;FRANCESCA B. PIZZINI;BEATRICE CARUSO;CLAUDIO GHIMENTON;ALBERTO BELTRAMELLO;MARIO ROMANO;ANTONIO VELLA;SERGIO MALUTA;SIMONE CESARO;RICCARDO ORTOLANI;B.M. ASSAEL;PAOLO BIBAN;FRANCESCO FIORINO;M. PALAZZI;FRANCO ALESSANDRINI;ENZO BONORA;MASSIMO FALCONI;NORA SARTORI;ANNA PEGORARO;E. SALONINI","4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PAOLO BIBAN;GIACOMO MUGNAI;FRANCESCA B. PIZZINI;ALBERTO BELTRAMELLO;E. SALONINI;GIOVANNA FATTOVICH;COSTANTINO CAROSELLI;FRANCESCO FIORINO;FRANCO BARBIERI;FRANCO ALESSANDRINI;ANTONIO BENITO PORCARO;ANTONIO VELLA;RICCARDO ORTOLANI;GUGLIELMO BRUNO;FRANCESCO MANARA;MASSIMO SOFFIATI;BEATRICE CARUSO;CLAUDIO GHIMENTON;ALESSANDRO DI MATTEO;MARIO ROMANO","1.33;1;0.65;0.65;0.64;0.5;0.46;0.45;0.45;0.4;0.37;0.35;0.35;0.33;0.33;0.33;0.29;0.28;0.27;0.27","ANDREA TUBARO;ANDREAS NEISIUS;ANNETTE SCHRÖDER;CHRISTIAN HAMPEL;CHRISTOPHER R. CHAPPLE;JOACHIM W. THÜROFF;KARL‐ERIK ANDERSSON;MARCUS J. DRAKE;PAUL ABRAMS;WALTER ARTIBANI;CARLO CASTELLANI;CHEE Y. OOI;ELIZABETH TULLIS;JULIAN ZIELENSKI;KATHERINE KEENAN;MARCO CIPOLLI;MARY COREY;PETER R. DURIE;RUSLAN DORFMAN;STEVEN D. FREEDMAN","346;346;346;346;346;346;346;346;346;346;234;234;234;234;234;234;234;234;234;234","WALTER ARTIBANI;CARLO CASTELLANI;MARCO CIPOLLI;A. MOLINO;ALESSANDRA MARCHI;ANNA MERCANTI;GINO RIGOTTI;PAOLO STRINGHINI;A. ANDREOLI;A. BACCI;A. TOSONI;ALBA A. BRANDES;ANDREA TALACCHI;C. GHIMENTON;ENRICO FRANCESCHI;FABIO CALBUCCI;GIANLUCA MARUCCI;LORENZO VOLPIN;LUCA MORANDI;MARINA PAOLA GARDIMAN","346;234;234;181;181;181;181;181;126;126;126;126;126;126;126;126;126;126;126;126","ALBERTO BELTRAMELLO;ALESSANDRO DI MATTEO;B.M. ASSAEL;BEATRICE CARUSO;E. SALONINI;FRANCESCA B. PIZZINI;FRANCESCO FIORINO;M. PALAZZI;MASSIMO FALCONI;NORA SARTORI;PAOLO PEDERZOLI;RICCARDO ORTOLANI;SERGIO MALUTA;SIMONE CESARO;A. ANDREOLI;A. BACCI;A. MOLINO;A. TOSONI;ALBA A. BRANDES;ALESSANDRA MARCHI","2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;PSYCHOLOGY;ECONOMICS;MATHEMATICS;PHILOSOPHY;POLITICAL SCIENCE;SOCIOLOGY","43;16;4;4;3;2;1;1;1;1;1","INTERNAL MEDICINE;IMMUNOLOGY;SURGERY;PATHOLOGY;ENVIRONMENTAL HEALTH;GENETICS;INTENSIVE CARE MEDICINE;BIOCHEMISTRY;RADIOLOGY;GASTROENTEROLOGY;NURSING;PEDIATRICS;PSYCHIATRY;UROLOGY;ANESTHESIA;CANCER RESEARCH;ONCOLOGY;PHYSICAL THERAPY;ENDOCRINOLOGY;NUCLEAR MEDICINE;PALEONTOLOGY","28;10;10;9;8;7;7;6;6;5;5;5;5;5;4;4;4;4;3;3;3","CANCER;DISEASE;POPULATION;GENE;TRANSPLANTATION;ANTIBODY;CHEMOTHERAPY;CYSTIC FIBROSIS;HORMONE;MAGNETIC RESONANCE IMAGING;MYELOID LEUKEMIA;NEUROLOGY;RADIATION THERAPY;STAGE (STRATIGRAPHY);ALTERNATIVE MEDICINE;BONE MARROW;HEARING LOSS;IMMUNE SYSTEM;IN VITRO;INSULIN;MAST CELL;NEUROSURGERY;PATHOPHYSIOLOGY;PSYCHOLOGICAL INTERVENTION;QUALITY OF LIFE (HEALTHCARE);RESPIRATORY SYSTEM;TESTOSTERONE (PATCH);VIRUS","10;8;8;5;5;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PROSTATE;PROSTATE CANCER;NEURORADIOLOGY;ADENOCARCINOMA;ANDROGEN;GEMCITABINE;GENOTYPE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;IMATINIB;IMMUNOGLOBULIN E;PANCREATIC CANCER;TEMOZOLOMIDE;ADRENOCORTICOTROPIC HORMONE;ALLERGEN;ANTERIOR CINGULATE CORTEX;APLASTIC ANEMIA;BASAL (MEDICINE);BREAST CANCER;CANCER CELL;CD19;CD8;CHEST TUBE;CINAHL;CISPLATIN;CONDUCTIVE HEARING LOSS;CONTINUOUS POSITIVE AIRWAY PRESSURE;CRITICAL APPRAISAL;CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;CYTOTOXICITY;ECONOMIC SHORTAGE;ELECTROCOCHLEOGRAPHY;EPSTEIN–BARR VIRUS;ESCHERICHIA COLI;ETOPOSIDE;EXTERNAL FIXATION;FIXATION (POPULATION GENETICS);FLUID-ATTENUATED INVERSION RECOVERY;FOOD ALLERGY;GHRELIN;HAEMATOPOIESIS;HAZARD RATIO;HEPATITIS B VIRUS;HYDROPNEUMOTHORAX;HYPOXIA (ENVIRONMENTAL);IMMUNOTHERAPY;INCLUSION AND EXCLUSION CRITERIA;INFECTIOUS DISEASE (MEDICAL SPECIALTY);INSULIN RESISTANCE;INTERFERON GAMMA;INTERMITTENT HYPOXIA;INTRACEREBRAL HEMORRHAGE;K562 CELLS;KIDNEY TRANSPLANTATION;LINOLEIC ACID;LIVER TRANSPLANTATION;LYMPHOPROLIFERATIVE DISORDERS;MAJOR HISTOCOMPATIBILITY COMPLEX;MENIERE'S DISEASE;METABOLIC SYNDROME;METHYLATION;MICRORNA;MONOCLONAL ANTIBODY;MTT ASSAY;NEONATOLOGY;NEVUS;NOISE (VIDEO);PANCREATIC DISEASE;PARKINSON'S DISEASE;PERFORMANCE STATUS;PERIPHERAL BLOOD MONONUCLEAR CELL;PERITUBULAR CAPILLARIES;PHASES OF CLINICAL RESEARCH;PLANT LIPID TRANSFER PROTEINS;PLEURODESIS;POLYMERASE CHAIN REACTION;POLYUNSATURATED FATTY ACID;POSTPRANDIAL;RESPIRATORY DISEASE;SOFT TISSUE INJURY;STROOP EFFECT;SYSTEMIC MASTOCYTOSIS;T CELL;THORACOSTOMY;TRYPTASE;TUBERCULOUS PERICARDITIS;TYPE 2 DIABETES;TYROSINE KINASE;VESTIBULAR EVOKED MYOGENIC POTENTIAL;VIABILITY ASSAY;VIRAL DISEASE;VIRAL LOAD","5;4;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PROSTATECTOMY;ANDROGEN DEPRIVATION THERAPY;ANDROSTENEDIONE;BASOPHIL;BREAST RECONSTRUCTION;CORONAVIRUS DISEASE 2019 (COVID-19);CUTANEOUS MASTOCYTOSIS;ENDOLYMPHATIC HYDROPS;ENTEROBACTERIACEAE;ERROR-RELATED NEGATIVITY;HBSAG;HERPESVIRIDAE;IMATINIB MESYLATE;LIVING DONOR LIVER TRANSPLANTATION;LOWER URINARY TRACT SYMPTOMS;LYMPHOCYTE SUBSETS;MASTECTOMY;METHYLTRANSFERASE;MHC CLASS I;MHC CLASS II;MICROVESICLES;MIXED LYMPHOCYTE REACTION;NILOTINIB;ORAL ALLERGY SYNDROME;ORAL FOOD CHALLENGE;PEANUT ALLERGY;PILON FRACTURE;PROSTATE-SPECIFIC ANTIGEN;PULSED-FIELD GEL ELECTROPHORESIS;SERRATIA MARCESCENS;SEX HORMONE-BINDING GLOBULIN;STEM CELL FACTOR;TRAMP","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;ADULT;AGED;ITALY;;MIDDLE AGED;PROSTATIC NEOPLASMS;ADENOCARCINOMA;CHILD;DEOXYCYTIDINE;DIABETES MELLITUS, TYPE 2;PANCREATIC NEOPLASMS;TREATMENT OUTCOME;ANTINEOPLASTIC AGENTS;BRAIN NEOPLASMS;INFLUENZA, HUMAN;METABOLIC SYNDROME;NEOPLASM RECURRENCE, LOCAL","34;24;19;16;13;13;12;12;11;10;7;7;7;7;7;6;5;5;5;5","DIAGNOSIS AND MANAGEMENT OF OTITIS MEDIA;EFFICACY AND RESISTANCE IN CML TREATMENT;GLIOMAS;PANCREATIC CANCER RESEARCH AND TREATMENT;PROSTATE CANCER RESEARCH AND TREATMENT;SLEEP-DISORDERED BREATHING AND HEALTH OUTCOMES;THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;ASTHMA;BIOMEDICAL APPLICATIONS OF SPECTROSCOPY TECHNIQUES;CEREBELLAR CONTRIBUTIONS TO NEUROLOGICAL DISORDERS AND FUNCTIONS;CLASSIFICATION AND TREATMENT OF VASCULAR ANOMALIES;DIAGNOSIS AND MANAGEMENT OF FOOD ALLERGY;DIAGNOSIS AND MANAGEMENT OF PERICARDIAL DISEASES;DIAGNOSIS AND MANAGEMENT OF PLEURAL DISEASES;DIAGNOSIS AND TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA;EFFECTS OF PHYSICAL ACTIVITY ON HEALTH OUTCOMES;EPIDEMIOLOGY AND TREATMENT OF BONE FRACTURES","2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","NEURORADIOLOGY;PROSTATE CANCER;CYSTIC FIBROSIS;GEMCITABINE;HEMATOPOIETIC CELL TRANSPLANTATION;HYPERTENSION;IMATINIB;METASTATIC PROSTATE CANCER;PATHOPHYSIOLOGY;TEMOZOLOMIDE;TREATMENT;AEROSOL THERAPY;AGE-RELATED HEARING LOSS;ANOREXIA;ANTIGEN PRESENTATION;APLASTIC ANEMIA;ATTENTIONAL NETWORKS;AUDITORY PROCESSING;BASAL (MEDICINE);BASOPHIL ACTIVATION","3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","PROSTATE CANCER;CANCER PATIENTS;CLINICAL STUDY;CYSTIC FIBROSIS;FREE TESTOSTERONE;GRAFT SURVIVAL;INVESTIGATIVE CLINICAL;MAGNETIC RESONANCE;MULTICENTER STUDY;RESONANCE IMAGING;TOTAL PSA;TREATMENT TRENDS;ACID ANALYSIS;ACTH-STIMULATED ANDROGEN;ACTIVATES TUMOR-SPECIFIC;ADVANCED LIFE;AEROSOLS INS;ALGORITMO TERAPEUTICO;ANEMIA REPORTED;APLASTIC ANEMIA;APNEA SYNDROME;ASSESSING PROSTATE;AUTHORS RESPONSE;AUTOIMMUNE DISEASES;AUTOLOGOUS LIPOASPIRATE;AUTOMATED REPETITIVE-SEQUENCE-BASED;BCR-ABL CELLS;BEE VENOM;BLEB NEVUS;BLOOD DONORS","6;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","METHYLATION STATUS;PIP SCORES;CYSTIC FIBROSIS;MGMT METHYLATION;CFTR GENOTYPES;INTERQUARTILE RANGE;MEDIAN AGE;MODERATE-SEVERE PIP;PANCREATITIS PATIENTS;ANDROGEN DEPRIVATION;CONTROL SUBJECTS;ER-MRI STAGING;SALINE INFUSION;STEROID METABOLITES;SUPERVISED WALKING;ACTH INFUSION;AEROSOL MEDICINE;ALLERGIC RHINITIS;ASTHMA ALLERGIC;BLOOD FA;CF POPULATION-BASED;CFTR GENOTYPE;CHRONICALLY INFECTED;CLINICAL CHARACTERISTICS;COMPLEX PATHOGENESIS;CONFIDENCE INTERVAL;CUMULATIVE PROPORTION;DEFINITIVE RADIATION;DETERMINED BASED;DEVELOPED PANCREATITIS","6;6;5;5;4;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",47,8,0.17,3,7,1,35,1,1,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,7.67,1,39,0,0,0,0,0,0,34,34,34,0,0,0,2,1,3,0,0,0,3,3,3,30,30,30,1,1,1,0,0,0,0,0,0,159.17,17,664,156.5,1,664
"AOU_VERONA",2011,84,11.6428571428571,3.14285714285714,0.318181818181818,0.321428571428571,0.392857142857143,0.30952380952381,0.392857142857143,1,34,23,8,14,0.4,0.27,0.1,0.17,41.17,0.967846638351967,0.261904761904762,0.821428571428571,NA,0.38360566376467,0.296905222437137,0.245626822157434,0.290094339622642,"GIOVANNI PIZZOLO;ANNAMARIA MOLINO;ROBERTA ZANOTTI;VERONICA CAPPA;BEATRICE CARUSO;STEFANIA GORI;R. CODOGNI;GIORGIO RICCI;MARIO OLIVIERI;MAURIZIO ROSSINI;MASSIMILIANO BONIFACIO;MARCO VENTURINI;ROBERTO DE MARCO;M ZANNONI;RICCARDO C. BONADONNA;ANNA ARTUSO;PAOLA MELOTTI;SIMONE CESARO;B.M. ASSAEL;PAOLO BIBAN","6;6;5;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3","GIUSEPPE CHIARIONI;PAOLO BIBAN;GIAMPAOLO TOMELLERI;PAOLO BOVI;GIOVANNI PIZZOLO;ANNAMARIA MOLINO;SIMONE CESARO;R. CODOGNI;GIORGIO RICCI;M ZANNONI;TOMMASO BOVI;IGNAZIO MARCOCCIO;STEFANIA SPAGGIARI;LUISA ZANOLLA;ROBERTO ADANI;ROBERTA ZANOTTI;ANNA PEGORARO;GIOVANNA SQUINTANI;FRANCESCA B. PIZZINI;FRANCESCO FIORINO","1;0.76;0.58;0.58;0.55;0.54;0.54;0.54;0.54;0.54;0.52;0.5;0.5;0.5;0.5;0.48;0.48;0.46;0.45;0.45","GIOVANNI PIZZOLO;ANNAMARIA MOLINO;ROBERTA ZANOTTI;BEATRICE CARUSO;STEFANIA GORI;R. CODOGNI;GIORGIO RICCI;MARIO OLIVIERI;MAURIZIO ROSSINI;MASSIMILIANO BONIFACIO;M ZANNONI;RICCARDO C. BONADONNA;ANNA ARTUSO;PAOLA MELOTTI;SIMONE CESARO;B.M. ASSAEL;PAOLO BIBAN;CLAUDIO GHIMENTON;ALBERTO ZAMÒ;TOMMASO BOVI","6;6;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3","GIUSEPPE CHIARIONI;PAOLO BIBAN;GIAMPAOLO TOMELLERI;PAOLO BOVI;GIOVANNI PIZZOLO;ANNAMARIA MOLINO;SIMONE CESARO;R. CODOGNI;GIORGIO RICCI;M ZANNONI;TOMMASO BOVI;STEFANIA SPAGGIARI;LUISA ZANOLLA;ROBERTO ADANI;ROBERTA ZANOTTI;ANNA PEGORARO;GIOVANNA SQUINTANI;FRANCESCO FIORINO;FRANCO BARBIERI;PAOLA PERFETTI","1;0.76;0.58;0.58;0.55;0.54;0.54;0.54;0.54;0.54;0.52;0.5;0.5;0.5;0.48;0.48;0.46;0.45;0.45;0.41","CARLO CASTELLANI;MANUELA SEIA;BATSHEVA KEREM;CLAUDE FÉREC;CORINNE BAREIL;CRISTINA BOMBIERI;DIANA BILTON;DN SHEPPARD;DRAGICA RADOJKOVIĆ;EITAN KEREM;ELIZABETH TULLIS;EMMANUELLE GIRODON;G.R. CUTTING;HARRY CUPPENS;ISABELLE SERMET‐GAUDELUS;J.A. DODGE;J.S. ELBORN;JULIAN ZIELENSKI;K. DE BOECK;K.W. SOUTHERN","391;391;370;370;370;370;370;370;370;370;370;370;370;370;370;370;370;370;370;370","CARLO CASTELLANI;MARTA CAMILOT;CARLO CAVEDON;QUIRINO PIUBELLO;GIULIANA LO CASCIO;BERNARDO DALLA BERNARDINA;FRANCESCA DARRA;LEONARDO ZOCCANTE;PATRIZIA BONADONNA;ANNAMARIA MOLINO;MAURIZIO ROSSINI;SILVANO ADAMI;GIANENRICO SENNA;DONATELLA IELUZZI;GIOVANNA FATTOVICH;MICHELA PASINO;ALBERTO BEDOGNI;ANDREA TOTOLA;DONATELLA SCHENA;GIORDANA BETTINI","391;341;242;213;207;185;185;185;185;179;173;155;143;135;135;135;125;125;125;125","PATRIZIA BONADONNA;ANNAMARIA MOLINO;GIORGIO RICCI;M ZANNONI;MAURIZIO ROSSINI;R. CODOGNI;BEATRICE CARUSO;ROBERTA ZANOTTI;SIMONE CESARO;B.M. ASSAEL;DONATELLA SCHENA;ENZO BONORA;GIAMPAOLO TOMELLERI;LUISA ZANOLLA;PAOLA MELOTTI;PAOLA PERFETTI;PAOLO BIBAN;PAOLO BOVI;RICCARDO C. BONADONNA;CARLO CASTELLANI","6;6;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;ENGINEERING;PSYCHOLOGY;MATHEMATICS;SOCIOLOGY;ECONOMICS;ENVIRONMENTAL SCIENCE;MATERIALS SCIENCE;BUSINESS;GEOGRAPHY","80;26;6;6;6;4;4;3;3;2;2;2;1;1","INTERNAL MEDICINE;SURGERY;ENVIRONMENTAL HEALTH;PATHOLOGY;ENDOCRINOLOGY;GENETICS;IMMUNOLOGY;RADIOLOGY;PSYCHIATRY;GASTROENTEROLOGY;ANESTHESIA;FAMILY MEDICINE;INTENSIVE CARE MEDICINE;PEDIATRICS;BIOCHEMISTRY;PALEONTOLOGY;CARDIOLOGY;ONCOLOGY;ANATOMY;NUCLEAR MEDICINE;NURSING;OPTICS","60;18;17;14;13;12;12;12;11;10;9;9;8;7;6;6;5;5;4;4;4;4","POPULATION;CANCER;GENE;ALTERNATIVE MEDICINE;ASTHMA;DIABETES MELLITUS;BONE MARROW;CHEMOTHERAPY;DISEASE;TRANSPLANTATION;ANTIBODY;ASYMPTOMATIC;CONFIDENCE INTERVAL;CONFOUNDING;COPD;CYSTIC FIBROSIS;INCIDENCE (GEOMETRY);KIDNEY DISEASE;MAGNETIC RESONANCE IMAGING;NEUROLOGY;OSTEOPOROSIS;VIRUS","16;10;10;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4","BREAST CANCER;NEURORADIOLOGY;SYSTEMIC MASTOCYTOSIS;GENOTYPE;MUTATION;RESPIRATORY DISEASE;TYPE 2 DIABETES;ALBUMINURIA;ALLELE;BONE MINERAL;CD34;CHEMOTHERAPY REGIMEN;CHROMOSOME;CROSS REACTIONS;CYANIDE POISONING;CYANOCOBALAMIN;HEMATOPOIETIC STEM CELL TRANSPLANTATION;IMMUNOGLOBULIN E;MENIERE'S DISEASE;METABOLIC SYNDROME;METHEMOGLOBIN;NEPHROPATHY;ONCOLYTIC VIRUS;PHENOTYPE;PLACEBO;PROSTATE;PROSTATE CANCER;SPIROMETRY;VITAMIN D DEFICIENCY","5;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CROSS-REACTIVITY;ENDOLYMPHATIC HYDROPS;HYDROXOCOBALAMIN;PROSTATE-SPECIFIC ANTIGEN;ABDOMINAL OBESITY;ACYL COA DEHYDROGENASE;ANTHRACYCLINE;BACLOFEN;BASOPHIL;BENDAMUSTINE;BREAKPOINT;BREAST CARCINOMA;BRONCHIAL HYPERRESPONSIVENESS;CD117;COMPARATIVE GENOMIC HYBRIDIZATION;COMPOUND HETEROZYGOSITY;CORE BIOPSY;CUTANEOUS MASTOCYTOSIS;CYBERKNIFE;DYSKINESIA;FLUORESCENCE IN SITU HYBRIDIZATION;FORMOTEROL;GENE MUTATION;GENOTYPING;HAPLOINSUFFICIENCY;HAPLOTYPE;HETEROZYGOTE ADVANTAGE;HOUSE DUST MITE;HYPERINSULINEMIC HYPOGLYCEMIA;IN SITU HYBRIDIZATION;INDACATEROL;INVASIVE CANDIDIASIS;ISOPROSTANE;KIENBÖCK'S DISEASE;LAMIVUDINE;LATERAL LEMNISCUS;MAMMOGRAPHY;MICROCOCCACEAE;ONCOLYTIC ADENOVIRUS;ORTHOTOPIC LIVER TRANSPLANTATION;PHLEGM;POSTERIOR INTEROSSEOUS NERVE;PRENATAL DIAGNOSIS;PULMONARY ARTERY CATHETER;RIBAVIRIN;SINGLE-NUCLEOTIDE POLYMORPHISM;STAPHYLOCOCCUS;TAMOXIFEN;TRIPLE-NEGATIVE BREAST CANCER;VANCOMYCIN;VIRAL VECTOR","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;ADULT;MIDDLE AGED;AGED;;BREAST NEOPLASMS;ITALY;CYSTIC FIBROSIS;ADOLESCENT;KIDNEY FAILURE, CHRONIC;YOUNG ADULT;AGED, 80 AND OVER;PROSTATIC NEOPLASMS;CHILD;MASTOCYTOSIS, SYSTEMIC;MEDICAL ONCOLOGY;TREATMENT OUTCOME;CHILD, PRESCHOOL","61;47;43;34;33;31;23;18;17;13;11;11;11;10;10;9;9;9;9;7","THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;ROLE OF MAST CELLS IN IMMUNOREGULATION AND DISEASE;MANAGEMENT OF VASCULAR ACCESS IN HEALTHCARE;STANDARDISATION AND MANAGEMENT OF COPD;CEREBELLAR CONTRIBUTIONS TO NEUROLOGICAL DISORDERS AND FUNCTIONS;CHRONIC KIDNEY DISEASE AND ITS IMPLICATIONS;CYANOGENIC GLYCOSIDES IN PLANTS AND INDUSTRIAL WASTEWATERS;DEVELOPMENT AND EVALUATION OF CLINICAL GUIDELINES;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;GENE THERAPY TECHNIQUES AND APPLICATIONS;HEALTH EFFECTS OF AIR POLLUTION;LYMPHOID NEOPLASMS;METABOLIC DISORDERS AND BIOCHEMICAL GENETICS;METABOLIC SYNDROME AND CARDIOVASCULAR DISEASE;;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ADVERSE DRUG REACTIONS AND PHARMACOVIGILANCE;ASTHMA;AUTOIMMUNE ENCEPHALITIS: CLINICAL CHARACTERISTICS AND MANAGEMENT;BIOCHEMICALS ASSOCIATED WITH MYOFASCIAL PAIN AND INFLAMMATION","5;4;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1","MASTOCYTOSIS;NEURORADIOLOGY;TREATMENT;CYSTIC FIBROSIS;ETIOLOGY;HEMODYNAMIC MONITORING;REGIMEN;ALBUMINURIA;AMYL NITRITE;AVAILABILITY OF MEDICINES;BONE REMODELING;BREAST CANCER SCREENING;CFTR;CHEMOTHERAPY REGIMEN;CLINICAL PRACTICE;CONCORDANCE;CROSS-REACTIVITY;CYANIDE POISONING;DIABETES;DRUG PRICING","4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","CYSTIC FIBROSIS;BREAST CANCER;INDOLENT SYSTEMIC;PRELIMINARY RESULTS;PROSTATE CANCER;RISK FACTORS;SYSTEMIC MASTOCYTOSIS;TYPE DIABETES;ACUTE CYANIDE;ANTI-CANCER DRUGS;APRICOT KERNELS;BEDSIDE SCREENING;BONE MARROW;BONE MINERAL;CANCER CLINICAL;CANCER PATIENTS;CARRIER TESTS;CLINICAL PRACTICE;CLINICAL STUDY;COMPUTER PROGRAM;CYANIDE POISONING;DISEASES PRELIMINARY;EDUCATE POTENTIAL;EFFECTIVELY EDUCATE;ENDOLYMPHATIC HYDROPS;EXPERIENCE AIOM;FIBROSIS CARRIER;FISTULA STENOSIS;GEIRD STUDY;HYDROXOCOBALAMIN TREATMENT","4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","TYPE DIABETES;CF PATIENTS;CHRONIC NEPHROPATHY;CYSTIC FIBROSIS;FISTULA STENOSIS;ACUTE CYANIDE;ARTERIAL PRESSURE;BONE EROSIONS;CYANIDE POISONING;HAEMODYNAMIC MONITORING;INFLOW STENOSIS;INTENSIVE CARE;LITRE MIN;MEASUREMENTS OBTAINED;PROXIMAL FISTULAE;QA LT;RS RS;SOFTWARE VERSION;TERMINAL DELETIONS;BM EXAMINATION;BONE MARROW;BREAST LESIONS;CLINICAL CYTOMETRY;CORE BIOPSY;CUTOFF TARGET;CUTOFF VALUES;DIAGNOSED TYPE;FIBROSIS CF;FILTRATION RATE;GLOMERULAR FILTRATION","10;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3",84,23,0.27,2,2.67,1,5,0,0,0,1,1,1,0,0,0,1,1,1,2.67,2,3,0,0,0,1,1,1,2.67,1,5,0,0,0,0,0,0,1.5,1,2,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,0.33,0,2,0.17,0,1,67.17,11,256,67.67,11,256
"AOU_VERONA",2012,112,10.3839285714286,2.96428571428571,0.337349397590361,0.4375,0.383928571428571,0.241071428571429,0.535714285714286,3,62,26,10,7,0.55,0.23,0.09,0.06,31.82,0.761855331402514,0.258928571428571,0.803571428571429,5.19557195571956,0.460181754539849,0.396736222578919,0.400293255131965,0.380952380952381,"ENZO BONORA;EMILIO BRIA;GIAMPAOLO TORTORA;GIOVANNI TARGHER;SIMONE CESARO;FRANCESCO MASSARI;CARLO NEGRI;RICCARDO C. BONADONNA;B.M. ASSAEL;GIACOMO ZOPPINI;MADDALENA TROMBETTA;PAOLO BIBAN;ALESSANDRO PICELLI;NICOLA SMANIA;PAOLO MOGHETTI;MICHEL CHONCHOL;FRANCESCA B. PIZZINI;DARIO REGIS;ANDREA SANDRI;FRANCO AVERSA","10;8;7;7;6;6;6;5;5;5;5;4;4;4;4;4;3;3;3;3","B.M. ASSAEL;PAOLO MOGHETTI;ENZO BONORA;GIOVANNI TARGHER;SERGIO MALUTA;SIMONE CESARO;CARLO NEGRI;ANDREA ROSSI;EMILIO BRIA;ROBERTA FONTANA;GIACOMO ZOPPINI;MADDALENA TROMBETTA;MICHEL CHONCHOL;PAOLO BIBAN;GIAMPAOLO TORTORA;FRANCESCA B. PIZZINI;ALBERTO BELTRAMELLO;DARIO REGIS;ANDREA SANDRI;RICCARDO C. BONADONNA","1.61;1.36;1.22;1.14;1;0.86;0.72;0.69;0.67;0.64;0.63;0.63;0.62;0.58;0.58;0.58;0.58;0.56;0.56;0.54","ENZO BONORA;EMILIO BRIA;GIAMPAOLO TORTORA;GIOVANNI TARGHER;SIMONE CESARO;FRANCESCO MASSARI;CARLO NEGRI;RICCARDO C. BONADONNA;B.M. ASSAEL;GIACOMO ZOPPINI;MADDALENA TROMBETTA;PAOLO BIBAN;NICOLA SMANIA;PAOLO MOGHETTI;FRANCESCA B. PIZZINI;DARIO REGIS;ANDREA SANDRI;ROBERTA FONTANA;ANDREA ROSSI;VINCENZO STOICO","10;8;7;7;6;6;6;5;5;5;5;4;4;4;3;3;3;3;3;3","B.M. ASSAEL;PAOLO MOGHETTI;ENZO BONORA;GIOVANNI TARGHER;SERGIO MALUTA;SIMONE CESARO;CARLO NEGRI;ANDREA ROSSI;EMILIO BRIA;ROBERTA FONTANA;GIACOMO ZOPPINI;MADDALENA TROMBETTA;PAOLO BIBAN;GIAMPAOLO TORTORA;FRANCESCA B. PIZZINI;ALBERTO BELTRAMELLO;DARIO REGIS;ANDREA SANDRI;RICCARDO C. BONADONNA;FRANCESCO MASSARI","1.61;1.36;1.22;1.14;1;0.86;0.72;0.69;0.67;0.64;0.63;0.63;0.58;0.58;0.58;0.58;0.56;0.56;0.54;0.51","ENZO BONORA;CARLO NEGRI;GIOVANNI TARGHER;GIACOMO ZOPPINI;MICHEL CHONCHOL;RICCARDO C. BONADONNA;PAOLO MOGHETTI;MADDALENA TROMBETTA;VINCENZO STOICO;ALESSANDRO PICELLI;NICOLA SMANIA;ELISABETTA BACCHI;MARIA ELISABETTA ZANOLIN;MASSIMO LANZA;DIANA JALAL;JEFFREY C. SIROTA;KIM MCFANN;ANDREA ROSSI;ANTONIO CEVESE;CHIARA MILANESE","730;625;583;529;463;409;331;315;296;289;289;252;252;252;235;235;235;224;201;201","GIOVANNI TARGHER;ENZO BONORA;CARLO NEGRI;RICCARDO C. BONADONNA;PAOLO MOGHETTI;GIACOMO ZOPPINI;NICOLA SMANIA;MADDALENA TROMBETTA;ANDREA ROSSI;NICCOLÒ FACCIOLI;ROBERTO CASTELLO;SIMONE CESARO;FRANCESCA TEOFOLI;MARTA CAMILOT;GIOVANNA FATTOVICH;LUIGINO BOSCHIERO;EMILIO BRIA;PAOLO BIBAN;GIAMPAOLO TORTORA;FRANCESCO PROCACCIO","583;500;427;409;331;299;289;283;224;201;161;137;119;119;117;107;101;101;100;98","ENZO BONORA;GIOVANNI TARGHER;EMILIO BRIA;GIAMPAOLO TORTORA;SIMONE CESARO;RICCARDO C. BONADONNA;B.M. ASSAEL;CARLO NEGRI;FRANCESCO MASSARI;NICOLA SMANIA;PAOLO BIBAN;PAOLO MOGHETTI;MADDALENA TROMBETTA;ALBERTO BEDOGNI;ANDREA ROSSI;G. MORETTO;GLORIA TRIDELLO;GIACOMO ZOPPINI;ANDREA SANDRI;ANNAMARIA MOLINO","8;8;7;6;6;5;5;5;5;4;4;4;3;3;3;3;3;3;2;2","MEDICINE;BIOLOGY;PHYSICS;PSYCHOLOGY;ENGINEERING;CHEMISTRY;MATERIALS SCIENCE;MATHEMATICS;POLITICAL SCIENCE;COMPUTER SCIENCE;ECONOMICS;SOCIOLOGY","106;30;8;8;7;5;5;5;3;2;1;1","INTERNAL MEDICINE;SURGERY;ENDOCRINOLOGY;GENETICS;INTENSIVE CARE MEDICINE;GASTROENTEROLOGY;ONCOLOGY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;PATHOLOGY;CARDIOLOGY;PEDIATRICS;CANCER RESEARCH;MECHANICAL ENGINEERING;RADIOLOGY;ANATOMY;ANESTHESIA;DERMATOLOGY;NEUROSCIENCE;NURSING;PHYSICAL MEDICINE AND REHABILITATION;PHYSICAL THERAPY;PSYCHIATRY;STATISTICS;UROLOGY","83;33;18;16;15;14;14;13;12;10;9;8;7;6;6;6;5;5;5;5;5;5;5;5;5;5","CANCER;CHEMOTHERAPY;DIABETES MELLITUS;GENE;POPULATION;DISEASE;RANDOMIZED CONTROLLED TRIAL;TRANSPLANTATION;BLOOD PRESSURE;VIRUS;ANTIBODY;EPIDEMIOLOGY;INSULIN;OBESITY;PREGNANCY;PROSPECTIVE COHORT STUDY;RENAL FUNCTION;STEM CELL;ANTIFUNGAL;CREATININE;INCIDENCE (GEOMETRY);KIDNEY DISEASE;MYOCARDIAL INFARCTION;ODDS RATIO;RECEPTOR;RETROSPECTIVE COHORT STUDY;STIMULATION;STROKE (ENGINE)","17;14;14;12;12;9;9;8;7;7;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4","TYPE 2 DIABETES;BREAST CANCER;INSULIN RESISTANCE;CISPLATIN;GENOTYPE;METABOLIC SYNDROME;NEUTROPENIA;VIRAL LOAD;DOCETAXEL;FATTY LIVER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PARKINSON'S DISEASE;PROSTATE CANCER;VIRAL DISEASE;ALBUMINURIA;ALLELE;BISPHOSPHONATE;CARCINOGENESIS;CD34;CHEMORADIOTHERAPY;CLINICAL ENDPOINT;DYSLIPIDEMIA;ESTIMATING EQUATIONS;FLUCONAZOLE;FLUID-ATTENUATED INVERSION RECOVERY;GAIT TRAINING;GASTROCNEMIUS MUSCLE;GENE EXPRESSION;GESTATIONAL AGE;HAEMATOPOIESIS;HEART RATE;HEPATITIS C VIRUS;HUMAN CYTOMEGALOVIRUS;IMMUNOGLOBULIN E;KIDNEY TRANSPLANTATION;MENIERE'S DISEASE;METFORMIN;NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY;PANCREATIC CANCER;PHASES OF CLINICAL RESEARCH;PSEUDOMONAS AERUGINOSA;RADIATION TREATMENT PLANNING;SEPTIC SHOCK;SPASTIC;T CELL;VIREMIA;VITAMIN D DEFICIENCY","11;7;6;4;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HERPESVIRIDAE;NEOADJUVANT THERAPY;ENDOLYMPHATIC HYDROPS;OSTEONECROSIS OF THE JAW;POLYCYSTIC OVARY;RIBAVIRIN;SINGLE-NUCLEOTIDE POLYMORPHISM;ADULT STEM CELL;ANDROGEN DEPRIVATION THERAPY;ANDROSTENEDIONE;ANTHRACYCLINE;BASOPHIL;BINGE-EATING DISORDER;BREAST CARCINOMA;BRONCHODILATOR AGENTS;BRONCHOPULMONARY DYSPLASIA;BUSERELIN;CARBOPLATIN;CASPOFUNGIN;CD43;COMPARATIVE GENOMIC HYBRIDIZATION;CUTANEOUS MASTOCYTOSIS;DEEP BRAIN STIMULATION;DUCTAL CARCINOMA;ECHINOCANDIN;ELISPOT;FEBRILE NEUTROPENIA;FILGRASTIM;FLUORESCENCE IN SITU HYBRIDIZATION;GANCICLOVIR;GENETIC VARIANTS;GENOTYPING;GERMINAL CENTER;GLUCOSE TOLERANCE TEST;GLYCATED HEMOGLOBIN;HEMATOPOIETIC STEM CELL;HEMORRHAGIC CYSTITIS;HYPERINSULINEMIA;HYPERTRIGLYCERIDEMIA;IL-2 RECEPTOR;IMP DEHYDROGENASE;IMPAIRED GLUCOSE TOLERANCE;IN SITU HYBRIDIZATION;INOSINE MONOPHOSPHATE;INSULIN SENSITIVITY;INVASIVE DUCTAL CARCINOMA;IRINOTECAN;KLEBSIELLA PNEUMONIAE;LEUKAPHERESIS;METASTATIC BREAST CANCER;MICAFUNGIN;MICROSATELLITE;MODIFIED RANKIN SCALE;MULTILOCUS SEQUENCE TYPING;NAB-PACLITAXEL;NEONATAL RESPIRATORY DISTRESS SYNDROME;NONALCOHOLIC FATTY LIVER DISEASE;PANCREATIC HORMONE;PEMETREXED;PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA;PHARMACONOMIST;PIOGLITAZONE;PLACENTA;POSACONAZOLE;POSTERIOR INTEROSSEOUS NERVE;PROMOTER;PROSTATE DISEASE;PULSED-FIELD GEL ELECTROPHORESIS;RECEPTOR ANTAGONIST;RETINOPATHY OF PREMATURITY;RUBELLA;SEROSTATUS;SOX2;TAQMAN;TAXANE;TERLIPRESSIN;THYMOGLOBULIN;TIME TRIAL;TOLL-LIKE RECEPTOR;TRASTUZUMAB;TUMOR INITIATION;TUMOR SUPPRESSOR GENE;VO2 MAX;ZEAXANTHIN","3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;;DIABETES MELLITUS, TYPE 2;ITALY;CARDIOVASCULAR DISEASES;BREAST NEOPLASMS;ADOLESCENT;RISK FACTORS;TREATMENT OUTCOME;AGED, 80 AND OVER;MAGNETIC RESONANCE IMAGING;PROSPECTIVE STUDIES;YOUNG ADULT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BLOOD GLUCOSE","83;65;51;49;38;35;29;25;19;15;14;13;13;13;10;10;10;10;9;9","BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;BOTULINUM TOXIN IN NEUROLOGY AND MEDICINE;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CHRONIC KIDNEY DISEASE AND ITS IMPLICATIONS;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;RENAL CELL CARCINOMA;THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;CEREBELLAR CONTRIBUTIONS TO NEUROLOGICAL DISORDERS AND FUNCTIONS;CLASSIFICATION AND INTERVENTIONS FOR CEREBRAL PALSY;DIAGNOSIS AND MANAGEMENT OF POLYCYSTIC OVARY SYNDROME;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;EPIDEMIOLOGY AND MANAGEMENT OF SEPSIS AND SEPTIC SHOCK;GENETIC BASIS OF NEUTROPENIA DISORDERS;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;HEPATITIS C INFECTION AND TREATMENT;HIP ARTHROPLASTY TECHNIQUES AND MATERIALS;KIDNEY TRANSPLANTATION;MATERNAL MORBIDITY ASSOCIATED WITH PREGNANCY AND CHILDBIRTH;PANCREATIC CANCER RESEARCH AND TREATMENT","3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","NEOADJUVANT THERAPY;STROKE (ENGINE);TYPE 2 DIABETES;ANTIFUNGAL RESISTANCE;ANTIFUNGAL THERAPY;CONTINUOUS GLUCOSE MONITORING;CYSTIC FIBROSIS;CYTOMEGALOVIRUS;DIABETES;REGIMEN;RENAL CELL CARCINOMA;AEROBIC EXERCISE;ALBUMINURIA;BREAST CANCER;CANCER INCIDENCE;CANCER RISK;CARDIAC IMAGING;CARDIOVASCULAR RISK ASSESSMENT;CHEMORADIOTHERAPY;CLINICAL ENDPOINT","4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","TYPE DIABETES;CONTROLLED TRIAL;RANDOMIZED CONTROLLED;NEWLY DIAGNOSED;CYSTIC FIBROSIS;DIAGNOSED TYPE;LIVER DISEASE;LOCALLY ADVANCED;PROSTATE CANCER;RANDOMIZED TRIAL;RENAL CELL;TRANSPLANT RECIPIENTS;TYPE DIABETIC;VENETO REGION;BOTULINUM TOXIN;BREAST CANCER;BREAST CARCINOMA;CARCINOMA RESULTS;CARDIOVASCULAR MORTALITY;CELL CANCER;CELL LINE;CELL LUNG;COHORT STUDY;COST EFFECTIVENESS;DIABETES RESULTS;DIABETES STUDY;DIABETIC PATIENTS;EFFECTIVENESS ANALYSIS;FATTY LIVER;FIRST-LINE TREATMENT","9;5;5;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","TYPE DIABETES;CARDIOVASCULAR MORTALITY;RS RS;TYPE DIABETIC;MLMIN NA;INSULIN SENSITIVITY;DIABETIC PATIENTS;GASTROCNEMIUS MUSCLE;IMMUNE RECONSTITUTION;LOBULAR BREAST;RISK FACTORS;STIMULATION GUIDANCE;ADJUVANT CHEMOTHERAPY;BETA CELL;BREAST CARCINOMA;CUSHINGS SYNDROME;EGFR DECLINE;ELECTRICAL STIMULATION;GLUCOSE TOLERANCE;HOSPITAL PHARMACY;INCREASED RISK;METABOLIC SYNDROME;NEEDLE PLACEMENT;SPECIFIC IMMUNOGLOBULIN;ABSTRACT PURPOSE;AGE YRS;ALL-CAUSE MORTALITY;ANTIVIRAL THERAPY;BLOOD PRESSURE;BOTULINUM TOXIN","16;11;11;10;9;8;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4",112,40,0.36,1,7.4,2,27,3,2,4,1,1,1,0,0,0,1,1,1,1.67,1,2,0,0,0,2,2,2,7.9,2,27,0,0,0,0,0,0,6,1,22,0,0,0,0,0,0,1,1,1,2.33,1,4,5,1,17,1,1,1,0.3,0,1,0,0,0,92.2,9,320,92.5,9,321
"AOU_VERONA",2013,137,10.9416058394161,2.57664233576642,0.388101983002833,0.364963503649635,0.277372262773723,0.138686131386861,0.35036496350365,4,71,32,7,17,0.52,0.23,0.05,0.12,37.82,1.08403660934046,0.299270072992701,0.81021897810219,4.95389048991354,0.431458565617444,0.34988038277512,0.343258891645988,0.349761526232115,"TEODORO SAVA;GIAMPAOLO TORTORA;ENZO BONORA;EMILIO BRIA;PAOLO MOGHETTI;GIOVANNI LO RE;MARIA ELISABETTA ZANOLIN;FRANCESCO MASSARI;GIOVANNI TARGHER;FLAVIA TOSI;RICCARDO C. BONADONNA;WALTER ARTIBANI;PAOLO MANGANOTTI;SARA PILOTTO;SIMONE CESARO;GIACOMO ZOPPINI;PAOLO BIBAN;ORAZIO CAFFO;GIOVANNA SQUINTANI;ROBERTO GEROSA","7;7;7;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4","CARLO CASTELLANI;EMILIO BRIA;ELISABETTA BACCHI CARLO NEGRI;E. VALVO;MARIA GRAZIA ZENTI;RICCARDO C. BONADONNA;PAOLO MOGHETTI;PAOLO BIBAN;SARA PILOTTO;CORRADO VASSANELLI;GIAMPAOLO TORTORA;FLAVIA TOSI;DARIO REGIS;ANDREA SANDRI;MARCELLA GAFFURI;ENZO BONORA;PAOLO MANGANOTTI;SILVIA FRANCESCA STORTI;GIOVANNI TARGHER;GIACOMO MUGNAI","1.27;1.01;1;1;1;0.94;0.93;0.87;0.84;0.84;0.8;0.74;0.67;0.67;0.67;0.65;0.6;0.6;0.6;0.58","TEODORO SAVA;GIAMPAOLO TORTORA;ENZO BONORA;EMILIO BRIA;PAOLO MOGHETTI;FRANCESCO MASSARI;GIOVANNI TARGHER;FLAVIA TOSI;RICCARDO C. BONADONNA;PAOLO MANGANOTTI;SARA PILOTTO;SIMONE CESARO;GIACOMO ZOPPINI;PAOLO BIBAN;GIOVANNA SQUINTANI;ROBERTO GEROSA;CORRADO VASSANELLI;CARLO CASTELLANI;GIUSEPPE MORETTO;PAOLO BOVI","7;7;7;6;6;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4","CARLO CASTELLANI;EMILIO BRIA;ELISABETTA BACCHI CARLO NEGRI;E. VALVO;MARIA GRAZIA ZENTI;RICCARDO C. BONADONNA;PAOLO MOGHETTI;PAOLO BIBAN;SARA PILOTTO;CORRADO VASSANELLI;GIAMPAOLO TORTORA;FLAVIA TOSI;DARIO REGIS;ANDREA SANDRI;MARCELLA GAFFURI;ENZO BONORA;PAOLO MANGANOTTI;GIOVANNI TARGHER;GIACOMO MUGNAI;TEODORO SAVA","1.27;1.01;1;1;1;0.94;0.93;0.87;0.84;0.84;0.8;0.74;0.67;0.67;0.67;0.65;0.6;0.6;0.58;0.51","ENZO BONORA;GIOVANNI TARGHER;CARLO CASTELLANI;GIACOMO ZOPPINI;PAOLO MOGHETTI;ANABELA S. RAMALHO;CHRISTOPHER M. PENLAND;DAVID L. MASICA;FREDRICK VAN GOOR;GARRY R. CUTTING;GEORGE P. PATRINOS;HAIHUI YU;JOHANNA M. ROMMENS;JULIAN ZIELENSKI;KAREN R. SIKLOSI;KYLE KANIECKI;LINDA MILLEN;MARGARIDA D. AMARAL;MARY COREY;MICHELLE LEWIS","737;718;655;620;608;571;571;571;571;571;571;571;571;571;571;571;571;571;571;571","CARLO CASTELLANI;GIOVANNI TARGHER;GIACOMO ZOPPINI;BERNARDO DALLA BERNADINA;ELENA FONTANA;FRANCESCA DARRA;ENZO BONORA;PAOLO MOGHETTI;ANDREA ROSSI;CARLO NEGRI;NICCOLÒ FACCIOLI;ELISABETTA BACCHI;RICCARDO C. BONADONNA;ALDO SCARPA;GIORGIO MALPELI;CECILIA BONIN;CHIARA SIGNORI;ALBERTO ZAMÒ;PATRIZIA BONADONNA;CORRADO VASSANELLI","655;598;500;448;448;448;358;349;333;325;325;313;279;270;248;239;216;213;213;165","EMILIO BRIA;GIAMPAOLO TORTORA;TEODORO SAVA;CARLO CASTELLANI;CORRADO VASSANELLI;ENZO BONORA;GIOVANNI TARGHER;PAOLO BIBAN;PAOLO MOGHETTI;RICCARDO C. BONADONNA;ROBERTO GEROSA;SARA PILOTTO;SIMONE CESARO;GIACOMO ZOPPINI;ROBERTO MALAGÒ;ANDREA ROSSI;FRANCESCO MASSARI;GIOVANNA SQUINTANI;GIUSEPPE GAMBINA;GIUSEPPE MORETTO","5;5;5;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;PSYCHOLOGY;COMPUTER SCIENCE;ECONOMICS;ENGINEERING;MATHEMATICS;PHILOSOPHY;POLITICAL SCIENCE;ART;BUSINESS;GEOLOGY;MATERIALS SCIENCE","132;36;15;14;10;6;6;6;3;2;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;IMMUNOLOGY;ENDOCRINOLOGY;GASTROENTEROLOGY;GENETICS;ONCOLOGY;CARDIOLOGY;PEDIATRICS;RADIOLOGY;BIOCHEMISTRY;CANCER RESEARCH;ANATOMY;INTENSIVE CARE MEDICINE;OPTICS;ENVIRONMENTAL HEALTH;NEUROSCIENCE;PSYCHIATRY;UROLOGY","99;34;22;20;17;17;17;17;16;13;12;10;10;8;8;8;7;7;7;7","CANCER;GENE;DISEASE;DIABETES MELLITUS;RANDOMIZED CONTROLLED TRIAL;CHEMOTHERAPY;CYSTIC FIBROSIS;INSULIN;MYOCARDIAL INFARCTION;ADVERSE EFFECT;POPULATION;ALTERNATIVE MEDICINE;CLINICAL TRIAL;INCIDENCE (GEOMETRY);LUNG;ODDS RATIO;CONFIDENCE INTERVAL;PREGNANCY;RENAL CELL CARCINOMA;ANTIBODY;ASTHMA;HEALTH CARE;INFLAMMATION;KIDNEY;MAGNETIC RESONANCE IMAGING;NEUROLOGY;PNEUMONIA;RETROSPECTIVE COHORT STUDY;STROKE (ENGINE)","26;17;15;12;12;11;11;8;8;7;7;6;6;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4","CLINICAL ENDPOINT;GENOTYPE;INSULIN RESISTANCE;PROSTATE CANCER;TYPE 2 DIABETES;ALLELE;BREAST CANCER;COLORECTAL CANCER;EPIDERMAL GROWTH FACTOR RECEPTOR;FATTY LIVER;GESTATIONAL AGE;PANCREATIC CANCER;PHENOTYPE;PLACEBO;THROMBOLYSIS;CORONARY ANGIOGRAPHY;CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;DOCETAXEL;FETUS;IMMUNOTHERAPY;MULTIDETECTOR COMPUTED TOMOGRAPHY;MUTATION;NEURORADIOLOGY;PROSTATE;TOLERABILITY","7;7;7;7;7;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","POLYCYSTIC OVARY;SINGLE-NUCLEOTIDE POLYMORPHISM;DUCTAL CARCINOMA;PRENATAL DIAGNOSIS;AMNIOTIC FLUID;ERLOTINIB;GEFITINIB;HORMONE RECEPTOR;HORMONE THERAPY;IVACAFTOR;KRAS;MALE BREAST CANCER;MASTECTOMY;PANCREATIC HORMONE;PROSTATE-SPECIFIC ANTIGEN;PROSTATECTOMY;RIBAVIRIN;ABL;ALLELE FREQUENCY;AMPLICON;ANDROGEN RECEPTOR;BASAL INSULIN;BRAIN METASTASIS;BRONCHOPULMONARY DYSPLASIA;BROTH MICRODILUTION;CETUXIMAB;COGNITIVE DECLINE;CONNECTIVE TISSUE DISEASE;CONTINUOUS GLUCOSE MONITORING;CORE BIOPSY;CRIZOTINIB;CYSTECTOMY;DASATINIB;DIFFUSING CAPACITY;DISCOVERY AND DEVELOPMENT OF MTOR INHIBITORS;DNA EXTRACTION;DOPPLER ECHOCARDIOGRAPHY;EGFR INHIBITORS;FILGRASTIM;FLEXOR CARPI ULNARIS;FLUORESCENCE IN SITU HYBRIDIZATION;GASTRIC ANTRAL VASCULAR ECTASIA;GENOTYPE-PHENOTYPE DISTINCTION;GLOMERULAR BASEMENT MEMBRANE;GLUTAMATE CARBOXYPEPTIDASE II;HAPLOTYPE;HETEROZYGOTE ADVANTAGE;HYPERINSULINEMIA;IMATINIB MESYLATE;IMPAIRED GLUCOSE TOLERANCE;INTESTINAL MALABSORPTION;IPILIMUMAB;IRINOTECAN;JUVENILE MYELOMONOCYTIC LEUKEMIA;KLEBSIELLA;KLEBSIELLA PNEUMONIAE;LEFT ATRIAL ENLARGEMENT;LIPOTOXICITY;MANIA;MECONIUM;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;MICROARRAY;MICROBIAL COLLAGENASE;MISSENSE MUTATION;MODIFIED RANKIN SCALE;NEUROSYPHILIS;NILOTINIB;NONALCOHOLIC FATTY LIVER DISEASE;NUMBER NEEDED TO TREAT;OXALIPLATIN;PANCREAS DIVISUM;PAZOPANIB;PENETRANCE;PHARMACOGENETICS;PHOSPHENE;POLYMORPHISM (COMPUTER SCIENCE);PROSTATE BIOPSY;PROSTATE DISEASE;RIGHT CORONARY ARTERY;ROS1;S-NITROSOGLUTATHIONE;SEX HORMONE-BINDING GLOBULIN;SLEEP SPINDLE;STEREOELECTROENCEPHALOGRAPHY;SUBLINGUAL IMMUNOTHERAPY;SUICIDE ATTEMPT;TAMOXIFEN;TERLIPRESSIN;TRANSCRANIAL ALTERNATING CURRENT STIMULATION;TRANSURETHRAL RESECTION OF THE PROSTATE;TREATMENT-RESISTANT DEPRESSION;TROPHERYMA WHIPPLEI;VANCOMYCIN;VASOPRESSIN RECEPTOR;VASOSPASTIC ANGINA;VO2 MAX","4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;;ADULT;ITALY;TREATMENT OUTCOME;CYSTIC FIBROSIS;DIABETES MELLITUS, TYPE 2;YOUNG ADULT;FATTY LIVER;PROSPECTIVE STUDIES;RETROSPECTIVE STUDIES;ADOLESCENT;STROKE;AGED, 80 AND OVER;ASTHMA;BREAST NEOPLASMS, MALE","99;63;63;48;44;38;36;27;23;22;19;16;15;14;14;13;13;12;12;12","THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ASTHMA;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;RENAL CELL CARCINOMA;DIAGNOSIS AND MANAGEMENT OF POLYCYSTIC OVARY SYNDROME;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;ADVANCEMENTS IN LUNG CANCER RESEARCH;BOTULINUM TOXIN IN NEUROLOGY AND MEDICINE;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;ELBOW INJURIES AND TREATMENTS IN ATHLETES AND ADULTS;HEPATITIS C INFECTION AND TREATMENT;MALE BREAST CANCER AND GYNECOMASTIA RESEARCH;MANAGEMENT OF DIABETES MELLITUS AND HYPOGLYCEMIA;OCCUPATIONAL EXPOSURE TO ANTINEOPLASTIC DRUGS;PANCREATIC CANCER RESEARCH AND TREATMENT;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;ROLE OF MAST CELLS IN IMMUNOREGULATION AND DISEASE","9;5;4;4;4;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2","CYSTIC FIBROSIS;CLINICAL ENDPOINT;CARDIOVASCULAR RISK ASSESSMENT;INSULIN RESISTANCE;TREATMENT;CARDIAC IMAGING;DIABETES;STROKE (ENGINE);BREAST CANCER;COMPUTED TOMOGRAPHY ANGIOGRAPHY;HEMATOLOGY;HYPERANDROGENISM;METASTATIC PANCREATIC CANCER;MULTIDETECTOR COMPUTED TOMOGRAPHY;NAFLD;NEURORADIOLOGY;POLYCYSTIC OVARY SYNDROME;SNP;SYSTEMIC SCLEROSIS;TOLERABILITY","8;7;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3","CYSTIC FIBROSIS;PROSTATE CANCER;RENAL CELL;TYPE DIABETES;FATTY LIVER;LIVER DISEASE;OVARY SYNDROME;POLYCYSTIC OVARY;RANDOMIZED CONTROLLED;BREAST CANCER;CANCER CRPC;CELL CARCINOMA;CORONARY ANGIOGRAPHY;ITALIAN CENTERS;METASTATIC RENAL;NON-ALCOHOLIC FATTY;PANCREATIC CANCER;PATIENTS PTS;ACUTE ISCHEMIC;AMNIOTIC FLUID;ANTICANCER DRUGS;ATRIAL FIBRILLATION;CANCER CLINICAL;CANCER PATIENTS;CARCINOMA MRCC;CASTRATION-RESISTANT PROSTATE;CELL CANCER;CELL TRANSPLANT;CHRONIC HEPATITIS;CLINICAL FEATURES","8;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","LUNG CANCER;MEDLINE CASGOOGLE;CASGOOGLE SCHOLAR;TYPE DIABETES;NON-SMALL-CELL LUNG;EGFR MUTATIONS;INSULIN SENSITIVITY;PHASE III;ADVANCED NSCLC;CYSTIC FIBROSIS;HR CI;ONCOL MEDLINE;EGFR TKIS;INSULIN RESISTANCE;T- -T-;AMNIOTIC FLUID;EGFR MUTATION;EXON DELETIONS;GROWTH FACTOR;PCOS WOMEN;TYROSINE KINASE;ADVERSE EVENTS;CONFIDENCE INTERVAL;EPIDERMAL GROWTH;INTRA-AMNIOTIC INFLAMMATION;KINASE INHIBITORS;ODDS RATIO;PATIENTS TREATED;SMOKING STATUS;T- T-","19;17;16;16;13;11;10;10;9;9;9;9;8;8;8;7;7;7;7;7;7;6;6;6;6;6;6;6;6;6",137,51,0.37,3,21.62,1,56,1.86,1,4,2,1,3,1,1,1,14.2,1,50,10,3,22,0,0,0,1,1,1,23.15,1,61,0,0,0,1,1,1,12.9,2,42,1,1,1,1,1,1,1,1,1,4.2,1,8,7.7,1,27,4.14,1,14,0.62,0,4,0,0,0,195.54,32,536,196.15,32,538
"AOU_VERONA",2014,145,13.4344827586207,2.99310344827586,0.334101382488479,0.303448275862069,0.344827586206897,0.117241379310345,0.462068965517241,1,76,41,7,13,0.52,0.28,0.05,0.09,32.95,0.87193016461075,0.393103448275862,0.875862068965517,5.35058823529412,0.460463667317446,0.516273849607183,0.481060606060606,0.494169096209913,"FRANCESCO MASSARI;GIAMPAOLO TORTORA;EMILIO BRIA;UGO DE GIORGI;TEODORO SAVA;MATTEO BRUNELLI;MICHÈLE MILELLA;GIUSEPPE PROCOPIO;ISABELLA SPERDUTI;UMBERTO BASSO;ALDO SCARPA;WALTER ARTIBANI;MATTEO SANTONI;GUIDO MARTIGNONI;DANIELE SANTINI;ORAZIO CAFFO;ALESSANDRO PICELLI;NICOLA SMANIA;GIOVANNI LO RE;ANTONIO BENITO PORCARO","18;17;15;13;11;11;10;10;10;9;8;8;7;7;7;6;6;6;6;6","GIAMPAOLO TORTORA;EMILIO BRIA;FRANCESCO MASSARI;PAOLO BIBAN;CHIARA CALETTI;MATTEO BRUNELLI;GUIDO ROCCA;MICHELE MAZZI;ALESSANDRO PICELLI;NICOLA SMANIA;GIULIANA LO CASCIO;CARLO CASTELLANI;WALTER ARTIBANI;UGO DE GIORGI;GUIDO MARTIGNONI;ISABELLA SPERDUTI;CORRADO VASSANELLI;GIUSEPPE MORETTO;TEODORO SAVA;STEFANIA MONTEMEZZI","1.3;1.15;1.14;1.12;1;0.95;0.83;0.83;0.82;0.82;0.76;0.68;0.64;0.64;0.63;0.63;0.62;0.59;0.59;0.58","FRANCESCO MASSARI;GIAMPAOLO TORTORA;EMILIO BRIA;TEODORO SAVA;MATTEO BRUNELLI;ALDO SCARPA;WALTER ARTIBANI;GUIDO MARTIGNONI;NICOLA SMANIA;ANTONIO BENITO PORCARO;CHIARA CICCARESE;DONATELLO GASPARRO;FRANCESCA MAINES;GIULIANA LO CASCIO;OMAR PERBELLINI;SARA PILOTTO;ANTONIO SANTO;SIMONE CESARO;PAOLO BIBAN;FRANCESCA PELLINI","18;17;15;11;11;8;8;7;6;6;5;5;5;5;4;4;4;4;4;4","GIAMPAOLO TORTORA;EMILIO BRIA;FRANCESCO MASSARI;PAOLO BIBAN;CHIARA CALETTI;MATTEO BRUNELLI;GUIDO ROCCA;MICHELE MAZZI;NICOLA SMANIA;GIULIANA LO CASCIO;CARLO CASTELLANI;WALTER ARTIBANI;GUIDO MARTIGNONI;CORRADO VASSANELLI;GIUSEPPE MORETTO;TEODORO SAVA;STEFANIA MONTEMEZZI;ALDO SCARPA;GIACOMO MUGNAI;ANTONIO BENITO PORCARO","1.3;1.15;1.14;1.12;1;0.95;0.83;0.83;0.82;0.76;0.68;0.64;0.63;0.62;0.59;0.59;0.58;0.55;0.5;0.49","BO HYUN YOON;FRANCESCA GOTSCH;JEZID MIRANDA;LAMI YEO;PIYA CHAEMSAITHONG;ROBERTO ROMERO;SONIA S. HASSAN;STEVEN J. KORZENIEWSKI;TINNAKORN CHAIWORAPONGSA;ZHONG DONG;CHONG JAI KIM;AHMED IBRAHIM AHMED;MARTA SARACCO;A SCHEJA;ALEXANDRA BALBIR‐GURMAN;ARMANDO GABRIELLI;BRITTA MAURER;CARINA MIHAI;CODRINA ANCUȚA;DOMINIQUE FARGE","785;785;785;785;785;785;785;785;785;785;600;408;403;401;401;401;401;401;401;401","FRANCESCA GOTSCH;PAOLA CARAMASCHI;PAOLA MELOTTI;GIOVANNI TONOLI;NICOLA SMANIA;GIOVANNI TARGHER;FRANCESCO MASSARI;ANNA MALPAGA;GIOVANNI BUTTURINI;ALESSANDRO MANTOVANI;ISABELLA PICHIRI;ENZO BONORA;GIACOMO ZOPPINI;WALTER ARTIBANI;GIAMPAOLO TORTORA;GIULIANA LO CASCIO;LUCIA MINGOLLA;MADDALENA TROMBETTA;VALENTINA CAVALIERI;ALDO SCARPA","785;401;373;309;272;255;207;199;199;194;194;187;185;175;166;148;139;139;139;114","FRANCESCO MASSARI;GIAMPAOLO TORTORA;EMILIO BRIA;TEODORO SAVA;MATTEO BRUNELLI;NICOLA SMANIA;ALDO SCARPA;GUIDO MARTIGNONI;WALTER ARTIBANI;CHIARA CICCARESE;GIULIANA LO CASCIO;ALESSANDRA MODENA;FRANCESCA PELLINI;GIOVANNI TARGHER;GLORIA TRIDELLO;PAOLO BIBAN;PATRIZIA BONADONNA;SARA PILOTTO;SIMONE CESARO;ANDREA ROSSI","17;16;15;10;7;6;5;5;5;5;5;4;4;4;4;4;4;4;4;3","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;ENGINEERING;COMPUTER SCIENCE;MATHEMATICS;POLITICAL SCIENCE;ECONOMICS;PSYCHOLOGY;BUSINESS;SOCIOLOGY;HISTORY;PHILOSOPHY;GEOLOGY","141;41;13;10;9;8;8;7;6;6;3;3;2;2;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;PATHOLOGY;GENETICS;GASTROENTEROLOGY;BIOCHEMISTRY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;PEDIATRICS;CARDIOLOGY;ENDOCRINOLOGY;INTENSIVE CARE MEDICINE;RADIOLOGY;UROLOGY;CANCER RESEARCH;PSYCHIATRY;ANESTHESIA;LAW;PHYSICAL THERAPY","117;40;37;34;25;24;17;17;13;12;11;11;11;11;10;9;9;8;7;7","CANCER;GENE;CHEMOTHERAPY;POPULATION;RANDOMIZED CONTROLLED TRIAL;RENAL CELL CARCINOMA;CYSTIC FIBROSIS;DISEASE;LUNG CANCER;ADVERSE EFFECT;CLINICAL TRIAL;CONFIDENCE INTERVAL;DIABETES MELLITUS;IMMUNOHISTOCHEMISTRY;PREGNANCY;ALTERNATIVE MEDICINE;CARCINOMA;COHORT;INCIDENCE (GEOMETRY);LUNG;STROKE (ENGINE);TRANSPLANTATION","43;22;17;13;12;10;9;9;8;7;6;6;6;6;6;5;5;5;5;5;5;5","PROSTATE CANCER;BREAST CANCER;ADENOCARCINOMA;CLINICAL ENDPOINT;DOCETAXEL;FETUS;PANCREATIC CANCER;COLORECTAL CANCER;MUTATION;HAZARD RATIO;METASTASIS;NEUTROPENIA;PROSTATE;SYSTEMIC MASTOCYTOSIS;EPIDERMAL GROWTH FACTOR RECEPTOR;GEMCITABINE;GERM CELL TUMORS;HEAT SHOCK PROTEIN;LUNG FUNCTION;NEURORADIOLOGY;POLYMERASE CHAIN REACTION;PROGRESSION-FREE SURVIVAL;PROTEIN KINASE B;TYPE 2 DIABETES;TYROSINE-KINASE INHIBITOR","8;7;6;6;6;6;6;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","PRENATAL DIAGNOSIS;AMNIOTIC FLUID;ANDROGEN DEPRIVATION THERAPY;CHORIOAMNIONITIS;DISCOVERY AND DEVELOPMENT OF MTOR INHIBITORS;ANDROGEN RECEPTOR;DIFFUSING CAPACITY;FLUORESCENCE IN SITU HYBRIDIZATION;GEFITINIB;HSP70;IN UTERO;LYMPHOVASCULAR INVASION;MICAFUNGIN;NON-SMALL CELL LUNG CANCER (NSCLC);NONALCOHOLIC FATTY LIVER DISEASE;OXALIPLATIN;PANCREATIC DUCTAL ADENOCARCINOMA;POSACONAZOLE;SANGER SEQUENCING;ACTINOMYCETALES;ACUTE PROMYELOCYTIC LEUKEMIA;ADOPTIVE CELL TRANSFER;ALLELE FREQUENCY;ALTERNATIVE SPLICING;AMNION;AMPLICON;AMPLICON SEQUENCING;ANAPLASTIC LYMPHOMA KINASE;ANGIOPOIETIN 2;ANTIANDROGEN;ANTIRETROVIRAL THERAPY;BILIARY ATRESIA;BK VIRUS;BREAST CARCINOMA;BROTH MICRODILUTION;CARBOPLATIN;CD15;CD38;CHIMERIC ANTIGEN RECEPTOR;CLEAR-CELL ADENOCARCINOMA;COLONOSCOPY;CONGENITAL DIAPHRAGMATIC HERNIA;CREUTZFELDT-JAKOB SYNDROME;CRIZOTINIB;CROSSOVER STUDY;CUTANEOUS MASTOCYTOSIS;DNA METHYLATION;ECHINOCANDIN;ENTEROBACTER AEROGENES;ENTEROBACTERIACEAE;ERLOTINIB;FILGRASTIM;GAIN OF FUNCTION;GENE MUTATION;GLUTAMATE CARBOXYPEPTIDASE II;GLYCATED HAEMOGLOBIN;GLYCATED HEMOGLOBIN;GROWTH HORMONE DEFICIENCY;GROWTH HORMONE TREATMENT;HEMATOPOIETIC GROWTH FACTOR;HEMORRHAGIC CYSTITIS;HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2;HYPOPHOSPHATASIA;IMIPENEM;INDACATEROL;INFLAMMATORY BREAST CANCER;INTRAEPITHELIAL NEOPLASIA;INVASIVE CANDIDIASIS;KLEBSIELLA PNEUMONIAE;KRAS;LDL APHERESIS;LUNG FIBROSIS;LYMPHATIC VESSEL;MECONIUM;MEMORY SPAN;MISSENSE MUTATION;MONOCLONAL;MYELOPROLIFERATIVE NEOPLASM;NAB-PACLITAXEL;NEOADJUVANT THERAPY;NEUROPSYCHOLOGICAL ASSESSMENT;NOCARDIOSIS;OSTEOCALCIN;PAX8;PAZOPANIB;POINT MUTATION;POLYCYSTIC OVARY;PREMATURE RUPTURE OF MEMBRANES;PROBAND;PROSTATE BIOPSY;PROSTATE DISEASES;PROSTATECTOMY;PROSTATITIS;QUANTITATIVE COMPUTED TOMOGRAPHY;RESTRICTION FRAGMENT LENGTH POLYMORPHISM;RNA SPLICING;RUPTURE OF MEMBRANES;TRAIL MAKING TEST;TRASTUZUMAB;VERY LOW-DENSITY LIPOPROTEIN","4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;;ADULT;AGED;AGED, 80 AND OVER;RETROSPECTIVE STUDIES;LUNG NEOPLASMS;NEOPLASM RECURRENCE, LOCAL;TREATMENT OUTCOME;ITALY;PANCREATIC NEOPLASMS;PROGNOSIS;FOLLOW-UP STUDIES;CARCINOMA, NON-SMALL-CELL LUNG;CARCINOMA, RENAL CELL;KIDNEY NEOPLASMS;ADOLESCENT","91;68;68;55;54;44;43;24;24;21;21;20;18;18;18;17;15;15;15;13","RENAL CELL CARCINOMA;THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;PANCREATIC CANCER RESEARCH AND TREATMENT;TESTICULAR GERM CELL TUMORS AND TREATMENT;BOTULINUM TOXIN IN NEUROLOGY AND MEDICINE;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;INFLAMMATION'S ROLE IN CANCER DEVELOPMENT AND PROGRESSION;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;DIAGNOSIS AND TREATMENT OF LUNG CANCER;EPIDEMIOLOGY AND CAUSES OF PRETERM BIRTH;ROLE OF MAST CELLS IN IMMUNOREGULATION AND DISEASE;;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;EPIDEMIOLOGY AND TREATMENT OF BONE FRACTURES;HER2 SIGNALING IN BREAST CANCER TREATMENT;INSULIN-LIKE GROWTH FACTORS IN HEALTH AND DISEASE;MOLECULAR CHAPERONES IN PROTEIN FOLDING AND DISEASE;MOLECULAR RESEARCH ON BREAST CANCER","8;7;6;6;5;5;4;4;4;3;3;3;3;2;2;2;2;2;2;2","TREATMENT;CLINICAL ENDPOINT;CYSTIC FIBROSIS;BREAST CANCER;RENAL CELL CARCINOMA;STROKE (ENGINE);METASTATIC PANCREATIC CANCER;ABIRATERONE ACETATE;ALPHA PARTICLE THERAPY;AMNIOCENTESIS;ANTIFUNGAL THERAPY;CFTR;CHORIOAMNIONITIS;EGFR MUTATIONS;GRADING (ENGINEERING);HEMATOLOGY;INTRAUTERINE INFECTION;INVASIVE FUNGAL INFECTIONS;MASTOCYTOSIS;MEDICAL MICROBIOLOGY","7;6;6;5;5;5;4;3;3;3;3;3;3;3;3;3;3;3;3;3","PATIENTS PTS;RENAL CELL;CELL CARCINOMA;BREAST CANCER;LUNG CANCER;PROSTATE CANCER;CYSTIC FIBROSIS;OBSERVATIONAL STUDY;METASTATIC RENAL;CELL RENAL;CELL TUMORS;CLINICAL OUTCOMES;CLINICAL SIGNIFICANCE;CONTROLLED TRIAL;GERM CELL;GROWTH HORMONE;MULTIPLE SCLEROSIS;PANCREATIC CANCER;RANDOMIZED CONTROLLED;SYSTEMIC MASTOCYTOSIS;TYPE DIABETES;TYROSINE KINASE;ABIRATERONE ACETATE;ADULT PATIENTS;BONE METASTASES;BOTULINUM TOXIN;CANCER MCRPC;CANCER NSCLC;CANCER PATIENTS;CASTRATION RESISTANT","9;9;8;7;7;7;5;5;4;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","LUNG FUNCTION;INTRA-AMNIOTIC INFLAMMATION;OXYGEN UPTAKE;ABSTRACT AIM;MEDIAN AGE;PREDICT VO;STERILE INTRA-AMNIOTIC;VO MAXKG;Β INTERFERONS;CYSTIC FIBROSIS;ESI MS;LDL APHERESIS;PCR ESI;USUAL CARE;ADVERSE EVENTS;LUNG CANCER;MONTHS CI;MULTIPLE SCLEROSIS;BKV-DNA LOAD;CANCER INSTITUTE;CARRIER SCREENING;DIALYSIS PATIENTS;ELENA NATIONAL;INSTITUTE ROME;INSULIN SENSITIVITY;NATIONAL CANCER;PATIENTS PTS;PATIENTS TREATED;RANDOMLY ASSIGNED;REGINA ELENA","14;13;10;8;8;8;8;8;8;7;7;7;7;7;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5",145,44,0.3,1.5,31,2,234,5.5,1,19,3.67,1,9,1,1,1,3.83,1,12,1.6,1,2,0,0,0,1,1,1,34.09,2,256,0,0,0,1,1,1,29.56,3,189,0,0,0,3,3,3,2,1,3,5.5,1,18,22.22,2,148,6.67,1,20,0.36,0,3,0,0,0,122.73,15,295,123.09,15,296
"AOU_VERONA",2015,169,13.5384615384615,3.301775147929,0.302867383512545,0.36094674556213,0.355029585798817,0.189349112426035,0.497041420118343,4,90,46,12,10,0.53,0.27,0.07,0.06,32.22,0.864515273155469,0.384615384615385,0.85207100591716,5.44781783681215,0.450046343964471,0.481318111053451,0.467786705624543,0.462528735632184,"GIAMPAOLO TORTORA;FRANCESCO MASSARI;EMILIO BRIA;MATTEO BRUNELLI;SIMONE CESARO;ENZO BONORA;ISABELLA SPERDUTI;UGO DE GIORGI;GIOVANNI TARGHER;DANIELE SANTINI;MATTEO SANTONI;GIACOMO ZOPPINI;ORAZIO CAFFO;CHIARA CICCARESE;GIUSEPPE PROCOPIO;FRANCESCA MAINES;WALTER ARTIBANI;ISABELLA PICHIRI;ALBERTO BELTRAMELLO;B.M. ASSAEL","19;19;14;12;11;10;10;10;10;10;8;8;8;8;8;8;7;7;7;6","ROBERTO ADANI;GIAMPAOLO TORTORA;EMILIO BRIA;FRANCESCO MASSARI;ANTONIO LASALVIA;MATTEO BRUNELLI;ENZO BONORA;GIOVANNI TARGHER;CARLA LOMBARDO;PATRIZIA BONADONNA;ISABELLA SPERDUTI;WALTER ARTIBANI;SIMONE CESARO;CHIARA CICCARESE;ORAZIO CAFFO;FRANCESCA MAINES;GIACOMO ZOPPINI;ALBERTO BELTRAMELLO;B.M. ASSAEL;FRANCESCO DONATO","3.14;1.67;1.33;1.31;1.28;1.02;0.92;0.87;0.86;0.86;0.83;0.8;0.79;0.77;0.74;0.74;0.69;0.69;0.68;0.66","GIAMPAOLO TORTORA;FRANCESCO MASSARI;EMILIO BRIA;MATTEO BRUNELLI;SIMONE CESARO;ENZO BONORA;GIOVANNI TARGHER;GIACOMO ZOPPINI;CHIARA CICCARESE;WALTER ARTIBANI;ISABELLA PICHIRI;ALBERTO BELTRAMELLO;B.M. ASSAEL;PAOLA CARAMASCHI;GUIDO MARTIGNONI;ANTONIO LASALVIA;ALDO SCARPA;SARA PILOTTO;PAOLO BIBAN;ALESSANDRO MANTOVANI","19;19;14;12;11;10;10;8;8;7;7;7;6;6;6;6;5;5;5;5","ROBERTO ADANI;GIAMPAOLO TORTORA;EMILIO BRIA;FRANCESCO MASSARI;ANTONIO LASALVIA;MATTEO BRUNELLI;ENZO BONORA;GIOVANNI TARGHER;CARLA LOMBARDO;PATRIZIA BONADONNA;WALTER ARTIBANI;SIMONE CESARO;CHIARA CICCARESE;GIACOMO ZOPPINI;ALBERTO BELTRAMELLO;B.M. ASSAEL;FRANCESCO DONATO;PAOLO BIBAN;ISABELLA PICHIRI;GUIDO MARTIGNONI","3.14;1.67;1.33;1.31;1.28;1.02;0.92;0.87;0.86;0.86;0.8;0.79;0.77;0.69;0.69;0.68;0.66;0.66;0.62;0.6","FÉLIX RATJEN;J.S. ELBORN;CARLA COLOMBO;MARCO CIPOLLI;BONNIE W. RAMSEY;CLAIRE WAINWRIGHT;DAVID WALTZ;EDWARD F. MCKONE;GAUTHAM MARIGOWDA;JANE C. DAVIES;K. DE BOECK;KAREN MCCOY;MICHAEL BOYLE;MICHAEL W. KONSTAN;PATRICK A. FLUME;STEVEN M. ROWE;SUSANNA A. MCCOLLEY;XIAOHONG HUANG;À. MUNCK;GIOVANNI TARGHER","1609;1603;1538;1508;1492;1492;1492;1492;1492;1492;1492;1492;1492;1492;1492;1492;1492;1492;1492;514","MARCO CIPOLLI;GIOVANNI TARGHER;ENZO BONORA;GIACOMO ZOPPINI;ISABELLA PICHIRI;CARLO CASTELLANI;CORINNA BERGAMINI;FRANCESCO MASSARI;ANTONIO LASALVIA;ALESSANDRO MANTOVANI;GIAMPAOLO TORTORA;MATTEO PERNIGO;FRANCESCA GOTSCH;EMILIO BRIA;SIMONE CESARO;CARLO NEGRI;MARCO DAURIZ;PAOLO BIBAN;SARA PILOTTO;CORINNA BRANGANI","1508;514;494;428;416;366;288;258;239;235;229;223;218;214;205;200;195;195;195;193","FRANCESCO MASSARI;GIAMPAOLO TORTORA;EMILIO BRIA;SIMONE CESARO;MATTEO BRUNELLI;ENZO BONORA;GIOVANNI TARGHER;GIACOMO ZOPPINI;ISABELLA PICHIRI;ALBERTO BELTRAMELLO;ANTONIO LASALVIA;B.M. ASSAEL;PAOLA CARAMASCHI;CHIARA CICCARESE;WALTER ARTIBANI;ALESSANDRO MANTOVANI;CORINNA BERGAMINI;CARLO CASTELLANI;GUIDO MARTIGNONI;PAOLO BIBAN","17;16;13;11;10;10;10;8;7;6;6;6;6;6;6;5;5;5;5;5","MEDICINE;BIOLOGY;PHYSICS;PSYCHOLOGY;COMPUTER SCIENCE;MATHEMATICS;CHEMISTRY;ENGINEERING;ECONOMICS;GEOGRAPHY;SOCIOLOGY;ART;MATERIALS SCIENCE;PHILOSOPHY;POLITICAL SCIENCE","162;44;17;16;13;13;9;7;5;3;3;2;2;2;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;IMMUNOLOGY;GASTROENTEROLOGY;PATHOLOGY;GENETICS;PEDIATRICS;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;CARDIOLOGY;BIOCHEMISTRY;PSYCHIATRY;RADIOLOGY;CANCER RESEARCH;PHYSICAL THERAPY;INTENSIVE CARE MEDICINE;OPTICS;NEUROSCIENCE;UROLOGY","135;37;35;34;30;29;23;23;22;17;16;15;14;14;13;11;10;9;8;8","CANCER;DISEASE;POPULATION;GENE;CONFIDENCE INTERVAL;DIABETES MELLITUS;CHEMOTHERAPY;CYSTIC FIBROSIS;ALTERNATIVE MEDICINE;ODDS RATIO;TRANSPLANTATION;ADVERSE EFFECT;COHORT;PROPORTIONAL HAZARDS MODEL;INCIDENCE (GEOMETRY);RECEPTOR;BLOOD PRESSURE;RENAL CELL CARCINOMA;RETROSPECTIVE COHORT STUDY;ANTIBODY;MAGNETIC RESONANCE IMAGING;MULTIVARIATE ANALYSIS;PROSPECTIVE COHORT STUDY","37;23;17;16;13;13;12;11;10;10;10;9;9;9;8;8;7;7;7;6;6;6;6","PROSTATE CANCER;TYPE 2 DIABETES;COLORECTAL CANCER;DOCETAXEL;HEMATOPOIETIC STEM CELL TRANSPLANTATION;SUNITINIB;BREAST CANCER;FATTY LIVER;HAZARD RATIO;ALLELE;GEMCITABINE;GENOTYPE;NEURORADIOLOGY;PI3K/AKT/MTOR PATHWAY;PROGRESSION-FREE SURVIVAL;ANAPHYLAXIS;CLINICAL ENDPOINT;CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;DIASTOLE;ERYTHROPOIESIS;HEPATITIS C VIRUS;LOG-RANK TEST;METASTASIS;MUTATION;NEUTROPENIA;PANCREATIC CANCER;SYSTEMIC MASTOCYTOSIS;TOLERABILITY;UNIVARIATE ANALYSIS","12;8;7;7;7;7;6;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3","ANDROGEN RECEPTOR;ANDROGEN DEPRIVATION THERAPY;NONALCOHOLIC FATTY LIVER DISEASE;CAPECITABINE;INEFFECTIVE ERYTHROPOIESIS;METASTATIC BREAST CANCER;POLYMORPHISM (COMPUTER SCIENCE);TRASTUZUMAB;CUTANEOUS MASTOCYTOSIS;DIFFUSING CAPACITY;DISEASE MANAGEMENT;GEFITINIB;HAPLOTYPE;IVACAFTOR;OXALIPLATIN;PAZOPANIB;POLYCYSTIC OVARY;RIBAVIRIN;SINGLE-NUCLEOTIDE POLYMORPHISM;SYSTEMIC VASCULITIS;UROTHELIAL CARCINOMA","8;5;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;MALE;FEMALE;;MIDDLE AGED;AGED;ADULT;CYSTIC FIBROSIS;ITALY;TREATMENT OUTCOME;RETROSPECTIVE STUDIES;ADOLESCENT;YOUNG ADULT;ADENOCARCINOMA;CHILD;LUNG NEOPLASMS;DIABETES MELLITUS, TYPE 2;KIDNEY NEOPLASMS;AGED, 80 AND OVER;ANTINEOPLASTIC AGENTS","102;81;77;66;54;50;49;31;23;23;22;21;20;18;18;18;17;17;16;16","THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;RENAL CELL CARCINOMA;ANALYSIS OF BRAIN FUNCTIONAL CONNECTIVITY NETWORKS;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AND RELATED DISORDERS;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;RECOMMENDATIONS FOR CARDIAC CHAMBER QUANTIFICATION BY ECHOCARDIOGRAPHY;ADVANCEMENTS IN LUNG CANCER RESEARCH;ROLE OF MAST CELLS IN IMMUNOREGULATION AND DISEASE;CANCER IMMUNOTHERAPY;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CLASSIFICATION AND MANAGEMENT OF VASCULITIDES;DIAGNOSIS AND MANAGEMENT OF POLYCYSTIC OVARY SYNDROME;DIAGNOSIS AND TREATMENT OF LUNG CANCER;GENETIC BASIS OF NEUTROPENIA DISORDERS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;GUILLAIN-BARRÉ SYNDROME AND RELATED NEUROPATHIES;HEMATOPOIETIC STEM CELL BIOLOGY","9;8;5;4;4;4;4;4;4;3;3;2;2;2;2;2;2;2;2;2","CYSTIC FIBROSIS;ENZALUTAMIDE;TREATMENT;LEFT VENTRICULAR FUNCTION;METASTATIC PROSTATE CANCER;ABIRATERONE ACETATE;BREAST CANCER;NEURORADIOLOGY;PROGRESSION-FREE SURVIVAL;PROSTATE CANCER;RENAL CELL CARCINOMA;CABAZITAXEL;CFTR;CLINICAL ENDPOINT;DIASTOLIC FUNCTION;ETIOLOGY;HEMATOLOGY;INEFFECTIVE ERYTHROPOIESIS;INTERVENTIONAL RADIOLOGY;LOG-RANK TEST","7;7;6;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3","PROSTATE CANCER;CYSTIC FIBROSIS;TYPE DIABETES;RENAL CELL;CASTRATION-RESISTANT PROSTATE;CELL CARCINOMA;METASTATIC CASTRATION-RESISTANT;METASTATIC RENAL;BREAST CANCER;CANCER MCRPC;LEFT VENTRICULAR;PATIENTS PTS;LUNG CANCER;PATHOLOGICAL FACTORS;RETROSPECTIVE ANALYSIS;STEM CELL;SYSTEMIC SCLEROSIS;ABIRATERONE ACETATE;CELL TRANSPLANTATION;CLINICAL OUTCOMES;CLONAL MAST;COGNITIVE IMPAIRMENT;COHORT STUDY;COMPLETE REMISSION;DOCETAXEL DOC;FATTY LIVER;HEMATOPOIETIC STEM;LIVER DISEASE;NEWLY DIAGNOSED;NONALCOHOLIC FATTY","11;10;9;8;7;7;6;6;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","HR CI;CYSTIC FIBROSIS;MULTIVARIATE ANALYSIS;ADJUVANT SYSTEMIC;SYSTEMIC THERAPY;TYPE DIABETES;DE NOVO;DONOR SITE;VERONA ITALY;CLINICAL TRIALS;CONFIDENCE INTERVAL;DISEASE PROGRESSION;FOREARM FLAP;RENAL ANGIOMYOLIPOMA;SCCA IGM;BREAST CANCER;EDSS SCORE;ODDS RATIO;PEDICLE FLAPS;RADIAL FOREARM;ADULT-ONSET SSC;BONE MARROW;CELL CARCINOMA;CF PATIENTS;GRADE III;INDEPENDENT PREDICTORS;ITALY DEPARTMENT;PCOS WOMEN;PROGRESSION-FREE SURVIVAL;RATIO CI","15;13;13;12;12;10;9;9;9;8;8;8;8;8;8;7;7;7;7;7;6;6;6;6;6;6;6;6;6;6",169,63,0.37,1.6,10.62,1,34,3.57,1,7,1,1,1,2,1,3,1.38,1,3,0,0,0,0,0,0,1,1,1,12,1,38,0,0,0,1,1,1,9.08,1,22,0,0,0,2.5,2,3,1.75,1,2,2.62,1,9,5.38,1,14,2.5,1,4,0,0,0,0,0,0,89.25,20,210,89.25,20,210
"AOU_VERONA",2016,219,13.3196347031963,3.42922374429224,0.291611185086551,0.351598173515982,0.360730593607306,0.324200913242009,0.47945205479452,2,126,40,17,20,0.58,0.18,0.08,0.09,19.26,0.592793207535018,0.292237442922374,0.867579908675799,5.49,0.504693682247236,0.513474025974026,0.510501224069063,0.503480924533556,"GIAMPAOLO TORTORA;MATTEO BRUNELLI;SARA PILOTTO;EMILIO BRIA;FRANCESCO MASSARI;LUISA CARBOGNIN;ORAZIO CAFFO;ISABELLA SPERDUTI;STEFANIA MONTEMEZZI;WALTER ARTIBANI;SIMONE CESARO;NICOLÒ DE LUYK;ANTONIO BENITO PORCARO;FRANCESCA MAINES;TEODORO SAVA;MARIA ANGELA CERRUTO;UGO DE GIORGI;PAOLO CORSI;ENZO BONORA;GIOVANNI TARGHER","29;23;17;17;14;13;13;13;12;11;11;10;10;10;9;9;9;9;8;8","GIAMPAOLO TORTORA;MATTEO BRUNELLI;STEFANIA MONTEMEZZI;EMILIO BRIA;SARA PILOTTO;CARLO CAVEDON;RICCARDO RIGOLON;FRANCESCO MASSARI;SIMONE CESARO;MARCO DALLA VALLE;LUISA CARBOGNIN;BRUNO MAGNAN;CHIARA CICCARESE;G. MELIADÒ;WALTER ARTIBANI;CORRADO VASSANELLI;ISABELLA SPERDUTI;GLORIA TRIDELLO;B.M. ASSAEL;GIOVANNI TARGHER","2.69;1.74;1.58;1.52;1.41;1.37;1.24;1.23;1;1;0.96;0.95;0.91;0.9;0.89;0.88;0.86;0.82;0.82;0.81","GIAMPAOLO TORTORA;MATTEO BRUNELLI;SARA PILOTTO;EMILIO BRIA;FRANCESCO MASSARI;LUISA CARBOGNIN;STEFANIA MONTEMEZZI;WALTER ARTIBANI;SIMONE CESARO;NICOLÒ DE LUYK;ANTONIO BENITO PORCARO;TEODORO SAVA;MARIA ANGELA CERRUTO;PAOLO CORSI;ENZO BONORA;GIOVANNI TARGHER;IRENE TAMANINI;ALESSANDRO TAFURI;CHIARA CICCARESE;MARCO SEBBEN","29;23;17;17;14;13;12;11;11;10;10;9;9;9;8;8;7;7;7;7","GIAMPAOLO TORTORA;MATTEO BRUNELLI;STEFANIA MONTEMEZZI;EMILIO BRIA;SARA PILOTTO;CARLO CAVEDON;RICCARDO RIGOLON;FRANCESCO MASSARI;SIMONE CESARO;MARCO DALLA VALLE;LUISA CARBOGNIN;BRUNO MAGNAN;CHIARA CICCARESE;G. MELIADÒ;WALTER ARTIBANI;CORRADO VASSANELLI;GLORIA TRIDELLO;B.M. ASSAEL;GIOVANNI TARGHER;GIUSEPPE MORETTO","2.69;1.74;1.58;1.52;1.41;1.37;1.24;1.23;1;1;0.96;0.95;0.91;0.9;0.89;0.88;0.82;0.82;0.81;0.79","GIOVANNI TARGHER;ADIL E. BHARUCHA;ALLISON MALCOLM;ARNOLD WALD;CHARLES H. KNOWLES;GIUSEPPE CHIARIONI;R. J. F. FELT‐BERSMA;SATISH S.C. RAO;SIMONE CESARO;ENZO BONORA;EMILIO BRIA;GIACOMO ZOPPINI;MATTEO BRUNELLI;LUCIA DE FRANCESCHI;ALESSANDRO MATTÈ;GIAMPAOLO TORTORA;ALDO SCARPA;UGO DE GIORGI;RICCARDO RIGOLON;MATTEO SANTONI","490;402;402;402;402;402;402;402;402;338;315;298;290;250;248;227;210;209;203;196","GIOVANNI TARGHER;GIUSEPPE CHIARIONI;SIMONE CESARO;EMILIO BRIA;GIACOMO ZOPPINI;LUCIA DE FRANCESCHI;ALESSANDRO MATTÈ;ENZO BONORA;MATTEO BRUNELLI;GIAMPAOLO TORTORA;RICCARDO RIGOLON;ALESSANDRO MANTOVANI;TEODORO SAVA;GIOVANNI MORANI;ISABELLA PICHIRI;FRANCESCO MASSARI;MARCO DAURIZ;FRANCESCA LA RUSSA;GIUSEPPE LIPPI;LUISA CARBOGNIN","419;402;402;315;298;250;248;233;226;219;203;193;188;184;171;166;150;136;135;134","GIAMPAOLO TORTORA;MATTEO BRUNELLI;SARA PILOTTO;EMILIO BRIA;STEFANIA MONTEMEZZI;LUISA CARBOGNIN;FRANCESCO MASSARI;SIMONE CESARO;TEODORO SAVA;GIOVANNI TARGHER;CARLO CAVEDON;G. MELIADÒ;ENZO BONORA;GIACOMO ZOPPINI;PAOLA MELOTTI;WALTER ARTIBANI;CHIARA CICCARESE;ROBERTO IACOVELLI;ANTONIO SANTO;MARIA ANGELA CERRUTO","28;19;15;15;12;11;11;10;8;7;6;6;6;6;6;6;6;6;5;5","MEDICINE;BIOLOGY;PHYSICS;PSYCHOLOGY;CHEMISTRY;ENGINEERING;COMPUTER SCIENCE;MATHEMATICS;POLITICAL SCIENCE;ECONOMICS;SOCIOLOGY;ART;BUSINESS;GEOLOGY;MATERIALS SCIENCE","211;55;19;15;13;12;8;8;4;3;3;1;1;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;PATHOLOGY;GASTROENTEROLOGY;RADIOLOGY;CARDIOLOGY;GENETICS;ENVIRONMENTAL HEALTH;PEDIATRICS;IMMUNOLOGY;UROLOGY;BIOCHEMISTRY;ENDOCRINOLOGY;NUCLEAR MEDICINE;PSYCHIATRY;CANCER RESEARCH;PALEONTOLOGY;GYNECOLOGY;OPTICS;PHYSICAL THERAPY","182;65;46;37;36;32;28;27;24;19;18;18;17;16;14;13;12;11;10;10;10","CANCER;POPULATION;GENE;CONFIDENCE INTERVAL;DISEASE;CHEMOTHERAPY;COHORT;CYSTIC FIBROSIS;DIABETES MELLITUS;LOGISTIC REGRESSION;MULTIVARIATE ANALYSIS;LUNG CANCER;CLINICAL TRIAL;MAGNETIC RESONANCE IMAGING;INCIDENCE (GEOMETRY);ODDS RATIO;RANDOMIZED CONTROLLED TRIAL;RETROSPECTIVE COHORT STUDY;ADVERSE EFFECT;ALTERNATIVE MEDICINE;PROPORTIONAL HAZARDS MODEL;RENAL CELL CARCINOMA","71;24;21;20;20;19;15;15;13;13;13;12;11;11;10;10;10;10;9;9;9;9","PROSTATE CANCER;BREAST CANCER;HAZARD RATIO;PROGRESSION-FREE SURVIVAL;DOCETAXEL;PROSTATE;TYPE 2 DIABETES;UNIVARIATE ANALYSIS;COLORECTAL CANCER;SUNITINIB;EJECTION FRACTION;ALLELE;GENOTYPE;MUTATION;ADENOCARCINOMA;CLEAR CELL;GEMCITABINE;GENE EXPRESSION;IMMUNOTHERAPY;OVERWEIGHT;PANCREATIC CANCER;PSEUDOMONAS AERUGINOSA","24;22;12;12;10;9;8;8;7;7;6;5;5;5;4;4;4;4;4;4;4;4","PROSTATE-SPECIFIC ANTIGEN;ANDROGEN RECEPTOR;PROSTATECTOMY;ANDROGEN DEPRIVATION THERAPY;PAZOPANIB;KRAS;MAMMOGRAPHY;PROSTATE BIOPSY;TRASTUZUMAB;CHROMOPHOBE CELL;GEFITINIB;HORMONAL THERAPY;ARTIFICIAL PANCREAS;CAPECITABINE;CARDIAC RESYNCHRONIZATION THERAPY;FRACTIONAL ANISOTROPY;FRACTIONAL FLOW RESERVE;IDH1;INVASIVE DUCTAL CARCINOMA;IRINOTECAN;METASTATIC BREAST CANCER;MICROARRAY;MICROSATELLITE;NAB-PACLITAXEL;NIVOLUMAB;NONALCOHOLIC FATTY LIVER DISEASE;OXALIPLATIN;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;STAT PROTEIN;TRANSCRIPTOME","10;6;6;5;5;4;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;;MALE;FEMALE;MIDDLE AGED;AGED;ADULT;ITALY;PROSTATIC NEOPLASMS;BREAST NEOPLASMS;RETROSPECTIVE STUDIES;AGED, 80 AND OVER;CYSTIC FIBROSIS;RISK FACTORS;TREATMENT OUTCOME;ANTINEOPLASTIC AGENTS;LUNG NEOPLASMS;ADOLESCENT;CHILD;PROGNOSIS","116;101;92;87;69;63;46;42;35;32;31;28;26;26;26;18;18;16;16;15","ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;RENAL CELL CARCINOMA;MOLECULAR RESEARCH ON BREAST CANCER;THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;PROSTATE CANCER RESEARCH AND TREATMENT;MANAGEMENT OF VALVULAR HEART DISEASE;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;GENETIC BASIS OF NEUTROPENIA DISORDERS;PANCREATIC CANCER RESEARCH AND TREATMENT;CANCER IMMUNOTHERAPY;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;MAGNETIC RESONANCE IMAGING APPLICATIONS IN MEDICINE;MANAGEMENT OF DIABETES MELLITUS AND HYPOGLYCEMIA;RECOMMENDATIONS FOR CARDIAC CHAMBER QUANTIFICATION BY ECHOCARDIOGRAPHY;REGULATION OF IRON METABOLISM AND ANEMIA;ATRIAL FIBRILLATION","13;11;10;8;7;6;5;5;4;4;4;3;3;3;3;3;3;3;3;2","PROSTATE CANCER;PROGRESSION-FREE SURVIVAL;METASTATIC PROSTATE CANCER;UNIVARIATE ANALYSIS;STROKE (ENGINE);ENZALUTAMIDE;LEFT VENTRICULAR FUNCTION;TREATMENT;BREAST CANCER;CONCOMITANT;DIASTOLIC FUNCTION;PAZOPANIB;RENAL CELL CARCINOMA;ABIRATERONE ACETATE;BREAST MRI;CABAZITAXEL;CANCER;CONTINUOUS GLUCOSE MONITORING;FUNCTIONAL MRI;METASTATIC BREAST CANCER","14;13;11;9;7;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4","PROSTATE CANCER;BREAST CANCER;CANCER PATIENTS;CYSTIC FIBROSIS;CELL LUNG;LUNG CANCER;PRELIMINARY RESULTS;CANCER MCRPC;CASTRATION RESISTANT;METASTATIC CASTRATION;RESISTANT PROSTATE;TYPE DIABETES;METASTATIC RENAL;PROGNOSTIC ROLE;RENAL CELL;RETROSPECTIVE MULTICENTER;RHEUMATOID ARTHRITIS;SYSTEMIC SCLEROSIS;BALLOON-EXPANDABLE VALVE;BREAST CARCINOMA;CANCER RESULTS;CASTRATION-RESISTANT PROSTATE;CELL CARCINOMA;CLINICAL OUTCOME;HEART FAILURE;ITALIAN PATIENTS;ITALIAN RETROSPECTIVE;LEFT VENTRICULAR;LONGITUDINAL STUDY;MULTICENTER STUDY","21;9;9;9;8;7;7;6;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4","PUBMED SCOPUS;CROSSREF PUBMED;FECAL INCONTINENCE;RISK FACTORS;INCREASED RISK;PUBMED GOOGLE;CELL LINES;GASTROENTEROL -CROSSREF;PELVIC FLOOR;TYPE DIABETES;BREAST CANCER;GOODE PS;COLON RECTUM;FUNCTIONAL ANORECTAL;MEDIAN AGE;ZINSMEISTER AR;ADVERSE EVENTS;ANORECTAL DISORDERS;BHARUCHA AE;MONTHS CI;MULTIVARIATE ANALYSIS;PATIENTS PTS;PSAFT INDEX;SERUM CHOLESTEROL;AE ZINSMEISTER;ALFECAL INCONTINENCE;CLINICAL PRACTICE;DISEASE PROGRESSION;DISORDERS NETWORKFECAL;GPD DEFICIENCY","63;49;33;25;15;15;14;13;13;13;11;11;10;10;10;10;9;9;9;9;9;9;9;9;8;8;8;8;8;8",219,76,0.35,1.625,11,1,27,1.67,1,3,1.2,1,2,1,1,1,3.82,1,16,5,5,5,0,0,0,1,1,1,12.68,1,42,0,0,0,0,0,0,8.35,1,23,0,0,0,0,0,0,1.25,1,2,2.1,1,8,6.18,1,17,1.43,1,3,0,0,0,0,0,0,56.37,4,120,56.37,4,120
"AOU_VERONA",2017,215,15.6976744186047,3.46976744186047,0.288203753351206,0.325581395348837,0.311627906976744,0.32093023255814,0.548837209302326,0,112,56,15,22,0.52,0.26,0.07,0.1,21.69,0.735979756111789,0.348837209302326,0.893023255813953,5.11938202247192,0.537204498057821,0.470867052023121,0.52797783933518,0.479633027522936,"GIAMPAOLO TORTORA;WALTER ARTIBANI;EMILIO BRIA;MATTEO BRUNELLI;MIRELLA RUGGERI;MARCELLA BELLANI;PAOLO BRAMBILLA;ISABELLA SPERDUTI;SIMONE CESARO;CINZIA PERLINI;ANTONIO BENITO PORCARO;ROBERTO IACOVELLI;UGO DE GIORGI;SALVATORE SIRACUSANO;MAURIZIO ROSSINI;GLORIA TRIDELLO;MARIA ANGELA CERRUTO;GIOVANNI TARGHER;ALESSANDRO TAFURI;SARA PILOTTO","21;18;16;15;14;14;14;13;12;12;11;10;10;9;9;9;9;9;8;8","WALTER ARTIBANI;MARCELLA BELLANI;PAOLO BRAMBILLA;GIAMPAOLO TORTORA;MIRELLA RUGGERI;GIOVANNI MORANI;CINZIA PERLINI;ENZO BONORA;MATTEO BRUNELLI;MAURIZIO ROSSINI;MANUEL CAPPELLARI;STEFANO FORLIVESI;EMILIO BRIA;PAOLO BOVI;GIUSEPPE DELVECCHIO;ANTONIO BENITO PORCARO;F. PRESTI;DAVIDE GATTI;LUCA IDOLAZZI;SIMONE CESARO","1.48;1.33;1.33;1.26;1.22;1.13;1.06;1.02;0.98;0.96;0.95;0.95;0.91;0.9;0.88;0.88;0.85;0.84;0.84;0.83","GIAMPAOLO TORTORA;WALTER ARTIBANI;EMILIO BRIA;MATTEO BRUNELLI;MIRELLA RUGGERI;MARCELLA BELLANI;SIMONE CESARO;CINZIA PERLINI;ANTONIO BENITO PORCARO;ROBERTO IACOVELLI;SALVATORE SIRACUSANO;MAURIZIO ROSSINI;GLORIA TRIDELLO;MARIA ANGELA CERRUTO;GIOVANNI TARGHER;ALESSANDRO TAFURI;SARA PILOTTO;ANTONIO SANTO;MARCO SEBBEN;NICOLÒ DE LUYK","21;18;16;15;14;14;12;12;11;10;9;9;9;9;9;8;8;8;8;8","WALTER ARTIBANI;MARCELLA BELLANI;GIAMPAOLO TORTORA;MIRELLA RUGGERI;GIOVANNI MORANI;CINZIA PERLINI;ENZO BONORA;MATTEO BRUNELLI;MAURIZIO ROSSINI;MANUEL CAPPELLARI;STEFANO FORLIVESI;EMILIO BRIA;PAOLO BOVI;ANTONIO BENITO PORCARO;F. PRESTI;DAVIDE GATTI;LUCA IDOLAZZI;SIMONE CESARO;OMBRETTA VIAPIANA;GIOVANNI TARGHER","1.48;1.33;1.26;1.22;1.13;1.06;1.02;0.98;0.96;0.95;0.95;0.91;0.9;0.88;0.85;0.84;0.84;0.83;0.82;0.82","GIAMPAOLO TORTORA;SIMONE CESARO;GIOVANNI TARGHER;ANTONIO LASALVIA;MIRELLA RUGGERI;MARCELLA BELLANI;PAOLO BRAMBILLA;GLORIA TRIDELLO;CINZIA PERLINI;CORA N. STERNBERG;ANDREA NECCHI;ARISTOTELIS BAMIAS;AUDE FLÉCHON;AVIVIT PEER;FREDRIK LAESTADIUS;LAJOS GÉCZI;NOBUAKI MATSUBARA;ALDO P. MAGGIONI;ALICE MULÈ;ANDREA TORTELLI","496;465;463;461;389;383;383;351;338;321;320;320;320;320;320;320;320;306;288;288","GIAMPAOLO TORTORA;SIMONE CESARO;GIOVANNI TARGHER;ANTONIO LASALVIA;MARCELLA BELLANI;GLORIA TRIDELLO;MIRELLA RUGGERI;ENZO BONORA;ALESSANDRO PICELLI;MARIALUISA GANDOLFI;NICOLA SMANIA;MARIA GRAZIA FRANZOSI;MARCO DAURIZ;ADRIANA BONORA;DAVIDE MELISI;GIACOMO ZOPPINI;ALESSANDRO MANTOVANI;GIOVANNI MORANI;ELISA CICERI;NICOLA DUSI","484;465;463;461;374;351;269;223;220;220;220;192;191;176;173;167;154;149;145;139","GIAMPAOLO TORTORA;WALTER ARTIBANI;MARCELLA BELLANI;MATTEO BRUNELLI;SIMONE CESARO;ROBERTO IACOVELLI;GIOVANNI TARGHER;GLORIA TRIDELLO;MAURIZIO ROSSINI;EMILIO BRIA;ANTONIO SANTO;MIRELLA RUGGERI;GIOVANNI MORANI;DAVIDE GATTI;LUCA IDOLAZZI;OMBRETTA VIAPIANA;ANTONIO LASALVIA;GIACOMO ZOPPINI;ENZO BONORA;SARA PILOTTO","17;12;12;10;10;10;9;9;9;9;8;8;8;7;7;7;7;6;6;6","MEDICINE;BIOLOGY;PSYCHOLOGY;ENGINEERING;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;MATHEMATICS;ECONOMICS;POLITICAL SCIENCE;GEOLOGY;SOCIOLOGY;BUSINESS;MATERIALS SCIENCE;PHILOSOPHY;GEOGRAPHY;HISTORY","209;45;25;13;13;12;8;6;4;4;3;3;2;2;2;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;CARDIOLOGY;GASTROENTEROLOGY;PATHOLOGY;ENDOCRINOLOGY;GENETICS;ENVIRONMENTAL HEALTH;RADIOLOGY;PSYCHIATRY;IMMUNOLOGY;NEUROSCIENCE;UROLOGY;PEDIATRICS;INTENSIVE CARE MEDICINE;MECHANICAL ENGINEERING;BIOCHEMISTRY;CANCER RESEARCH;DERMATOLOGY;GYNECOLOGY","171;50;39;33;30;28;26;26;25;24;22;19;15;15;14;12;11;9;9;9;9","CANCER;POPULATION;CONFIDENCE INTERVAL;COHORT;DISEASE;DIABETES MELLITUS;GENE;CHEMOTHERAPY;MAGNETIC RESONANCE IMAGING;HEART FAILURE;ADVERSE EFFECT;MYOCARDIAL INFARCTION;PROPORTIONAL HAZARDS MODEL;RANDOMIZED CONTROLLED TRIAL;RETROSPECTIVE COHORT STUDY;STROKE (ENGINE);CLINICAL TRIAL;LOGISTIC REGRESSION;MULTIVARIATE ANALYSIS;RENAL CELL CARCINOMA;SCHIZOPHRENIA (OBJECT-ORIENTED PROGRAMMING)","50;23;18;17;17;15;15;14;14;13;10;10;10;10;10;10;9;9;9;9;9","PROSTATE CANCER;BREAST CANCER;EJECTION FRACTION;HAZARD RATIO;PROSTATE;TYPE 2 DIABETES;DOCETAXEL;PROGRESSION-FREE SURVIVAL;WHITE MATTER;CLINICAL ENDPOINT;PANCREATIC CANCER;THROMBOLYSIS;ADENOCARCINOMA;BIPOLAR DISORDER;COLORECTAL CANCER;EPIDERMAL GROWTH FACTOR RECEPTOR;FETUS;HEMATOPOIETIC STEM CELL TRANSPLANTATION;SUNITINIB;WNT SIGNALING PATHWAY","17;10;10;10;10;9;8;8;8;6;6;6;5;5;5;5;5;5;5;5","ANDROGEN DEPRIVATION THERAPY;ANDROGEN RECEPTOR;PROSTATE-SPECIFIC ANTIGEN;PROSTATECTOMY;CARDIAC RESYNCHRONIZATION THERAPY;ERLOTINIB;PAZOPANIB;VOXEL-BASED MORPHOMETRY;NONALCOHOLIC FATTY LIVER DISEASE;ACROMEGALY;BONE MARROW FAILURE;DUCTAL CARCINOMA;GLYCATED HEMOGLOBIN;HEMOPEXIN;INVASIVE DUCTAL CARCINOMA;KRAS;MAMMOGRAPHY;MYELIN OLIGODENDROCYTE GLYCOPROTEIN;NIVOLUMAB;OLIGODENDROCYTE;OSTEOCALCIN;PANCREATIC DUCTAL ADENOCARCINOMA;PENETRANCE;POSACONAZOLE;PRENATAL DIAGNOSIS;PROBAND;PROSTATE BIOPSY;REGORAFENIB;ROS1;SCLEROSTIN;SEROSTATUS;SMALL FOR GESTATIONAL AGE;TRANSCRIPTOME","5;5;5;5;4;4;4;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;;MALE;FEMALE;MIDDLE AGED;AGED;ADULT;ITALY;PROSTATIC NEOPLASMS;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;RISK FACTORS;YOUNG ADULT;DIABETES MELLITUS, TYPE 2;MAGNETIC RESONANCE IMAGING;AGED, 80 AND OVER;ADOLESCENT;PSYCHOTIC DISORDERS;STROKE;SCHIZOPHRENIA","121;94;91;90;67;58;57;43;31;28;26;22;22;21;20;17;16;16;16;15","ADVANCEMENTS IN PROSTATE CANCER RESEARCH;RENAL CELL CARCINOMA;MOLECULAR RESEARCH ON BREAST CANCER;ADVANCEMENTS IN LUNG CANCER RESEARCH;PROSTATE CANCER RESEARCH AND TREATMENT;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;EPIDEMIOLOGY AND MANAGEMENT OF BIPOLAR DISORDER;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;PANCREATIC CANCER RESEARCH AND TREATMENT;CLASSIFICATION AND TREATMENT OF SPONDYLOARTHRITIS;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;ROLE OF MAST CELLS IN IMMUNOREGULATION AND DISEASE;THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;BRAIN LATERALIZATION AND HANDEDNESS IN HUMANS AND ANIMALS;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;DIFFUSION MAGNETIC RESONANCE IMAGING;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;LABORATORY MEDICINE AND TESTING PROCEDURES;MANAGEMENT OF DIABETES MELLITUS AND HYPOGLYCEMIA","8;8;7;6;6;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3","TREATMENT;METASTATIC PROSTATE CANCER;STROKE (ENGINE);PROSTATE CANCER;PROGRESSION-FREE SURVIVAL;DISCONTINUATION;CLINICAL ENDPOINT;ABIRATERONE ACETATE;CABAZITAXEL;ENZALUTAMIDE;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;METASTATIC PANCREATIC CANCER;NEUROIMAGING DATA ANALYSIS;REGIMEN;CONCOMITANT;ECHOCARDIOGRAPHY;EVEROLIMUS;HEMATOLOGY;INFARCTION TREATMENT;PATHOPHYSIOLOGY","14;10;10;9;8;7;6;5;5;5;5;5;5;5;4;4;4;4;4;4","PROSTATE CANCER;CELL CARCINOMA;ITALIAN STUDY;RENAL CELL;BREAST CANCER;CARCINOMA MRCC;HEART FAILURE;METASTATIC RENAL;MULTICENTER ITALIAN;TYPE DIABETES;BIPOLAR DISORDER;CANCER MCRPC;CASTRATION-RESISTANT PROSTATE;LUNG CANCER;METASTATIC CASTRATION-RESISTANT;PATIENTS PTS;SYSTOLIC DYSFUNCTION;CELL LUNG;CLINICAL FACTORS;CLINICAL OUTCOMES;CYSTIC FIBROSIS;FACTORS PREDICTING;INFECTIOUS DISEASES;INVASIVE LOBULAR;LOBULAR BREAST;PROGNOSTIC IMPACT;PSORIATIC ARTHRITIS;PURE INVASIVE;REAL WORLD;ADJUVANT CLINICAL","14;7;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;3","HR CI;ADVERSE EVENTS;MEDIAN AGE;LIVER DISEASE;HEART DISEASE;HEART FAILURE;INCREASED RISK;PATIENTS TREATED;TYPE DIABETES;CONFIDENCE INTERVAL;MEDIAN FOLLOW-UP;MONTHS CI;PROGRESSION-FREE SURVIVAL;CLINICAL PRACTICE;HAZARD RATIO;PATIENTS PTS;PSORIATIC ARTHRITIS;PSYCHOTIC DISORDERS;RISK FACTORS;WHITE MATTER;BONE MARROW;HEALTHY CONTROLS;JAK VF;RATIO CI;STATISTICALLY SIGNIFICANT;STRUCTURAL HEART;CLINICAL TRIAL;FIRST-EPISODE PSYCHOSIS;ITALY DEPARTMENT;LEFT VENTRICULAR","19;17;15;14;11;11;11;11;11;10;10;10;10;9;9;9;9;9;9;9;8;8;8;8;8;8;7;7;7;7",215,93,0.43,2.6,27.46,1,318,2.54,1,10,1.25,1,2,1.33,1,2,10.56,1,72,1.33,1,2,0,0,0,1.5,1,2,34.67,1,439,1,1,1,0,0,0,26.89,2,229,0,0,0,0,0,0,1.22,1,3,7.08,1,36,17.11,1,134,9,1,56,0,0,0,0,0,0,81.17,6,367,81.17,6,367
"AOU_VERONA",2018,213,13.6338028169014,2.94366197183099,0.339712918660287,0.366197183098592,0.352112676056338,0.234741784037559,0.568075117370892,2,92,58,21,22,0.43,0.27,0.1,0.1,20.15,0.66063857324559,0.342723004694836,0.896713615023474,4.61768219832735,0.456966077413004,0.484983811544044,0.480693459416864,0.498873873873874,"SIMONE CESARO;WALTER ARTIBANI;GIAMPAOLO TORTORA;ROBERTO IACOVELLI;MATTEO BRUNELLI;ALESSANDRO MANTOVANI;EMILIO BRIA;GIOVANNI TARGHER;MAURIZIO ROSSINI;ANTONIO BENITO PORCARO;ISABELLA SPERDUTI;BRUNO BONETTI;ANTONIO LASALVIA;PAOLO BOVI;LUISA CARBOGNIN;MARCO SEBBEN;SALVATORE SIRACUSANO;MIRELLA RUGGERI;ANNA CANDONI;ALESSANDRO TAFURI","20;15;15;15;13;11;10;10;9;8;8;8;8;8;7;7;6;6;6;6","ANTONIO LASALVIA;ALESSANDRO MANTOVANI;GIOVANNI TARGHER;SIMONE CESARO;GIAMPAOLO TORTORA;ILARIA TEOBALDI;WALTER ARTIBANI;ROBERTO IACOVELLI;MAURIZIO ROSSINI;CHRISTOPHER D. BYRNE;FRANCESCO AMADDEO;MIRELLA RUGGERI;BRUNO BONETTI;FRANCESCO SAVERIO CAMOGLIO;NICOLA ZAMPIERI;MATTEO BRUNELLI;MANUEL CAPPELLARI;STEFANO FORLIVESI;FLAVIO RIBICHINI;ROBERTO GORLA","2;1.84;1.42;1.38;1.29;1.27;1.21;1.16;1.11;1.09;1;1;0.99;0.83;0.83;0.82;0.78;0.78;0.72;0.67","SIMONE CESARO;WALTER ARTIBANI;GIAMPAOLO TORTORA;ROBERTO IACOVELLI;MATTEO BRUNELLI;ALESSANDRO MANTOVANI;EMILIO BRIA;GIOVANNI TARGHER;MAURIZIO ROSSINI;ANTONIO BENITO PORCARO;BRUNO BONETTI;ANTONIO LASALVIA;PAOLO BOVI;LUISA CARBOGNIN;MARCO SEBBEN;SALVATORE SIRACUSANO;MIRELLA RUGGERI;ALESSANDRO TAFURI;MANUEL CAPPELLARI;TANIA PROCESSALI","20;15;15;15;13;11;10;10;9;8;8;8;8;7;7;6;6;6;6;6","ANTONIO LASALVIA;ALESSANDRO MANTOVANI;GIOVANNI TARGHER;SIMONE CESARO;GIAMPAOLO TORTORA;ILARIA TEOBALDI;WALTER ARTIBANI;ROBERTO IACOVELLI;MAURIZIO ROSSINI;FRANCESCO AMADDEO;MIRELLA RUGGERI;BRUNO BONETTI;FRANCESCO SAVERIO CAMOGLIO;NICOLA ZAMPIERI;MATTEO BRUNELLI;MANUEL CAPPELLARI;STEFANO FORLIVESI;FLAVIO RIBICHINI;GIAMPIERO GIROLOMONI;EMILIO BRIA","2;1.84;1.42;1.38;1.29;1.27;1.21;1.16;1.11;1;1;0.99;0.83;0.83;0.82;0.78;0.78;0.72;0.67;0.65","SIMONE CESARO;MARIO TUMBARELLO;ENRICO MARIA TRECARICHI;CARLO TASCINI;ERCOLE CONCIA;FRANCESCO MENICHETTI;GIOVANNI TARGHER;MATTEO BASSETTI;ALESSANDRA MULARONI;ALBERTO CORONA;ALESSANDRO CAPONE;ANDREA DE GASPERI;ANGELA RAFFAELLA LOSITO;CARLO PALLOTTO;CATERINA CAMPOLI;CLAUDIO VISCOLI;CRISTINA MUSSINI;DANIELE ROBERTO GIACOBBE;E. MAZZA;ELDA RIGHI","627;415;392;336;336;336;335;326;323;302;302;302;302;302;302;302;302;302;302;302","SIMONE CESARO;ERCOLE CONCIA;GIOVANNI TARGHER;ENRICO COSTA;WALTER ARTIBANI;ANTONIO LASALVIA;ALESSANDRO MANTOVANI;ROBERTO IACOVELLI;MAURIZIO ROSSINI;BRUNO BONETTI;GIAMPAOLO TORTORA;LISA SALVATORE;GLORIA TRIDELLO;PAOLO BOVI;ANTONIO BENITO PORCARO;MARCO SEBBEN;MATTEO BRUNELLI;GIACOMO ZOPPINI;ALESSANDRO TAFURI;MANUEL CAPPELLARI","616;336;335;294;243;221;205;196;191;179;167;167;159;157;142;128;125;116;110;110","SIMONE CESARO;WALTER ARTIBANI;ROBERTO IACOVELLI;GIAMPAOLO TORTORA;GIOVANNI TARGHER;ALESSANDRO MANTOVANI;ANTONIO BENITO PORCARO;ANTONIO LASALVIA;BRUNO BONETTI;MATTEO BRUNELLI;MAURIZIO ROSSINI;MARCO SEBBEN;PAOLO BOVI;ALESSANDRO TAFURI;MANUEL CAPPELLARI;PAOLO CORSI;SALVATORE SIRACUSANO;STEFANO FORLIVESI;TANIA PROCESSALI;LISA SALVATORE","19;15;14;11;10;9;8;8;8;8;7;7;7;6;6;6;6;6;6;5","MEDICINE;BIOLOGY;PHYSICS;ENGINEERING;PSYCHOLOGY;CHEMISTRY;ECONOMICS;POLITICAL SCIENCE;COMPUTER SCIENCE;MATHEMATICS;ART;BUSINESS;GEOLOGY;SOCIOLOGY;GEOGRAPHY;MATERIALS SCIENCE;PHILOSOPHY","203;43;18;17;17;11;10;10;8;5;4;4;4;4;3;3;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;GASTROENTEROLOGY;GENETICS;IMMUNOLOGY;CARDIOLOGY;ENVIRONMENTAL HEALTH;UROLOGY;PEDIATRICS;ENDOCRINOLOGY;PATHOLOGY;PSYCHIATRY;OPTICS;RADIOLOGY;BIOCHEMISTRY;MECHANICAL ENGINEERING;DERMATOLOGY;FAMILY MEDICINE;LAW;PHYSICAL THERAPY","173;56;38;26;26;26;25;24;21;19;17;17;16;14;14;13;13;11;10;10;10","CANCER;CHEMOTHERAPY;DISEASE;POPULATION;GENE;INCIDENCE (GEOMETRY);CONFIDENCE INTERVAL;CLINICAL TRIAL;RETROSPECTIVE COHORT STUDY;COHORT;DIABETES MELLITUS;HEART FAILURE;MYOCARDIAL INFARCTION;RENAL CELL CARCINOMA;LOGISTIC REGRESSION;TRANSPLANTATION;STROKE (ENGINE);ADVERSE EFFECT;CYSTIC FIBROSIS;ODDS RATIO;RANDOMIZED CONTROLLED TRIAL","54;24;24;24;14;14;13;12;12;11;11;11;11;11;10;10;9;8;8;8;8","PROSTATE CANCER;BREAST CANCER;CLINICAL ENDPOINT;PANCREATIC CANCER;PROSTATE;HAZARD RATIO;HEMATOPOIETIC STEM CELL TRANSPLANTATION;EJECTION FRACTION;IMMUNOTHERAPY;TYPE 2 DIABETES;FATTY LIVER;NEUTROPENIA;THROMBOLYSIS;BACTEREMIA;COLORECTAL CANCER;CYCLOPHOSPHAMIDE;DOCETAXEL;HAEMATOPOIESIS;ISCHEMIC STROKE;CABOZANTINIB;CUMULATIVE INCIDENCE;DIABETIC FOOT;ETANERCEPT;FETUS;GENE EXPRESSION;GENE SILENCING;INTRACEREBRAL HEMORRHAGE;METASTASIS;PHASES OF CLINICAL RESEARCH;PI3K/AKT/MTOR PATHWAY;PSEUDOMONAS AERUGINOSA;PSORIATIC ARTHRITIS;RNA;SCLERODERMA (FUNGUS);SUNITINIB","15;14;9;8;8;7;7;6;6;6;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","PROSTATECTOMY;NIVOLUMAB;TRASTUZUMAB;KRAS;METASTATIC BREAST CANCER;OXALIPLATIN;POSACONAZOLE;PROSTATE-SPECIFIC ANTIGEN;BONE MARROW FAILURE;BUSULFAN;CETUXIMAB;CONNECTIVE TISSUE DISEASE;DNA METHYLATION;GERMLINE MUTATION;HERPESVIRIDAE;IRINOTECAN;LEUKOARAIOSIS;LOWER URINARY TRACT SYMPTOMS;MODIFIED RANKIN SCALE;PAZOPANIB;PEMBROLIZUMAB;PROSTATE BIOPSY;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;SPONTANEOUS INTRACEREBRAL HEMORRHAGE;TRANSIENT ELASTOGRAPHY;VINCRISTINE","8;6;5;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;;MIDDLE AGED;AGED;ADULT;ITALY;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;KIDNEY NEOPLASMS;AGED, 80 AND OVER;CARCINOMA, RENAL CELL;RISK FACTORS;STROKE;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;PANCREATIC NEOPLASMS;PROSTATIC NEOPLASMS;BREAST NEOPLASMS;HEART FAILURE","126;88;86;85;70;65;48;42;37;31;30;27;27;20;20;19;19;19;18;18","RENAL CELL CARCINOMA;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;PANCREATIC CANCER RESEARCH AND TREATMENT;PROSTATE CANCER RESEARCH AND TREATMENT;THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;CANCER IMMUNOTHERAPY;GENETIC BASIS OF NEUTROPENIA DISORDERS;HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AND RELATED DISORDERS;LIVER CIRRHOSIS AND ASSOCIATED COMPLICATIONS;PELVIC FLOOR DISORDERS;RECOMMENDATIONS FOR CARDIAC CHAMBER QUANTIFICATION BY ECHOCARDIOGRAPHY;RHEUMATOID ARTHRITIS;SARCOPENIA: DEFINITION, DIAGNOSIS, AND IMPLICATIONS;","8;7;7;7;7;6;6;5;4;3;3;3;3;3;3;3;3;3;3;2","CLINICAL ENDPOINT;STROKE (ENGINE);TREATMENT;METASTATIC PROSTATE CANCER;PROSTATE CANCER;CYSTIC FIBROSIS;METASTATIC PANCREATIC CANCER;BREAST CANCER;RENAL CELL CARCINOMA;BACTEREMIA;BIOMARKERS FOR IMMUNOTHERAPY;DISCONTINUATION;ECHOCARDIOGRAPHY;HEMATOPOIETIC CELL TRANSPLANTATION;NOMOGRAM;NUTRITIONAL STATUS;PANCREATIC CANCER;SINGLE CENTER;TRASTUZUMAB;","9;9;9;8;7;6;6;5;5;4;4;4;4;4;4;4;4;4;4;3","CELL CARCINOMA;CYSTIC FIBROSIS;PROSTATE CANCER;RENAL CELL;METASTATIC RENAL;BREAST CANCER;CANCER PATIENTS;PANCREATIC CANCER;ACUTE LEUKEMIA;CELL TRANSPLANTATION;PATIENTS AFFECTED;RETROSPECTIVE STUDY;STEM CELL;TYPE DIABETES;COLORECTAL CANCER;FATTY LIVER;HEART FAILURE;LIVER DISEASE;METASTATIC PANCREATIC;NON-ALCOHOLIC FATTY;PATIENTS TREATED;PATIENTS UNDERGOING;PHASE II;PRELIMINARY RESULTS;RADICAL PROSTATECTOMY;RHEUMATOID ARTHRITIS;SYSTEMIC SCLEROSIS;ACCESS PROGRAM;CARCINOMA MRCC;HEART DISEASE","9;9;9;9;8;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3","PATIENTS TREATED;PROSTATE CANCER;CAS GOOGLE;MEDLINE CAS;TYPE DIABETES;CELL CARCINOMA;CROSSREF MEDLINE;HR CI;RENAL CELL;RISK FACTORS;CONFIDENCE INTERVAL;LEFT VENTRICULAR;IQR PLT;RESPONSE RATE;CLINICAL PRACTICE;LUNG CANCER;PERSONAL CONTINUITY;PLASMA CERAMIDES;PATIENTS AFFECTED;SPEAKERS BUREAU;VESSEL DISEASE;ACCESS PROGRAM;CLINICAL OUTCOMES;GROWTH FACTOR;MEDIAN AGE;MEDIAN FOLLOW-UP;PROGRESSION-FREE SURVIVAL;STEM CELL;TUMOR CELLS;BONE METASTASES","26;24;22;21;18;17;16;16;15;15;14;13;12;12;11;11;11;11;10;10;10;9;9;9;9;9;9;9;9;8",213,92,0.43,2,27.57,1,126,2.27,1,4,1,1,1,2,2,2,2,1,5,2,2,2,0,0,0,1,1,1,31.7,1,134,1,1,1,1,1,1,26.55,2,115,0,0,0,1,1,1,1.73,1,4,5.56,1,25,17.55,2,76,6.92,2,20,0,0,0,0,0,0,77.22,11,186,77.22,11,186
"AOU_VERONA",2019,230,16.6869565217391,2.88695652173913,0.346385542168675,0.317391304347826,0.269565217391304,0.243478260869565,0.591304347826087,1,117,60,18,10,0.51,0.26,0.08,0.04,18.14,0.746126676059039,0.404347826086957,0.934782608695652,5.15553235908143,0.450822674121176,0.502493074792244,0.541302447552447,0.510957066189624,"GIAMPAOLO TORTORA;WALTER ARTIBANI;GIOVANNI TARGHER;SALVATORE SIRACUSANO;EMILIO BRIA;MATTEO BRUNELLI;ALESSANDRO TAFURI;SIMONE CESARO;MARCO SEBBEN;NELIA AMIGONI;ANTONIO BENITO PORCARO;MARCO PIROZZI;ANTONIO LASALVIA;ALIASGER SHAKIR;ALESSANDRO MANTOVANI;TANIA PROCESSALI;RICCARDO RIZZETTO;MIRELLA RUGGERI;SARA PILOTTO;CHRISTOPHER D. BYRNE","22;17;15;14;14;14;13;13;11;11;11;11;11;11;10;10;10;9;9;9","GIAMPAOLO TORTORA;GIOVANNI TARGHER;WALTER ARTIBANI;SIMONE CESARO;ALESSANDRO MANTOVANI;SALVATORE SIRACUSANO;EMRE BAKIRCIOĞLU;FRANCESCO SAVERIO CAMOGLIO;MATTEO BRUNELLI;ALESSANDRO TAFURI;ANTONIO LASALVIA;CHRISTOPHER D. BYRNE;ANTONIO BENITO PORCARO;GIOVANNI GAMBARO;EMILIO BRIA;ALIASGER SHAKIR;MARCO PIROZZI;NICOLA ZAMPIERI;MARCO SEBBEN;NELIA AMIGONI","1.44;1.39;1.2;1.05;1.01;1.01;1;0.99;0.96;0.95;0.91;0.86;0.83;0.81;0.81;0.79;0.79;0.79;0.77;0.75","GIAMPAOLO TORTORA;WALTER ARTIBANI;GIOVANNI TARGHER;SALVATORE SIRACUSANO;EMILIO BRIA;MATTEO BRUNELLI;ALESSANDRO TAFURI;SIMONE CESARO;MARCO SEBBEN;NELIA AMIGONI;ANTONIO BENITO PORCARO;MARCO PIROZZI;ANTONIO LASALVIA;ALESSANDRO MANTOVANI;TANIA PROCESSALI;RICCARDO RIZZETTO;MIRELLA RUGGERI;SARA PILOTTO;FILIPPO MIGLIORINI;MICHÈLE MILELLA","22;17;15;14;14;14;13;13;11;11;11;11;11;10;10;10;9;9;8;8","GIAMPAOLO TORTORA;GIOVANNI TARGHER;WALTER ARTIBANI;SIMONE CESARO;ALESSANDRO MANTOVANI;SALVATORE SIRACUSANO;EMRE BAKIRCIOĞLU;FRANCESCO SAVERIO CAMOGLIO;MATTEO BRUNELLI;ALESSANDRO TAFURI;ANTONIO LASALVIA;ANTONIO BENITO PORCARO;GIOVANNI GAMBARO;EMILIO BRIA;MARCO PIROZZI;NICOLA ZAMPIERI;MARCO SEBBEN;NELIA AMIGONI;MATTEO BALZARRO;TANIA PROCESSALI","1.44;1.39;1.2;1.05;1.01;1.01;1;0.99;0.96;0.95;0.91;0.83;0.81;0.81;0.79;0.79;0.77;0.75;0.73;0.67","GIOVANNI TARGHER;FEDERICO CAPPUZZO;DIANA GIANNARELLI;CHRISTOPHER D. BYRNE;ALESSANDRO MANTOVANI;WALTER ARTIBANI;BRUNO BONETTI;GIAMPAOLO TORTORA;ANGELO DELMONTE;FILIPPO DE MARINIS;MANUEL CAPPELLARI;FRANCESCO GROSSI;LUCIO CRINÓ;ENRICO CORTESI;SALVATORE SIRACUSANO;ADIL E. BHARUCHA;ALLISON MALCOLM;ANTHONY LEMBO;ANTON EMMANUEL;C. J. VAIZEY","496;418;409;398;350;318;308;307;298;298;291;289;289;260;246;223;223;223;223;223","GIOVANNI TARGHER;WALTER ARTIBANI;BRUNO BONETTI;MANUEL CAPPELLARI;GIAMPAOLO TORTORA;SALVATORE SIRACUSANO;GUISEPPE CHIARIONI;EMILIO BRIA;ALESSANDRO MANTOVANI;ALESSANDRO TAFURI;SIMONE CESARO;MARCO CIPOLLI;ANTONIO COLECCHIA;ANTONIO LASALVIA;ANTONIO SANTO;ANGELA MAROTTA;ENZO BONORA;MADDALENA TROMBETTA;MARCO SEBBEN;MATTEO BRUNELLI","328;312;308;291;282;240;223;184;182;182;180;179;168;158;140;122;120;120;116;116","GIAMPAOLO TORTORA;WALTER ARTIBANI;SIMONE CESARO;SALVATORE SIRACUSANO;ALESSANDRO TAFURI;GIOVANNI TARGHER;ANTONIO LASALVIA;ANTONIO BENITO PORCARO;NELIA AMIGONI;MARCO PIROZZI;MARCO SEBBEN;MATTEO BRUNELLI;MANUEL CAPPELLARI;RICCARDO RIZZETTO;SARA PILOTTO;TANIA PROCESSALI;FILIPPO MIGLIORINI;ROBERTO IACOVELLI;ALESSANDRO MANTOVANI;MIRELLA RUGGERI","15;15;13;12;11;11;11;11;9;9;9;9;8;8;8;8;7;7;7;6","MEDICINE;BIOLOGY;PSYCHOLOGY;CHEMISTRY;PHYSICS;ENGINEERING;MATHEMATICS;BUSINESS;COMPUTER SCIENCE;ECONOMICS;GEOGRAPHY;PHILOSOPHY;POLITICAL SCIENCE;GEOLOGY;MATERIALS SCIENCE;SOCIOLOGY","220;65;17;16;16;15;11;3;3;3;2;2;2;1;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;PATHOLOGY;GASTROENTEROLOGY;GENETICS;IMMUNOLOGY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;UROLOGY;PSYCHIATRY;RADIOLOGY;CARDIOLOGY;BIOCHEMISTRY;CANCER RESEARCH;PEDIATRICS;PHYSICAL THERAPY;INTENSIVE CARE MEDICINE;PALEONTOLOGY;CLINICAL PSYCHOLOGY;NUCLEAR MEDICINE","188;51;46;45;39;35;27;26;26;26;24;24;20;18;18;16;16;12;12;11;11","CANCER;GENE;DISEASE;POPULATION;CONFIDENCE INTERVAL;DIABETES MELLITUS;PROSPECTIVE COHORT STUDY;CHEMOTHERAPY;COHORT;ALTERNATIVE MEDICINE;CYSTIC FIBROSIS;RANDOMIZED CONTROLLED TRIAL;PROPORTIONAL HAZARDS MODEL;LOGISTIC REGRESSION;LUNG CANCER;RECEIVER OPERATING CHARACTERISTIC;STROKE (ENGINE);ADVERSE EFFECT;BODY MASS INDEX;BONE MARROW;CLINICAL TRIAL;LUNG;MAGNETIC RESONANCE IMAGING;ODDS RATIO;RENAL CELL CARCINOMA","61;36;28;24;21;17;17;16;13;11;11;11;10;9;9;9;9;8;8;8;8;8;8;8;8","PROSTATE CANCER;HAZARD RATIO;PROSTATE;PANCREATIC CANCER;CLINICAL ENDPOINT;TYPE 2 DIABETES;MUTATION;BREAST CANCER;FATTY LIVER;GENOTYPE;IMMUNOTHERAPY;COLORECTAL CANCER;PLACEBO;NEUTROPENIA;PHENOTYPE;ADENOCARCINOMA;LIVER BIOPSY;BIPOLAR DISORDER;CABOZANTINIB;EJECTION FRACTION;GENE EXPRESSION;INSULIN RESISTANCE;ISCHEMIC STROKE;METABOLIC SYNDROME;NEPHRECTOMY;OVERWEIGHT;POLYMERASE;RANDOMIZATION;SPUTUM","19;14;13;11;10;10;9;8;8;8;8;7;7;6;6;5;5;4;4;4;4;4;4;4;4;4;4;4;4","PROSTATECTOMY;NIVOLUMAB;POLY ADP RIBOSE POLYMERASE;PROSTATE BIOPSY;PROSTATE-SPECIFIC ANTIGEN;TRANSIENT ELASTOGRAPHY;ANDROGEN RECEPTOR;BONE MARROW FAILURE;BRCA MUTATION;CRIZOTINIB;GEFITINIB;NONALCOHOLIC FATTY LIVER DISEASE;STEATOHEPATITIS;VITAMIN K ANTAGONIST;DNA METHYLATION;ERLOTINIB;FRACTIONAL ANISOTROPY;HISTONE METHYLTRANSFERASE;IVACAFTOR;PANCREATIC DUCTAL ADENOCARCINOMA;UNDERWEIGHT;V600E","10;6;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","HUMANS;MALE;;FEMALE;MIDDLE AGED;AGED;ADULT;ITALY;NON-ALCOHOLIC FATTY LIVER DISEASE;RETROSPECTIVE STUDIES;AGED, 80 AND OVER;PSYCHOTIC DISORDERS;PROSTATIC NEOPLASMS;PROSPECTIVE STUDIES;DIABETES MELLITUS, TYPE 2;TREATMENT OUTCOME;ADOLESCENT;RISK FACTORS;BIOMARKERS;PROGNOSIS","130;101;97;97;76;67;54;39;37;30;28;24;23;22;21;20;19;19;18;18","EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;PANCREATIC CANCER RESEARCH AND TREATMENT;PROSTATE CANCER RESEARCH AND TREATMENT;THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;CANCER IMMUNOTHERAPY;RENAL CELL CARCINOMA;ADVANCEMENTS IN LUNG CANCER RESEARCH;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;PELVIC FLOOR DISORDERS;ROLE OF MAST CELLS IN IMMUNOREGULATION AND DISEASE;ATRIAL FIBRILLATION;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GENETIC BASIS OF NEUTROPENIA DISORDERS;MANAGEMENT OF FEBRILE NEUTROPENIA IN CANCER PATIENTS;POLY(ADP-RIBOSE) POLYMERASE INHIBITION IN CANCER THERAPY;SCHIZOPHRENIA RESEARCH AND TREATMENT;ACUTE MYELOID LEUKEMIA;BORDERLINE PERSONALITY DISORDER: PSYCHOPATHOLOGY AND TREATMENT","13;11;11;10;7;6;6;5;4;4;4;4;3;3;3;3;3;3;2;2","PROSTATE CANCER;TREATMENT;CLINICAL ENDPOINT;NAFLD;STROKE (ENGINE);METASTATIC PROSTATE CANCER;PANCREATIC CANCER;CYSTIC FIBROSIS;METASTATIC PANCREATIC CANCER;DISCONTINUATION;TUMOR MICROENVIRONMENT;HEMATOLOGY;INTERQUARTILE RANGE;METASTATIC COLORECTAL CANCER;MRI IMAGING;CABOZANTINIB;CANCER THERAPY;DIAGNOSIS;ECHOCARDIOGRAPHY;EGFR MUTATIONS","12;12;10;10;9;8;8;7;7;6;6;5;5;5;5;4;4;4;4;4","PROSTATE CANCER;PANCREATIC CANCER;PATIENTS PTS;CYSTIC FIBROSIS;RADICAL PROSTATECTOMY;RENAL CELL;CELL CARCINOMA;COLORECTAL CANCER;FATTY LIVER;LIVER DISEASE;LUNG CANCER;METASTATIC RENAL;TYPE DIABETES;BREAST CANCER;CANCER PATIENTS;CELL LUNG;PHASE II;PROSPECTIVE MULTICENTER;BRCA MUTATION;GERMLINE BRCA;ISCHEMIC STROKE;LEFT VENTRICULAR;LYMPH NODE;METASTATIC PANCREATIC;MULTICENTER STUDY;NON-ALCOHOLIC FATTY;NON-SMALL CELL;OBSERVATIONAL STUDY;PHASE III;BLOODSTREAM INFECTIONS","11;10;10;9;7;7;6;6;6;6;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;3","PUBMED SCOPUS;MAST CELL;CELL ACTIVATION;CROSSREF PUBMED;PROSTATE CANCER;HR CI;ALLERGY CLIN;HONORARIA INSTITUTION;ANGELES CALIFORNIA;LOS ANGELES;CALIFORNIA LOS;ARESTY DEPARTMENT;JOSEPH ARESTY;KECK SCHOOL;MEDICINE UNIVERSITY;SOUTHERN CALIFORNIA;UROLOGY KECK;USC INSTITUTE;BONE MARROW;ADVISORY CONSULTANCY;CLIN IMMUNOL;ACCOMMODATION EXPENSES;MEDIAN AGE;TRAVEL ACCOMMODATION;MULTIVARIATE ANALYSIS;PROGRESSION-FREE SURVIVAL;SERUM TRYPTASE;GLUCOSE TOLERANCE;LIVER DISEASE;LOGISTIC REGRESSION","68;61;40;40;38;34;31;31;30;30;29;28;28;28;28;28;28;28;25;24;23;18;18;18;16;16;16;15;15;15",230,106,0.46,2.05,24.85,1,217,1.6,1,3,1.25,1,2,0,0,0,2.8,1,18,2,2,2,0,0,0,1,1,1,28.81,1,252,1,1,1,0,0,0,23.88,3,206,0,0,0,2.5,1,4,1.53,1,5,3.68,1,14,14.08,3,115,7.1,1,72,0,0,0,0,0,0,77.15,5,278,77.15,5,278
"AOU_VERONA",2020,327,17.2507645259939,3.10091743119266,0.322485207100592,0.363914373088685,0.299694189602446,0.220183486238532,0.577981651376147,5,153,97,14,19,0.47,0.3,0.04,0.06,18.8,0.746001369024106,0.370030581039755,0.908256880733945,5.72916666666667,0.518004411390992,0.518785193390566,0.52897388914338,0.510090011614402,"SIMONE CESARO;ALESSANDRO ANTONELLI;GIOVANNI TARGHER;GIAMPAOLO TORTORA;ALESSANDRO MANTOVANI;MICHÈLE MILELLA;ALESSANDRO TAFURI;SALVATORE SIRACUSANO;FILIPPO MIGLIORINI;WALTER ARTIBANI;ANTONIO BENITO PORCARO;SARA PILOTTO;MATTEO BRUNELLI;RICCARDO RIZZETTO;MANUEL CAPPELLARI;ANDREA DALBENI;CHRISTOPHER D. BYRNE;ALIASGER SHAKIR;MARCO SEBBEN;NELIA AMIGONI","28;27;21;20;19;18;17;14;14;14;13;12;12;12;11;11;11;11;10;10","NICOLA ZAMPIERI;ALESSANDRO MANTOVANI;SIMONE CESARO;GIOVANNI TARGHER;ALESSANDRO ANTONELLI;ANDREA DALBENI;MAURO SPINA;MASSIMO BALSANO;ALESSANDRO TAFURI;GIAMPAOLO TORTORA;CLAUDIO MICHELETTO;MICHÈLE MILELLA;CHIARA ZUSI;FILIPPO MIGLIORINI;CHRISTOPHER D. BYRNE;ANTONIO BENITO PORCARO;MARIA ANGELA CERRUTO;SARA PILOTTO;MING‐HUA ZHENG;KENNETH I. ZHENG","3.7;3.69;2.68;2.47;2.19;1.6;1.53;1.38;1.35;1.24;1.24;1.21;1.19;1.08;1.01;1;0.85;0.84;0.81;0.81","SIMONE CESARO;ALESSANDRO ANTONELLI;GIOVANNI TARGHER;GIAMPAOLO TORTORA;ALESSANDRO MANTOVANI;MICHÈLE MILELLA;ALESSANDRO TAFURI;SALVATORE SIRACUSANO;FILIPPO MIGLIORINI;WALTER ARTIBANI;ANTONIO BENITO PORCARO;SARA PILOTTO;MATTEO BRUNELLI;RICCARDO RIZZETTO;MANUEL CAPPELLARI;ANDREA DALBENI;MARCO SEBBEN;NELIA AMIGONI;GLORIA TRIDELLO;ROBERTO IACOVELLI","28;27;21;20;19;18;17;14;14;14;13;12;12;12;11;11;10;10;10;10","NICOLA ZAMPIERI;ALESSANDRO MANTOVANI;SIMONE CESARO;GIOVANNI TARGHER;ALESSANDRO ANTONELLI;ANDREA DALBENI;MAURO SPINA;MASSIMO BALSANO;ALESSANDRO TAFURI;GIAMPAOLO TORTORA;CLAUDIO MICHELETTO;MICHÈLE MILELLA;CHIARA ZUSI;FILIPPO MIGLIORINI;ANTONIO BENITO PORCARO;MARIA ANGELA CERRUTO;SARA PILOTTO;ELISABETTA RINALDI;MATTEO BRUNELLI;MARCO CIPOLLI","3.7;3.69;2.68;2.47;2.19;1.6;1.53;1.38;1.35;1.24;1.24;1.21;1.19;1.08;1;0.85;0.84;0.8;0.79;0.78","SIMONE CESARO;CARLO SALVARANI;GIOVANNI DOLCI;MARCO MASSARI;MASSIMO COSTANTINI;NICOLA DUCCIO SALERNO;NICOLA FACCIOLONGO;GIOVANNI CENDERELLO;ANDREA ANGHEBEN;A BRIGNONE;ANGELINA PASSARO;CATERINA TURRÀ;CLAUDIO NORBIATO;DOMENICO FRANCO MERLO;ELISABETTA TEOPOMPI;FABRIZIO BONI;G SECONDO;ILARIA PIAZZA;LORENZO DONGHI;LORENZO ZAMMARCHI","768;759;759;759;759;759;759;718;662;654;654;654;654;654;654;654;654;654;654;654","SIMONE CESARO;NICOLA DUCCIO SALERNO;GIOVANNI TARGHER;ANTONIO LASALVIA;CHIARA BOVO;RAFFAELLA BELLINI;ALESSANDRO ANTONELLI;ANDREA DALBENI;ALESSANDRO MANTOVANI;MIRELLA RUGGERI;FRANCESCO AMADDEO;MICHÈLE MILELLA;ALESSANDRO TAFURI;SALVATORE SIRACUSANO;BRUNO BONETTI;GIOVANNA SQUINTANI;ANDREA RASERA;MANUEL CAPPELLARI;WALTER ARTIBANI;ANNA MANTOVANI","762;759;563;359;338;283;226;209;207;204;199;188;176;172;171;170;167;162;147;145","SIMONE CESARO;ALESSANDRO ANTONELLI;GIOVANNI TARGHER;ALESSANDRO TAFURI;MICHÈLE MILELLA;ALESSANDRO MANTOVANI;ANTONIO BENITO PORCARO;FILIPPO MIGLIORINI;SALVATORE SIRACUSANO;WALTER ARTIBANI;MATTEO BRUNELLI;GIAMPAOLO TORTORA;ANDREA DALBENI;MANUEL CAPPELLARI;RICCARDO RIZZETTO;GLORIA TRIDELLO;SARA PILOTTO;MARCO SEBBEN;NELIA AMIGONI;BRUNO BONETTI","27;23;17;17;16;15;14;14;13;13;12;11;11;11;11;10;10;10;10;9","MEDICINE;BIOLOGY;PSYCHOLOGY;ENGINEERING;PHYSICS;COMPUTER SCIENCE;CHEMISTRY;SOCIOLOGY;MATHEMATICS;ECONOMICS;POLITICAL SCIENCE;BUSINESS;MATERIALS SCIENCE;ART;GEOLOGY;PHILOSOPHY;ENVIRONMENTAL SCIENCE;HISTORY","319;65;19;18;18;17;14;11;10;9;7;4;3;2;2;2;1;1","INTERNAL MEDICINE;SURGERY;GASTROENTEROLOGY;ONCOLOGY;PATHOLOGY;PEDIATRICS;IMMUNOLOGY;ENDOCRINOLOGY;GENETICS;PSYCHIATRY;ENVIRONMENTAL HEALTH;UROLOGY;INTENSIVE CARE MEDICINE;CARDIOLOGY;PHYSICAL THERAPY;VIROLOGY;BIOCHEMISTRY;PALEONTOLOGY;NURSING;RADIOLOGY","272;92;62;60;52;39;38;33;31;31;30;30;27;26;19;18;17;17;16;15","DISEASE;CANCER;CONFIDENCE INTERVAL;POPULATION;CHEMOTHERAPY;DIABETES MELLITUS;GENE;CLINICAL TRIAL;LOGISTIC REGRESSION;ALTERNATIVE MEDICINE;BIOPSY;ODDS RATIO;RANDOMIZED CONTROLLED TRIAL;TRANSPLANTATION;OUTBREAK;PROSPECTIVE COHORT STUDY;COHORT;MULTIVARIATE ANALYSIS;PROPORTIONAL HAZARDS MODEL;RETROSPECTIVE COHORT STUDY","76;73;31;30;27;27;22;20;18;17;17;17;16;16;15;15;14;14;14;14","INFECTIOUS DISEASE (MEDICAL SPECIALTY);CLINICAL ENDPOINT;PROSTATE CANCER;FATTY LIVER;HAZARD RATIO;BREAST CANCER;TYPE 2 DIABETES;PLACEBO;2019-20 CORONAVIRUS OUTBREAK;HEMATOPOIETIC STEM CELL TRANSPLANTATION;IMMUNOTHERAPY;UNIVARIATE ANALYSIS;COLORECTAL CANCER;LIVER BIOPSY;PANCREATIC CANCER;PROSTATE;INSULIN RESISTANCE;PROGRESSION-FREE SURVIVAL;DOCETAXEL;NEURORADIOLOGY","25;21;20;17;17;13;13;12;11;11;11;10;9;9;9;9;8;8;7;7","CORONAVIRUS DISEASE 2019 (COVID-19);NONALCOHOLIC FATTY LIVER DISEASE;NIVOLUMAB;PROSTATECTOMY;ANDROGEN DEPRIVATION THERAPY;STEATOHEPATITIS;ANDROGEN RECEPTOR;POLY ADP RIBOSE POLYMERASE;PROSTATE BIOPSY;PROSTATE-SPECIFIC ANTIGEN;VINCRISTINE;CYSTECTOMY;IRINOTECAN;MODIFIED RANKIN SCALE;NERVE BIOPSY;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;VARICOCELE;ADIPONECTIN;AXITINIB;BASDAI;CARBOPLATIN;CASPOFUNGIN;CUTANEOUS MASTOCYTOSIS;DOUBLE BLIND;HOMEOSTATIC MODEL ASSESSMENT;MAMMOGRAPHY;MISSENSE MUTATION;NEOADJUVANT THERAPY;OVARIAN RESERVE;OXALIPLATIN;PANCREATIC DUCTAL ADENOCARCINOMA;PEMBROLIZUMAB;POSACONAZOLE;PRIMARY TUMOR;PROSTATITIS;TARGET LESION;TRANSIENT ELASTOGRAPHY;TRASTUZUMAB","25;9;7;7;6;6;5;5;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",";HUMANS;MALE;FEMALE;MIDDLE AGED;AGED;ITALY;COVID-19;ADULT;NON-ALCOHOLIC FATTY LIVER DISEASE;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;CORONAVIRUS INFECTIONS;LIVER;PNEUMONIA, VIRAL;SARS-COV-2;ADOLESCENT;AGED, 80 AND OVER;PROSPECTIVE STUDIES;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS","211;115;72;71;61;43;43;42;38;31;27;24;21;18;18;18;16;16;16;15","EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;PANCREATIC CANCER RESEARCH AND TREATMENT;RENAL CELL CARCINOMA;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;PROSTATE CANCER RESEARCH AND TREATMENT;THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;LYMPHOID NEOPLASMS;CORONAVIRUS DISEASE 2019;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;POLY(ADP-RIBOSE) POLYMERASE INHIBITION IN CANCER THERAPY;HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AND RELATED DISORDERS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ATRIAL FIBRILLATION;EPIDEMIOLOGY AND MANAGEMENT OF SEXUAL DYSFUNCTION;EPILEPSY AND SEIZURES;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GENETIC BASIS OF NEUTROPENIA DISORDERS","23;10;10;9;9;8;8;7;6;6;5;5;5;4;3;3;3;3;3;3","CLINICAL ENDPOINT;NAFLD;PANDEMIC;PROSTATE CANCER;STROKE (ENGINE);TREATMENT;2019-20 CORONAVIRUS OUTBREAK;UNIVARIATE ANALYSIS;INFARCTION TREATMENT;PANCREATIC CANCER;METASTATIC PANCREATIC CANCER;PROGRESSION-FREE SURVIVAL;CYSTIC FIBROSIS;NEURORADIOLOGY;METASTATIC PROSTATE CANCER;STEATOHEPATITIS;CABAZITAXEL;DIAGNOSIS;ENZALUTAMIDE;HEMATOLOGY","22;16;13;12;12;12;11;10;9;9;8;8;7;7;6;6;5;5;5;5","PROSTATE CANCER;CYSTIC FIBROSIS;TYPE DIABETES;CANCER PATIENTS;CELL TRANSPLANTATION;LIVER DISEASE;CELL CARCINOMA;FATTY LIVER;PANCREATIC CANCER;PATIENTS PTS;RENAL CELL;METASTATIC RENAL;STEM CELL;BREAST CANCER;HEMATOPOIETIC STEM;PARTIAL NEPHRECTOMY;PHASE II;RADICAL PROSTATECTOMY;ISCHEMIC STROKE;ITALIAN REGISTRY;LEFT VENTRICULAR;LYMPH NODE;MARROW TRANSPLANTATION;METASTATIC PANCREATIC;MULTICENTER STUDY;PATIENTS AFFECTED;ADVANCED PANCREATIC;BLADDER CANCER;CANCER MCRPC;CARCINOMA MRCC","16;12;11;10;10;10;9;9;9;9;9;8;8;7;6;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4","RESEARCH FUNDING;ADVISORY COMMITTEES;ENTITYS BOARD;SPEAKERS BUREAU;PAVIA ITALY;LIVER DISEASE;MAUGERI PAVIA;AC MMOLTENI;AC SN;CL CN;CLINICI SCIENTIFICI;CN LC;DK SM;FF PC;IRCCS ISTITUTI;ISTITUTI CLINICI;LC SGP;MMEMMI PG;MMOLTENI RB;MMORINI AC;NM TM;PC CL;PDC FF;PG AC;RB MMEMMI;RB RS;RS SS;SCIENTIFICI MAUGERI;SN RB;SS PDC","70;54;54;54;32;29;26;24;24;24;24;24;24;24;24;24;24;24;24;24;24;24;24;24;24;24;24;24;24;24",327,151,0.46,2.5,39.5,1,500,1.71,1,3,1.55,1,5,0,0,0,6.67,1,51,1,1,1,1,1,1,3,1,5,46.74,1,578,0,0,0,1,1,1,35.73,1,437,0,0,0,0,0,0,2.29,1,11,8.6,1,58,22.97,1,316,8.88,1,52,0,0,0,0,0,0,105.21,5,776,105.21,5,776
"AOU_VERONA",2021,313,16.9680511182109,2.98402555910543,0.335117773019272,0.284345047923323,0.284345047923323,0.223642172523962,0.635782747603834,2,128,93,15,28,0.41,0.3,0.05,0.09,11.29,0.732387071761311,0.373801916932907,0.92332268370607,6.04575645756458,0.472730538885773,0.515666598402621,0.493150684931507,0.494716183574879,"ALESSANDRO ANTONELLI;GIOVANNI TARGHER;SIMONE CESARO;ALESSANDRO TAFURI;MARIA ANGELA CERRUTO;CHRISTOPHER D. BYRNE;MING‐HUA ZHENG;MATTEO BRUNELLI;MICHÈLE MILELLA;BRUNO BONETTI;MANUEL CAPPELLARI;ANTONIO BENITO PORCARO;GLORIA TRIDELLO;CLAUDIO MICHELETTO;RICCARDO RIZZETTO;KENNETH I. ZHENG;FILIPPO MIGLIORINI;DOMENICO GIRELLI;NELIA AMIGONI;STEFANIA MONTEMEZZI","31;22;21;20;15;15;13;13;12;12;11;11;11;10;10;10;9;9;9;9","GIOVANNI TARGHER;ALESSANDRO ANTONELLI;ALESSANDRO MANTOVANI;ALESSANDRO TAFURI;NICOLA ZAMPIERI;SIMONE CESARO;CHRISTOPHER D. BYRNE;CLAUDIO MICHELETTO;MARIA ANGELA CERRUTO;ANDREA DALBENI;BRUNO BONETTI;MING‐HUA ZHENG;MANUEL CAPPELLARI;STEFANIA MONTEMEZZI;MICHÈLE MILELLA;DOMENICO GIRELLI;GIOVANNI GAMBARO;CECILIA ZIVELONGHI;NICOLA MICHELETTI;KENNETH I. ZHENG","2.8;2.51;1.47;1.44;1.33;1.3;1.27;1.27;1.17;1.14;1.08;1.02;1.01;0.97;0.94;0.86;0.83;0.82;0.8;0.79","ALESSANDRO ANTONELLI;GIOVANNI TARGHER;SIMONE CESARO;ALESSANDRO TAFURI;MARIA ANGELA CERRUTO;MATTEO BRUNELLI;MICHÈLE MILELLA;BRUNO BONETTI;MANUEL CAPPELLARI;ANTONIO BENITO PORCARO;GLORIA TRIDELLO;CLAUDIO MICHELETTO;RICCARDO RIZZETTO;FILIPPO MIGLIORINI;DOMENICO GIRELLI;NELIA AMIGONI;STEFANIA MONTEMEZZI;CLARA CERRATO;ALESSANDRA GOZZO;ANTONIO LASALVIA","31;22;21;20;15;13;12;12;11;11;11;10;10;9;9;9;9;9;9;9","GIOVANNI TARGHER;ALESSANDRO ANTONELLI;ALESSANDRO MANTOVANI;ALESSANDRO TAFURI;NICOLA ZAMPIERI;SIMONE CESARO;CLAUDIO MICHELETTO;MARIA ANGELA CERRUTO;ANDREA DALBENI;BRUNO BONETTI;MANUEL CAPPELLARI;STEFANIA MONTEMEZZI;MICHÈLE MILELLA;DOMENICO GIRELLI;GIOVANNI GAMBARO;CECILIA ZIVELONGHI;NICOLA MICHELETTI;ANTONIO LASALVIA;MATTEO BRUNELLI;FLAVIO RIBICHINI","2.8;2.51;1.47;1.44;1.33;1.3;1.27;1.17;1.14;1.08;1.01;0.97;0.94;0.86;0.83;0.82;0.8;0.78;0.74;0.73","GIOVANNI TARGHER;ANTONIO LASALVIA;CHIARA BONETTO;FRANCESCO AMADDEO;ANGELA CARTA;STEFANO PORRU;MIRELLA RUGGERI;ALESSANDRO ANTONELLI;CHIARA BOVO;STEFANO TARDIVO;SIMONE CESARO;CHRISTOPHER D. BYRNE;DOMENICO GIRELLI;MING‐HUA ZHENG;ALESSANDRO TAFURI;FABIANA BUSTI;GLORIA TRIDELLO;ALESSANDRO MANTOVANI;NINA KNELANGE;RAFAEL DE LA CÁMARA","368;364;346;336;298;298;278;269;262;259;202;201;200;165;163;156;152;136;131;131","GIOVANNI TARGHER;ANTONIO LASALVIA;FRANCESCO AMADDEO;ALESSANDRO ANTONELLI;MIRELLA RUGGERI;CHIARA BOVO;DOMENICO GIRELLI;SIMONE CESARO;ALESSANDRO TAFURI;FABIANA BUSTI;GLORIA TRIDELLO;ALESSANDRO MANTOVANI;MARIA ANGELA CERRUTO;PATRIZIA BONADONNA;STEFANIA MONTEMEZZI;MARCO CIPOLLI;ERNESTO CRISAFULLI;DANIELE GABBIANI;LUCA DALLE CARBONARE;MANUEL CAPPELLARI","368;359;336;269;266;262;190;180;158;152;152;136;105;94;93;88;85;84;76;75","ALESSANDRO ANTONELLI;GIOVANNI TARGHER;ALESSANDRO TAFURI;SIMONE CESARO;MARIA ANGELA CERRUTO;MATTEO BRUNELLI;MANUEL CAPPELLARI;ANTONIO BENITO PORCARO;GLORIA TRIDELLO;BRUNO BONETTI;RICCARDO RIZZETTO;CLAUDIO MICHELETTO;ALESSANDRA GOZZO;CLARA CERRATO;MICHÈLE MILELLA;NELIA AMIGONI;FILIPPO MIGLIORINI;ALBERTO BIANCHI;ANDREA DALBENI;STEFANIA MONTEMEZZI","31;22;19;19;15;12;11;11;11;10;10;10;9;9;9;9;9;8;8;8","MEDICINE;BIOLOGY;ENGINEERING;PHYSICS;PSYCHOLOGY;COMPUTER SCIENCE;MATHEMATICS;CHEMISTRY;ECONOMICS;SOCIOLOGY;PHILOSOPHY;POLITICAL SCIENCE;MATERIALS SCIENCE;ART;BUSINESS;GEOGRAPHY;HISTORY","306;76;24;21;20;16;14;13;11;11;9;8;4;2;2;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;GASTROENTEROLOGY;PATHOLOGY;GENETICS;ENDOCRINOLOGY;RADIOLOGY;CARDIOLOGY;PEDIATRICS;ENVIRONMENTAL HEALTH;UROLOGY;IMMUNOLOGY;INTENSIVE CARE MEDICINE;PSYCHIATRY;BIOCHEMISTRY;CANCER RESEARCH;MECHANICAL ENGINEERING;OPTICS;GYNECOLOGY;PALEONTOLOGY;PHYSICAL THERAPY","260;73;54;46;43;36;35;34;32;31;30;30;27;25;23;18;17;17;17;15;15;15","CANCER;DISEASE;CONFIDENCE INTERVAL;COHORT;POPULATION;GENE;DIABETES MELLITUS;OBSERVATIONAL STUDY;CHEMOTHERAPY;ODDS RATIO;RETROSPECTIVE COHORT STUDY;TRANSPLANTATION;INCIDENCE (GEOMETRY);LOGISTIC REGRESSION;MAGNETIC RESONANCE IMAGING;BIOPSY;CLINICAL TRIAL;HEART FAILURE;PROSPECTIVE COHORT STUDY;STROKE (ENGINE)","73;64;34;32;30;24;22;21;19;19;19;19;17;16;16;15;15;15;15;15","INFECTIOUS DISEASE (MEDICAL SPECIALTY);FATTY LIVER;PROSTATE CANCER;BREAST CANCER;HAZARD RATIO;CLINICAL ENDPOINT;IMMUNOTHERAPY;TYPE 2 DIABETES;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PROSTATE;2019-20 CORONAVIRUS OUTBREAK;LIVER BIOPSY;EJECTION FRACTION;NEURORADIOLOGY;BLADDER CANCER;COLORECTAL CANCER;UNIVARIATE ANALYSIS;HAEMATOPOIESIS;METASTASIS;NEPHRECTOMY;PROGRESSION-FREE SURVIVAL","22;19;18;17;16;12;11;11;10;10;9;9;8;8;7;7;7;6;6;6;6","CORONAVIRUS DISEASE 2019 (COVID-19);NONALCOHOLIC FATTY LIVER DISEASE;PROSTATE-SPECIFIC ANTIGEN;PROSTATECTOMY;CYSTECTOMY;NIVOLUMAB;LOWER URINARY TRACT SYMPTOMS;MAMMOGRAPHY;NEOADJUVANT THERAPY;PEMBROLIZUMAB;ADENOSINE DEAMINASE DEFICIENCY;ANDROGEN DEPRIVATION THERAPY;ANDROGEN RECEPTOR;CAPECITABINE;HEMATOPOIETIC CELL;METASTATIC BREAST CANCER;RIGHT CORONARY ARTERY;STEATOHEPATITIS;TRANSURETHRAL RESECTION OF THE PROSTATE;ACHROMOBACTER;ANTERIOR CEREBRAL ARTERY;BREAST RECONSTRUCTION;CARDIAC RESYNCHRONIZATION THERAPY;FEBRILE NEUTROPENIA;FERROPORTIN;GENOME INSTABILITY;HISTONE DEACETYLASE;INTRACYTOPLASMIC SPERM INJECTION;IPILIMUMAB;IVACAFTOR;MASTECTOMY;METERED-DOSE INHALER;MODIFIED RANKIN SCALE;NON-SMALL CELL LUNG CANCER (NSCLC);OXALIPLATIN;PANCREATIC DUCTAL ADENOCARCINOMA;POSACONAZOLE;PTEN;SPECKLE TRACKING ECHOCARDIOGRAPHY;TOTAL MESORECTAL EXCISION;TUMOR-INFILTRATING LYMPHOCYTES;VARICOCELE;VINCRISTINE;WHOLE GENOME SEQUENCING","22;9;7;7;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;;FEMALE;MALE;RETROSPECTIVE STUDIES;MIDDLE AGED;ADULT;AGED;ITALY;COVID-19;PROSTATIC NEOPLASMS;NON-ALCOHOLIC FATTY LIVER DISEASE;TREATMENT OUTCOME;CHILD;ADOLESCENT;KIDNEY NEOPLASMS;PROSPECTIVE STUDIES;RISK FACTORS;ROBOTIC SURGICAL PROCEDURES;LIVER CIRRHOSIS","158;153;69;69;48;40;36;36;35;32;29;27;26;19;18;18;18;18;18;16","EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;RENAL CELL CARCINOMA;PROSTATE CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;ASTHMA;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;PELVIC FLOOR DISORDERS;RADIOMICS IN MEDICAL IMAGING ANALYSIS;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;CANCER IMMUNOTHERAPY;DIAGNOSIS AND MANAGEMENT OF POLYCYSTIC OVARY SYNDROME;EPIDEMIOLOGY AND MANAGEMENT OF CONGENITAL HEART DISEASE;MANAGEMENT OF DIABETES MELLITUS AND HYPOGLYCEMIA;ROLE OF MAST CELLS IN IMMUNOREGULATION AND DISEASE;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ADVANCEMENTS IN LUNG CANCER RESEARCH;ATRIAL FIBRILLATION;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY","19;11;9;7;7;6;5;5;5;5;4;4;4;4;4;4;3;3;3;3","CLINICAL ENDPOINT;STROKE (ENGINE);TREATMENT;PROSTATE CANCER;NAFLD;PANDEMIC;2019-20 CORONAVIRUS OUTBREAK;CYSTIC FIBROSIS;DIABETES;METASTATIC PROSTATE CANCER;NEURORADIOLOGY;INTERQUARTILE RANGE;TYPE 1 DIABETES;UNIVARIATE ANALYSIS;CANCER IMAGING;CARDIAC IMAGING;CROSS-SECTIONAL STUDY;DISCONTINUATION;NEPHROLOGY;PROGRESSION-FREE SURVIVAL","14;13;12;10;9;9;8;8;8;8;8;7;7;7;6;6;6;6;6;6","LIVER DISEASE;FATTY LIVER;CYSTIC FIBROSIS;OBSERVATIONAL STUDY;PROSTATE CANCER;TYPE DIABETES;BREAST CANCER;CELL CARCINOMA;PHASE II;RENAL CELL;CELL TRANSPLANTATION;BLADDER CANCER;CANCER PATIENTS;CROSS-SECTIONAL STUDY;ENDOGENOUS TESTOSTERONE;EUROPEAN SOCIETY;HEMATOPOIETIC STEM;METASTATIC RENAL;NONALCOHOLIC FATTY;RADICAL CYSTECTOMY;SEVERE ASTHMA;STEM CELL;COVID- PANDEMIC;INFECTIOUS DISEASES;MARROW TRANSPLANTATION;PATIENTS TREATED;PROSPECTIVE STUDY;RETROSPECTIVE STUDY;ATRIAL FIBRILLATION;CARDIOVASCULAR RISK","16;13;11;11;11;10;9;9;8;8;7;6;6;6;6;6;6;6;6;6;6;6;5;5;5;5;5;5;4;4","ADVISORY COMMITTEES;ENTITYS BOARD;SPEAKERS BUREAU;RESEARCH FUNDING;CONSULTANCY HONORARIA;LIVER DISEASE;LIVER FIBROSIS;HR CI;HONORARIA MEMBERSHIP;FATTY LIVER;MEDIAN AGE;MULTIVARIATE ANALYSIS;IRON OVERLOAD;HEART FAILURE;LOGISTIC REGRESSION;RISK FACTORS;BONE MARROW;CONFIDENCE INTERVAL;COVID- PANDEMIC;INCREASED RISK;PB- PB-;PRIMARY ENDPOINT;AF PROPHYLAXIS;HONORARIA RESEARCH;INTENSIVE CARE;MEDIAN FOLLOW-UP;ODDS RATIO;PATIENTS TREATED;RADICAL CYSTECTOMY;RESPONSE RATE","70;70;56;50;41;29;29;28;27;18;18;18;17;16;16;16;15;15;15;15;15;14;13;13;13;13;13;13;13;13",313,170,0.54,1.8,18.81,1,70,2,1,4,1,1,1,0,0,0,1.12,1,3,0,0,0,0,0,0,2,2,2,22.95,1,85,1,1,1,0,0,0,18.26,1,67,0,0,0,0,0,0,1.75,1,6,4.1,1,12,11.62,1,53,3.71,1,11,0,0,0,0,0,0,45.09,10,550,44.98,10,550
"AOU_VERONA",2022,333,20.3033033033033,3.16516516516517,0.315939278937381,0.276276276276276,0.243243243243243,0.213213213213213,0.702702702702703,0,136,86,10,24,0.41,0.26,0.03,0.07,7.06,0.790546485287868,0.435435435435435,0.930930930930931,5.33483580167418,0.514147195179443,0.640649242153001,0.638923442270723,0.58117816091954,"ALESSANDRO ANTONELLI;ANDREA PANUNZIO;MARIA ANGELA CERRUTO;SHAHROKH F. SHARIAT;CARLO TERRONE;ZHE TIAN;FELIX K.‐H. CHUN;ALBERTO BRIGANTI;FRED SAAD;SIMONE CESARO;ALESSANDRO TAFURI;LUKAS HOHENHORST;GIOVANNI TARGHER;DERYA TILKI;STEFANO TAPPERO;GABRIELE SORCE;OTTAVIO DE COBELLI;CHRISTOPHER D. BYRNE;PIERRE I. KARAKIEWICZ;MATTEO BALZARRO","58;35;28;27;26;24;23;23;23;21;20;18;18;17;17;16;15;15;15;14","ALESSANDRO ANTONELLI;MARIA ANGELA CERRUTO;ANDREA PANUNZIO;GIOVANNI TARGHER;MATTEO BALZARRO;EMANUELE RUBILOTTA;CHRISTOPHER D. BYRNE;CARLO TERRONE;SHAHROKH F. SHARIAT;ZHE TIAN;ALESSANDRO MANTOVANI;ALESSANDRO TAFURI;FELIX K.‐H. CHUN;FRED SAAD;MARILENA GUBBIOTTI;ALBERTO BRIGANTI;SIMONE CESARO;DAVID SACERDOTI;MING‐HUA ZHENG;ANDREA DALBENI","3.89;2.18;1.98;1.97;1.85;1.67;1.6;1.31;1.29;1.27;1.24;1.23;1.21;1.21;1.2;1.16;1.13;1.01;1;0.98","ALESSANDRO ANTONELLI;ANDREA PANUNZIO;MARIA ANGELA CERRUTO;SIMONE CESARO;ALESSANDRO TAFURI;GIOVANNI TARGHER;MATTEO BALZARRO;MATTEO BRUNELLI;ANTONIO BENITO PORCARO;ANDREA DALBENI;EMANUELE RUBILOTTA;MASSIMILIANO BONIFACIO;ALBERTO BIANCHI;CLAUDIO MAFFEIS;DAVID SACERDOTI;FILIPPO CATTAZZO;MANUEL CAPPELLARI;SEBASTIAN GALLINA;MICHÈLE MILELLA;EMANUELE SERAFIN","58;35;28;21;20;18;14;12;12;12;11;11;11;10;10;9;9;9;8;8","ALESSANDRO ANTONELLI;MARIA ANGELA CERRUTO;ANDREA PANUNZIO;GIOVANNI TARGHER;MATTEO BALZARRO;EMANUELE RUBILOTTA;ALESSANDRO MANTOVANI;ALESSANDRO TAFURI;SIMONE CESARO;DAVID SACERDOTI;ANDREA DALBENI;FILIPPO CATTAZZO;MIRELLA RUGGERI;CLAUDIO MAFFEIS;MARCO CIPOLLI;FLAVIO RIBICHINI;F. RIBICHINI;ANTONIO BENITO PORCARO;ALBERTO BIANCHI;MATTEO BRUNELLI","3.89;2.18;1.98;1.97;1.85;1.67;1.24;1.23;1.13;1.01;0.98;0.93;0.86;0.76;0.75;0.7;0.67;0.65;0.64;0.63","ALESSANDRO ANTONELLI;SIMONE CESARO;LUCA TOMASI;GIOVANNI TARGHER;ANDREA PANUNZIO;SHAHROKH F. SHARIAT;CHRISTOPHER D. BYRNE;MING‐HUA ZHENG;CARLO TERRONE;ARMANDO SANTORO;MANUEL CAPPELLARI;ALESSIO GARGARO;ANDREA RADINOVIC;DANIELA ORSIDA;DANIELE GIACOPELLI;F. PENTIMALLI;FRANCESCA BARATTO;FRÉDÉRIC SACHER;GIOVANNI PERETTO;JOÃO DE SOUSA","249;180;171;159;154;154;153;145;140;134;122;120;120;120;120;120;120;120;120;120","ALESSANDRO ANTONELLI;SIMONE CESARO;LUCA TOMASI;GIOVANNI TARGHER;ANDREA PANUNZIO;MANUEL CAPPELLARI;MARIA ANGELA CERRUTO;ALESSANDRO TAFURI;FLAVIO RIBICHINI;SARA MIRANDOLA;MARCO CIPOLLI;ANDREA BORDUGO;GIOVANNI PAOLO POLLINI;GIOVANNA ZANONI;PAOLA MELOTTI;CLAUDIO MAFFEIS;GLORIA TRIDELLO;CLARA CERRATO;ELISABETTA ALLEGRINI;MATTEO BRUNELLI","249;175;171;159;151;122;92;89;89;86;81;79;78;76;61;57;55;53;52;51","ALESSANDRO ANTONELLI;ANDREA PANUNZIO;MARIA ANGELA CERRUTO;SIMONE CESARO;GIOVANNI TARGHER;ALESSANDRO TAFURI;MATTEO BALZARRO;ANDREA DALBENI;ANTONIO BENITO PORCARO;MATTEO BRUNELLI;ALBERTO BIANCHI;EMANUELE RUBILOTTA;MASSIMILIANO BONIFACIO;MANUEL CAPPELLARI;SEBASTIAN GALLINA;ALESSANDRO MANTOVANI;ANNA MANTOVANI;CLAUDIO MAFFEIS;DAVID SACERDOTI;EMANUELE SERAFIN","58;32;28;19;18;18;14;12;12;12;11;11;11;9;9;8;8;8;8;8","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;PSYCHOLOGY;COMPUTER SCIENCE;ENGINEERING;SOCIOLOGY;MATHEMATICS;POLITICAL SCIENCE;ECONOMICS;PHILOSOPHY;BUSINESS;HISTORY;MATERIALS SCIENCE;ENVIRONMENTAL SCIENCE;GEOGRAPHY;GEOLOGY","323;77;33;19;19;13;13;11;7;7;6;5;2;2;2;1;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;GASTROENTEROLOGY;UROLOGY;CARDIOLOGY;PATHOLOGY;IMMUNOLOGY;ENDOCRINOLOGY;GENETICS;ENVIRONMENTAL HEALTH;PEDIATRICS;PSYCHIATRY;RADIOLOGY;OPTICS;INTENSIVE CARE MEDICINE;PALEONTOLOGY;BIOCHEMISTRY;MECHANICAL ENGINEERING;NURSING","273;80;67;55;46;42;40;36;34;34;32;27;26;24;23;19;19;17;13;13","CANCER;DISEASE;COHORT;POPULATION;CONFIDENCE INTERVAL;GENE;CHEMOTHERAPY;DIABETES MELLITUS;PROPORTIONAL HAZARDS MODEL;ODDS RATIO;INCIDENCE (GEOMETRY);PROSPECTIVE COHORT STUDY;RETROSPECTIVE COHORT STUDY;CYSTIC FIBROSIS;TRANSPLANTATION;LOGISTIC REGRESSION;BONE MARROW;CLINICAL TRIAL;ADVERSE EFFECT;HEART FAILURE;OBSERVATIONAL STUDY;RENAL CELL CARCINOMA;STAGE (STRATIGRAPHY)","76;69;37;32;29;27;24;24;21;20;19;18;18;17;17;15;14;14;13;13;13;13;13","INFECTIOUS DISEASE (MEDICAL SPECIALTY);FATTY LIVER;HAZARD RATIO;PROSTATE CANCER;BLADDER CANCER;TYPE 2 DIABETES;PROSTATE;BREAST CANCER;IMMUNOTHERAPY;CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;NEPHRECTOMY;EJECTION FRACTION;HEMATOPOIETIC STEM CELL TRANSPLANTATION;NEUTROPENIA;MYELOFIBROSIS;CLINICAL ENDPOINT;CUMULATIVE INCIDENCE;ADENOCARCINOMA;CYCLOPHOSPHAMIDE;LIVER BIOPSY;MUTATION;POISSON REGRESSION;TYPE 1 DIABETES","31;19;18;18;17;16;12;11;11;10;10;9;8;8;7;6;6;5;5;5;5;5;5","CORONAVIRUS DISEASE 2019 (COVID-19);CYSTECTOMY;PROSTATECTOMY;NIVOLUMAB;NONALCOHOLIC FATTY LIVER DISEASE;STEATOHEPATITIS;RUXOLITINIB;PROSTATE-SPECIFIC ANTIGEN;BONE MARROW FAILURE;IVACAFTOR;TRASTUZUMAB;UROTHELIAL CARCINOMA;VINCRISTINE;ACUTE LYMPHOCYTIC LEUKEMIA;ANAPLASTIC LYMPHOMA KINASE;ANDROGEN DEPRIVATION THERAPY;BLINATUMOMAB;CASPOFUNGIN;CHLORAMBUCIL;CONGENITAL NEUTROPENIA;CUTANEOUS MASTOCYTOSIS;FRACTIONAL FLOW RESERVE;GLYCATED HEMOGLOBIN;GREY MATTER;IMPAIRED GLUCOSE TOLERANCE;LOWER URINARY TRACT SYMPTOMS;MISSENSE MUTATION;MYELOPROLIFERATIVE NEOPLASM;NEOADJUVANT THERAPY;POSACONAZOLE;PROSTATE BIOPSY;ROS1;SENTINEL LYMPH NODE;STROKE VOLUME;SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS;TRANSIENT ELASTOGRAPHY;UROTHELIAL CANCER","31;13;12;6;6;6;5;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",";HUMANS;MALE;COVID-19;RETROSPECTIVE STUDIES;FEMALE;PROSTATIC NEOPLASMS;TREATMENT OUTCOME;KIDNEY NEOPLASMS;STROKE;CARCINOMA, RENAL CELL;CHILD;ADULT;URINARY BLADDER NEOPLASMS;NON-ALCOHOLIC FATTY LIVER DISEASE;PROSTATECTOMY;PROSPECTIVE STUDIES;BRAIN ISCHEMIA;DIABETES MELLITUS, TYPE 2;ITALY","174;157;41;36;36;32;25;25;24;24;22;22;21;21;20;19;17;16;15;15","EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;RENAL CELL CARCINOMA;THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;PROSTATE CANCER RESEARCH AND TREATMENT;PELVIC FLOOR DISORDERS;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;GENETIC BASIS OF NEUTROPENIA DISORDERS;PANCREATIC CANCER RESEARCH AND TREATMENT;ROLE OF MAST CELLS IN IMMUNOREGULATION AND DISEASE;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;ACUTE MYELOID LEUKEMIA;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;EPIDEMIOLOGY AND PATHOGENESIS OF RESPIRATORY VIRAL INFECTIONS;GENETICS AND PATHOGENESIS OF TYPE 1 DIABETES","23;19;15;12;11;8;7;7;6;6;6;5;4;3;3;3;3;3;3;3","PANDEMIC;CYSTIC FIBROSIS;PROSTATE CANCER;STROKE (ENGINE);METASTATIC BLADDER CANCER;TREATMENT;DIABETES;INTERQUARTILE RANGE;NAFLD;RENAL CELL CARCINOMA;BLADDER CANCER;CONCOMITANT;DISCONTINUATION;ETIOLOGY;METASTATIC PROSTATE CANCER;CLINICAL ENDPOINT;CUMULATIVE INCIDENCE;LIVER BIOPSY;NEPHROLOGY;STEATOHEPATITIS","13;12;12;12;10;10;9;9;9;9;8;8;8;7;7;6;6;6;6;6","CYSTIC FIBROSIS;CANCER PATIENTS;CELL CARCINOMA;FATTY LIVER;LIVER DISEASE;PROSTATE CANCER;RADICAL CYSTECTOMY;PATIENTS TREATED;RADICAL PROSTATECTOMY;BLADDER CANCER;RENAL CELL;TYPE DIABETES;BREAST CANCER;STEM CELL;CELL TRANSPLANTATION;COVID- PANDEMIC;LYMPH NODE;METASTATIC RENAL;NON-ALCOHOLIC FATTY;PHASE II;HEART FAILURE;ISCHEMIC STROKE;OBSERVATIONAL STUDY;ACUTE LYMPHOBLASTIC;COHORT STUDY;FIBROSIS TRANSMEMBRANE;HEPATOCELLULAR CARCINOMA;MULTICENTER STUDY;REGISTRY STUDY;TRANSMEMBRANE CONDUCTANCE","17;13;13;13;13;13;13;12;11;10;10;10;9;8;7;7;7;7;7;7;6;6;6;5;5;5;5;5;5;5","PATIENTS TREATED;HR CI;RENAL FUNCTION;CROSSREF PUBMED;PUBMED SCOPUS;MELANOMA CELLS;TYPE DIABETES;MEDIAN AGE;LIVER FIBROSIS;PATIENTS RECEIVING;PATIENTS UNDERGOING;HEART FAILURE;LIVER DISEASE;LOGISTIC REGRESSION;DISEASE PROGRESSION;LYMPH NODE;PCA PATIENTS;REGRESSION MODELS;BONE MARROW;CFTR MODULATORS;COVID- PANDEMIC;MRCC PATIENTS;SARS-COV- INFECTION;SOX PROTEIN;SURVIVAL OS;VIEW LARGEDOWNLOAD;FATTY LIVER;ODDS RATIO;STATISTICALLY SIGNIFICANT;BLADDER CANCER","30;24;24;22;22;21;21;19;18;18;17;16;16;16;15;15;15;15;14;14;14;14;14;14;14;14;13;13;13;12",333,151,0.45,1.5,142.11,1,3608,1.71,1,4,1.8,1,3,0,0,0,12.56,1,75,0,0,0,1,1,1,1,1,1,189.13,1,5142,0,0,0,1,1,1,142.86,1,3604,0,0,0,4,4,4,2.4,1,7,7.6,1,48,128.75,1,3542,7.9,1,39,0,0,0,0,0,0,26.39,2,120,26.39,2,120
"AOU_VERONA",2023,357,21.5742296918768,3.19047619047619,0.313432835820896,0.285714285714286,0.249299719887955,0.179271708683473,0.649859943977591,0,171,88,15,16,0.48,0.25,0.04,0.04,4.41,1.00526410297018,0.436974789915966,0.943977591036415,5.11077844311378,0.499901261294987,0.503010752688172,0.583044982698962,0.449103375527426,"ALESSANDRO ANTONELLI;SIMONE CESARO;MICHÈLE MILELLA;DAVIDE MELISI;MARCO CIPOLLI;MARIA ANGELA CERRUTO;ANDREA PANUNZIO;MASSIMILIANO BONIFACIO;FRANCESCO DITONNO;EMANUELE RUBILOTTA;MANUEL CAPPELLARI;CLAUDIO MAFFEIS;FLAVIO RIBICHINI;MATTEO BALZARRO;ALBERTO BRIGANTI;GLORIA TRIDELLO;CARLO TERRONE;GIOVANNI TARGHER;ANTONIO LASALVIA;SHAHROKH F. SHARIAT","45;19;18;18;17;17;17;16;15;15;15;14;14;14;13;13;12;11;11;11","ALESSANDRO ANTONELLI;EMANUELE RUBILOTTA;MATTEO BALZARRO;MARCO CIPOLLI;SIMONE CESARO;MARIA ANGELA CERRUTO;CLAUDIO MAFFEIS;MICHÈLE MILELLA;FRANCESCO DITONNO;DAVIDE MELISI;GIOVANNI TARGHER;STEFANIA MONTEMEZZI;FRANCESCA LUCCA;ANTONIO LASALVIA;ANDREA PANUNZIO;MARILENA GUBBIOTTI;FLAVIO RIBICHINI;MANUEL CAPPELLARI;ALESSANDRO MANTOVANI;CHIARA BONETTO","3.03;1.65;1.63;1.57;1.31;1.11;1.08;1.01;1.01;1;0.96;0.93;0.92;0.87;0.86;0.83;0.83;0.82;0.81;0.81","ALESSANDRO ANTONELLI;SIMONE CESARO;MICHÈLE MILELLA;DAVIDE MELISI;MARCO CIPOLLI;MARIA ANGELA CERRUTO;ANDREA PANUNZIO;MASSIMILIANO BONIFACIO;FRANCESCO DITONNO;EMANUELE RUBILOTTA;MANUEL CAPPELLARI;CLAUDIO MAFFEIS;FLAVIO RIBICHINI;MATTEO BALZARRO;GLORIA TRIDELLO;GIOVANNI TARGHER;ANTONIO LASALVIA;ALESSANDRO VECCIA;MIRELLA RUGGERI;ALDO SCARPA","45;19;18;18;17;17;17;16;15;15;15;14;14;14;13;11;11;11;10;10","ALESSANDRO ANTONELLI;EMANUELE RUBILOTTA;MATTEO BALZARRO;MARCO CIPOLLI;SIMONE CESARO;MARIA ANGELA CERRUTO;CLAUDIO MAFFEIS;MICHÈLE MILELLA;FRANCESCO DITONNO;DAVIDE MELISI;GIOVANNI TARGHER;STEFANIA MONTEMEZZI;FRANCESCA LUCCA;ANTONIO LASALVIA;ANDREA PANUNZIO;FLAVIO RIBICHINI;MANUEL CAPPELLARI;ALESSANDRO MANTOVANI;GLORIA TRIDELLO;FRANCESCA MONTANARO","3.03;1.65;1.63;1.57;1.31;1.11;1.08;1.01;1.01;1;0.96;0.93;0.92;0.87;0.86;0.83;0.82;0.81;0.77;0.7","DAVIDE MELISI;AHMED O. KASEB;ANN‐LII CHENG;ARNDT VOGEL;CHUNXIA CHEN;DMITRIY M. PONOMARENKO;FANG YANG;HONG REN;IVAN SINIELNIKOV;JIANPING XIONG;JUN LIANG;LIANG XIAO;LINNA WANG;MARGARYTA PISETSKA;MONIKA PAZGAN−SIMON;SHANZHI GU;SHUKUI QIN;STEPHEN L. CHAN;TSAI‐SHENG YANG;WEI LI","657;458;458;458;458;458;458;458;458;458;458;458;458;458;458;458;458;458;458;458","DAVIDE MELISI;DA JIANG;DA LI;ALESSANDRO ANTONELLI;ALESSANDRO VECCIA;GIOVANNI TARGHER;SIMONE CESARO;ALESSANDRO MANTOVANI;MARIA ANGELA CERRUTO;MARCO CIPOLLI;MANUEL CAPPELLARI;MICHELE PAVARANA;FLAVIO RIBICHINI;VALENTINO BEZZERRI;CHRISTIAN BONI;GLORIA TRIDELLO;CLAUDIO MAFFEIS;MASSIMILIANO BONIFACIO;ELENA BALDISSERI;SONIA VOLPI","651;229;229;139;78;65;65;62;59;57;45;45;44;42;39;39;36;36;35;34","ALESSANDRO ANTONELLI;MARIA ANGELA CERRUTO;SIMONE CESARO;DAVIDE MELISI;MARCO CIPOLLI;MANUEL CAPPELLARI;EMANUELE RUBILOTTA;FRANCESCO DITONNO;MASSIMILIANO BONIFACIO;FLAVIO RIBICHINI;MATTEO BALZARRO;ANDREA PANUNZIO;ALESSANDRO VECCIA;CLAUDIO MAFFEIS;GLORIA TRIDELLO;ALBERTO BIANCHI;GIOVANNI TARGHER;MICHÈLE MILELLA;FRANCESCA LUCCA;ANTONIO BENITO PORCARO","43;18;17;16;16;15;15;15;15;14;14;12;11;11;10;10;10;10;9;9","MEDICINE;BIOLOGY;PHYSICS;PSYCHOLOGY;COMPUTER SCIENCE;ENGINEERING;CHEMISTRY;MATHEMATICS;POLITICAL SCIENCE;ECONOMICS;SOCIOLOGY;PHILOSOPHY;MATERIALS SCIENCE;GEOGRAPHY;GEOLOGY;BUSINESS;HISTORY","346;82;33;25;21;21;20;14;11;10;10;5;3;2;2;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;GASTROENTEROLOGY;GENETICS;CARDIOLOGY;UROLOGY;PATHOLOGY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;PEDIATRICS;PSYCHIATRY;BIOCHEMISTRY;INTENSIVE CARE MEDICINE;PALEONTOLOGY;FAMILY MEDICINE;MECHANICAL ENGINEERING;OPTICS;RADIOLOGY","301;96;68;52;40;39;39;38;34;34;31;29;29;27;25;22;19;19;18;16","CANCER;DISEASE;GENE;COHORT;CONFIDENCE INTERVAL;CHEMOTHERAPY;POPULATION;RANDOMIZED CONTROLLED TRIAL;DIABETES MELLITUS;CYSTIC FIBROSIS;TRANSPLANTATION;RETROSPECTIVE COHORT STUDY;PROPORTIONAL HAZARDS MODEL;ADVERSE EFFECT;INCIDENCE (GEOMETRY);ODDS RATIO;STROKE (ENGINE);PROPENSITY SCORE MATCHING;LOGISTIC REGRESSION;PROSPECTIVE COHORT STUDY","79;51;39;37;33;32;31;24;22;21;21;20;19;18;17;17;17;14;13;13","HAZARD RATIO;CLINICAL ENDPOINT;PROSTATE CANCER;BREAST CANCER;COLORECTAL CANCER;CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;INFECTIOUS DISEASE (MEDICAL SPECIALTY);TYPE 2 DIABETES;GEMCITABINE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;NEUTROPENIA;BLADDER CANCER;FATTY LIVER;ISCHEMIC STROKE;NEPHRECTOMY;GENOTYPE;MUTATION;PROGRESSION-FREE SURVIVAL;PROSTATE;THROMBOLYSIS","22;21;17;15;15;13;12;12;11;11;11;10;9;9;9;7;7;7;7;7","CORONAVIRUS DISEASE 2019 (COVID-19);IVACAFTOR;PROSTATECTOMY;CYSTECTOMY;OXALIPLATIN;IRINOTECAN;TRANSIENT ELASTOGRAPHY;KRAS;MASTECTOMY;MODIFIED RANKIN SCALE;NONALCOHOLIC FATTY LIVER DISEASE;DASATINIB;FEBRILE NEUTROPENIA;IMATINIB MESYLATE;MAMMOGRAPHY;NILOTINIB;RUXOLITINIB;SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS;VENETOCLAX;ANDROGEN DEPRIVATION THERAPY;ANDROGEN RECEPTOR;ANTIMICROBIAL STEWARDSHIP;BLINATUMOMAB;BROMODOMAIN;CARFILZOMIB;DNA METHYLATION;DUCTAL CARCINOMA;FERTILITY PRESERVATION;HEMATOPOIETIC CELL;HUMAN METAPNEUMOVIRUS;IMPAIRED GLUCOSE TOLERANCE;LOWER RESPIRATORY TRACT INFECTION;LYMPHOVASCULAR INVASION;METASTATIC BREAST CANCER;MICROSATELLITE;MISSENSE MUTATION;NEOADJUVANT THERAPY;NIVOLUMAB;POSACONAZOLE;SINGLE-NUCLEOTIDE POLYMORPHISM;SURFACTANT THERAPY;TRASTUZUMAB;TRIPLE-NEGATIVE BREAST CANCER;UROTHELIAL CARCINOMA;VEMURAFENIB","12;12;11;8;7;6;5;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;;RETROSPECTIVE STUDIES;FEMALE;MALE;STROKE;COVID-19;TREATMENT OUTCOME;BRAIN ISCHEMIA;ADULT;AGED;ITALY;PROSPECTIVE STUDIES;CHILD;HEMATOPOIETIC STEM CELL TRANSPLANTATION;MIDDLE AGED;CYSTIC FIBROSIS;PANCREATIC NEOPLASMS;PROSTATIC NEOPLASMS;RISK FACTORS","193;162;46;37;37;37;30;30;26;21;20;19;19;18;18;17;16;16;16;16","PANCREATIC CANCER RESEARCH AND TREATMENT;THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;RENAL CELL CARCINOMA;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;MANAGEMENT OF VALVULAR HEART DISEASE;PROSTATE CANCER RESEARCH AND TREATMENT;ATRIAL FIBRILLATION;CORONAVIRUS DISEASE 2019;EFFICACY AND RESISTANCE IN CML TREATMENT;MOLECULAR RESEARCH ON BREAST CANCER;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;GENETIC BASIS OF NEUTROPENIA DISORDERS;HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AND RELATED DISORDERS;IMPACT OF COVID-19 ON MENTAL HEALTH;LYMPHOID NEOPLASMS;MANAGEMENT OF DIABETES MELLITUS AND HYPOGLYCEMIA;ROLE OF MAST CELLS IN IMMUNOREGULATION AND DISEASE","15;15;14;12;11;9;9;9;6;6;5;5;4;4;4;4;4;4;4;4","CLINICAL ENDPOINT;STROKE (ENGINE);IVACAFTOR;INFARCTION TREATMENT;PROSTATE CANCER;TRANSCATHETER AORTIC-VALVE REPLACEMENT;DISCONTINUATION;METASTATIC PROSTATE CANCER;INTERQUARTILE RANGE;LIVER BIOPSY;PANDEMIC;PROGRESSION-FREE SURVIVAL;REFRACTORY (PLANETARY SCIENCE);RENAL CELL CARCINOMA;CANCER GENOMICS;CONCOMITANT;CYSTIC FIBROSIS;DIABETES;HEART VALVE SURGERY;LIVER DISEASE","22;17;11;10;9;9;8;8;7;7;7;7;7;7;6;6;6;6;6;6","CYSTIC FIBROSIS;TYPE DIABETES;PROSTATE CANCER;DUCTAL ADENOCARCINOMA;PANCREATIC DUCTAL;STEM CELL;AORTIC VALVE;CELL TRANSPLANTATION;CELL CARCINOMA;TRANSCATHETER AORTIC;CLINICAL OUTCOMES;METASTATIC PANCREATIC;PATIENTS UNDERGOING;RADICAL PROSTATECTOMY;BREAST CANCER;CANCER PATIENTS;COHORT STUDY;INFECTIOUS DISEASES;MYELOID LEUKEMIA;PATIENTS TREATED;PHASE STUDY;RADICAL CYSTECTOMY;RENAL CELL;RISK FACTORS;ADENOCARCINOMA MPDAC;ATRIAL FIBRILLATION;BLADDER CANCER;HEMATOPOIETIC STEM;LUNG DISEASE;MULTICENTER STUDY","18;13;12;11;11;11;9;9;8;8;7;7;7;7;6;6;6;6;6;6;6;6;6;6;5;5;5;5;5;5","SARS-COV- INFECTION;HR CI;MEDIAN AGE;ADVERSE EVENTS;MEDIAN FOLLOW-UP;PATIENTS TREATED;LIVER DISEASE;RISK FACTORS;DISEASE PROGRESSION;ELDERLY PATIENTS;LIVER FIBROSIS;SURVIVAL OS;MONTHS CI;WM PATIENTS;CONFIDENCE INTERVAL;CYSTIC FIBROSIS;HAZARD RATIO;MULTIVARIABLE ANALYSIS;MULTIVARIATE ANALYSIS;STATISTICALLY SIGNIFICANT;ISCHEMIC STROKE;INCLUDED PATIENTS;SIGNIFICANT DIFFERENCE;WM TREATMENT;INCREASED RISK;LOGISTIC REGRESSION;MEDIAN TIME;PATIENTS UNDERGOING;PRIMARY ENDPOINT;RESPONSE RATE","39;36;27;24;23;21;20;20;18;18;18;18;17;17;15;15;15;15;15;15;14;13;13;13;12;12;12;12;12;12",357,143,0.4,2.2,38.31,2,324,1.12,1,2,1.38,1,3,0,0,0,20.44,1,165,1,1,1,0,0,0,0,0,0,44.61,2,356,1,1,1,0,0,0,30.88,1,251,1,1,1,0,0,0,2.22,1,10,5.66,1,45,18.74,1,169,7.11,1,50,0,0,0,0,0,0,11.22,1,60,11.22,1,60
"AOU_VERONA",2024,331,20.5135951661631,3.32930513595166,0.300362976406534,0.29607250755287,0.244712990936556,0.13595166163142,0.61631419939577,1,144,89,11,22,0.44,0.27,0.03,0.07,0.76,0.793454601774508,0.435045317220544,0.945619335347432,4.11143021252154,0.511386227551086,0.556571911061075,0.578259005145798,0.572404371584699,"ALESSANDRO ANTONELLI;RICCARDO BERTOLO;ALESSANDRO VECCIA;FRANCESCO DITONNO;MARIA ANGELA CERRUTO;FRANCESCA MONTANARO;FLAVIO RIBICHINI;RICCARDO AUTORINO;FRANCESCO ARTONI;EMANUELE RUBILOTTA;SIMONE CESARO;MATTEO BRUNELLI;RICCARDO RIZZETTO;ALBERTO BAIELLI;MANUEL CAPPELLARI;MICHELE BOLDINI;ALBERTO BIANCHI;ANTONIO BENITO PORCARO;ALESSANDRO PEZZINI;COSIMO DE NUNZIO","49;24;22;21;16;16;15;15;14;13;13;13;13;13;12;12;12;11;11;11","ALESSANDRO ANTONELLI;RICCARDO BERTOLO;ALESSANDRO VECCIA;FRANCESCO DITONNO;GIOVANNI GAMBARO;EMANUELE RUBILOTTA;ALESSANDRO MANTOVANI;RICCARDO AUTORINO;PIETRO MANUEL FERRARO;ANTONIO BENITO PORCARO;MATTEO BALZARRO;FLAVIO RIBICHINI;FRANCESCA MONTANARO;MARIA ANGELA CERRUTO;GIOVANNI TARGHER;MICHELE BOLDINI;SIMONE CESARO;GRETA PETTENUZZO;GIANMARCO LOMBARDI;LESLIE CLAIRE LICARI","3.77;2.22;1.58;1.46;1.45;1.44;1.28;1.19;1.11;1.1;1.03;1.02;1.02;0.96;0.95;0.87;0.81;0.8;0.8;0.79","ALESSANDRO ANTONELLI;RICCARDO BERTOLO;ALESSANDRO VECCIA;FRANCESCO DITONNO;MARIA ANGELA CERRUTO;FRANCESCA MONTANARO;FLAVIO RIBICHINI;FRANCESCO ARTONI;EMANUELE RUBILOTTA;SIMONE CESARO;MATTEO BRUNELLI;RICCARDO RIZZETTO;ALBERTO BAIELLI;MANUEL CAPPELLARI;MICHELE BOLDINI;ALBERTO BIANCHI;ANTONIO BENITO PORCARO;VINCENZO DE MARCO;EMANUELE SERAFIN;ALESSANDRO MANTOVANI","49;24;22;21;16;16;15;14;13;13;13;13;13;12;12;12;11;11;10;10","ALESSANDRO ANTONELLI;RICCARDO BERTOLO;ALESSANDRO VECCIA;FRANCESCO DITONNO;GIOVANNI GAMBARO;EMANUELE RUBILOTTA;ALESSANDRO MANTOVANI;PIETRO MANUEL FERRARO;ANTONIO BENITO PORCARO;MATTEO BALZARRO;FLAVIO RIBICHINI;FRANCESCA MONTANARO;MARIA ANGELA CERRUTO;MICHELE BOLDINI;SIMONE CESARO;GRETA PETTENUZZO;GIANMARCO LOMBARDI;ALBERTO BIANCHI;FRANCESCO ARTONI;RICCARDO RIZZETTO","3.77;2.22;1.58;1.46;1.45;1.44;1.28;1.11;1.1;1.03;1.02;1.02;0.96;0.87;0.81;0.8;0.8;0.79;0.78;0.76","ALESSANDRO ANTONELLI;ALESSANDRO VECCIA;FRANCESCO DITONNO;IGNACIO J. AMAT‐SANTOS;FRANCESCA MONTANARO;GRETA PETTENUZZO;ANTONIO LIGUORI;CELESTE MANFREDI;PIER LUIGI ZINZANI;RICCARDO BERTOLO;VINCENZO DE MARCO;GIANLUCA CAMPO;GIANNI CASELLA;RAÚL MORENO;ROBERTO SCARSINI;SIMONE BISCAGLIA;VINCENZO GUIDUCCI;CARLO VISCO;EMMANUEL TSOCHATZIS;EVA GINÉ","48;30;30;27;22;22;20;20;20;20;20;19;19;19;19;19;19;18;18;18","ALESSANDRO ANTONELLI;ALESSANDRO VECCIA;FRANCESCO DITONNO;GRETA PETTENUZZO;FRANCESCA MONTANARO;VINCENZO DE MARCO;RICCARDO BERTOLO;ROBERTO SCARSINI;MARIA ANGELA CERRUTO;MIRKO ZONCAPÈ;FLAVIO RIBICHINI;RICCARDO RIZZETTO;FABIO BENEDETTI;ALBERTO BAIELLI;FRANCESCO ARTONI;SARAH MALANDRA;SIMONE CESARO;ANTONIO BENITO PORCARO;SONIA COSTANTINO;ALESSANDRO MANTOVANI","48;30;29;22;20;20;19;19;18;18;17;17;16;15;15;15;12;10;10;9","ALESSANDRO ANTONELLI;FRANCESCO DITONNO;RICCARDO BERTOLO;ALESSANDRO VECCIA;MARIA ANGELA CERRUTO;FRANCESCA MONTANARO;ANTONIO BENITO PORCARO;FLAVIO RIBICHINI;SIMONE CESARO;FRANCESCO ARTONI;RICCARDO RIZZETTO;ALBERTO BAIELLI;ALBERTO BIANCHI;MICHELE BOLDINI;VINCENZO DE MARCO;MANUEL CAPPELLARI;ALESSANDRO MANTOVANI;EMANUELE SERAFIN;MATTEO BRUNELLI;GIOVANNI MAZZUCATO","53;24;22;20;16;15;14;14;13;13;13;12;12;11;11;11;10;10;10;9","MEDICINE;BIOLOGY;ENGINEERING;COMPUTER SCIENCE;PSYCHOLOGY;MATHEMATICS;PHYSICS;CHEMISTRY;SOCIOLOGY;ECONOMICS;POLITICAL SCIENCE;BUSINESS;GEOGRAPHY;PHILOSOPHY;MATERIALS SCIENCE;ENVIRONMENTAL SCIENCE;GEOLOGY","318;75;36;29;28;21;21;19;12;8;8;5;3;3;2;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;UROLOGY;CARDIOLOGY;INTENSIVE CARE MEDICINE;GENETICS;RADIOLOGY;GASTROENTEROLOGY;PATHOLOGY;PSYCHIATRY;IMMUNOLOGY;PEDIATRICS;ENDOCRINOLOGY;MECHANICAL ENGINEERING;ENVIRONMENTAL HEALTH;GENERAL SURGERY;PALEONTOLOGY;ANESTHESIA;FAMILY MEDICINE","254;108;53;48;46;30;29;29;28;27;27;26;25;22;22;21;20;19;17;17","CANCER;DISEASE;RETROSPECTIVE COHORT STUDY;CONFIDENCE INTERVAL;GENE;RANDOMIZED CONTROLLED TRIAL;CHEMOTHERAPY;POPULATION;STROKE (ENGINE);COHORT;KIDNEY;MYOCARDIAL INFARCTION;TRANSPLANTATION;OBSERVATIONAL STUDY;PROPORTIONAL HAZARDS MODEL;DIABETES MELLITUS;ODDS RATIO;SINGLE CENTER;RENAL FUNCTION;STAGE (STRATIGRAPHY)","68;35;23;21;21;19;18;18;18;17;16;15;14;13;12;11;11;11;10;10","PROSTATE CANCER;PROSTATE;NEPHRECTOMY;HAZARD RATIO;BREAST CANCER;REVASCULARIZATION;CLINICAL ENDPOINT;COLORECTAL CANCER;HAEMATOPOIESIS;PANCREATIC CANCER;TYPE 1 DIABETES;TYPE 2 DIABETES;CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;HEMATOPOIETIC STEM CELL TRANSPLANTATION;IMMUNOTHERAPY;ISCHEMIC STROKE;ADENOCARCINOMA;BLADDER CANCER;GEMCITABINE;GENOTYPE;NEURORADIOLOGY","26;16;14;13;10;9;8;8;7;7;7;7;6;6;6;6;5;5;5;5;5","PROSTATECTOMY;IVACAFTOR;CORONAVIRUS DISEASE 2019 (COVID-19);BENIGN PROSTATIC HYPERPLASIA (BPH);CYSTECTOMY;IRINOTECAN;LOWER URINARY TRACT SYMPTOMS;MACE;MAMMOGRAPHY;ANDROGEN DEPRIVATION THERAPY;BLADDER OUTLET OBSTRUCTION;BONE MARROW FAILURE;BRONCHOPULMONARY DYSPLASIA;CONTINUOUS GLUCOSE MONITORING;DISEASE MANAGEMENT;DNA METHYLATION;DNA MISMATCH REPAIR;ESOPHAGECTOMY;FIRST TRIMESTER;FLUORESCENCE IN SITU HYBRIDIZATION;HEMATOPOIETIC CELL;IBRUTINIB;MANAGEMENT OF PROSTATE CANCER;MODIFIED RANKIN SCALE;NAB-PACLITAXEL;NEOADJUVANT THERAPY;NIVOLUMAB;OXALIPLATIN;PANCREATIC DUCTAL ADENOCARCINOMA;PROSTATE-SPECIFIC ANTIGEN;SINGLE-NUCLEOTIDE POLYMORPHISM","15;6;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",";HUMANS;MALE;FEMALE;AGED;MIDDLE AGED;ADULT;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;RISK FACTORS;ITALY;AGED, 80 AND OVER;CHILD;PROSPECTIVE STUDIES;ADOLESCENT;PROGNOSIS;RISK ASSESSMENT;ROBOTIC SURGICAL PROCEDURES;INCIDENCE;KIDNEY NEOPLASMS","210;119;73;69;55;51;36;32;25;21;20;19;18;14;12;12;12;11;9;9","RENAL CELL CARCINOMA;PROSTATE CANCER RESEARCH AND TREATMENT;PANCREATIC CANCER RESEARCH AND TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;STANDARDISATION OF LOWER URINARY TRACT FUNCTION;THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;MANAGEMENT OF VALVULAR HEART DISEASE;PELVIC FLOOR DISORDERS;ATRIAL FIBRILLATION;INNOVATIONS IN TRANSGASTRIC SURGICAL TECHNIQUES;LYMPHOID NEOPLASMS;MANAGEMENT OF DIABETES MELLITUS AND HYPOGLYCEMIA;ROLE OF MAST CELLS IN IMMUNOREGULATION AND DISEASE;ACUTE MYELOID LEUKEMIA;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND MANAGEMENT OF FOOD ALLERGY","16;14;9;8;8;7;6;5;5;5;5;4;4;4;4;4;3;3;3;3","STROKE (ENGINE);SINGLE CENTER;TREATMENT;METASTATIC PROSTATE CANCER;CLINICAL ENDPOINT;PROSTATE CANCER;PORT (CIRCUIT THEORY);INFARCTION TREATMENT;INTERQUARTILE RANGE;BIOCHEMICAL RECURRENCE;DIABETES;HEMATOLOGY;IVACAFTOR;MYOCARDIAL REVASCULARIZATION;NOMOGRAM;TRANSCATHETER AORTIC-VALVE REPLACEMENT;CENTER (CATEGORY THEORY);CONTINUOUS GLUCOSE MONITORING;HYPERTENSION;NEPHROLOGY","18;11;11;10;9;9;8;7;7;6;6;6;6;6;6;6;5;5;5;5","PROSTATE CANCER;PARTIAL NEPHRECTOMY;CANCER PATIENTS;ISCHEMIC STROKE;TYPE DIABETES;CELL TRANSPLANTATION;RADICAL PROSTATECTOMY;STEM CELL;BREAST CANCER;FUNCTIONAL OUTCOMES;MYOCARDIAL INFARCTION;PATIENTS TREATED;BRIGANTI NOMOGRAM;OBSERVATIONAL STUDY;PILOT STUDY;RANDOMIZED CONTROLLED;REFERRAL CENTER;SINGLE CENTER;BENIGN PROSTATIC;CELL CARCINOMA;CENTER EXPERIENCE;CHRONIC KIDNEY;CYSTIC FIBROSIS;DELPHI CONSENSUS;HEMATOPOIETIC STEM;INTERMEDIATE-RISK PROSTATE;ITALIAN ASSOCIATION;ITALIAN SOCIETY;KIDNEY DISEASE;METASTATIC PANCREATIC","20;10;8;8;8;7;7;7;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4","GENETIC TESTING;PUBMED SCOPUS;CROSSREF PUBMED;GENETIC COUNSELING;RISK FACTORS;PATIENTS UNDERGOING;DISEASE PROGRESSION;LYNCH SYNDROME;PATIENTS TREATED;HR CI;ADVERSE EVENTS;CLIN ONCOL;ONCOL -CROSSREF;RF RDN;BLOOD PRESSURE;COLORECTAL CANCER;PRIMARY ENDPOINT;PROSTATE CANCER;CLINICAL PRACTICE;LYNCH ALERT;CV RISK;LOGISTIC REGRESSION;PCA PROGRESSION;BRIGANTI NOMOGRAM;CONFIDENCE INTERVAL;HAZARD RATIO;ISCHEMIC STROKE;LYMPH NODE;MLH PROMOTER;PARTIAL NEPHRECTOMY","33;33;32;23;21;20;18;18;18;16;15;15;15;15;14;14;14;13;12;12;11;11;11;10;10;10;10;10;10;10",331,1,0,3.45,6,6,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,6,6,0,0,0,0,0,0,6,6,6,0,0,0,0,0,0,1,1,1,2,2,2,2,2,2,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0
